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ABSTRACT 
A study of the mechanism of motor neuron death in Amyotrophic Lateral Sclerosis 
Kristin A. Politi 
Amyotrophic Lateral Sclerosis (ALS) is a fatal adult-onset paralytic disorder for which there is 
currently no cure. Underlying the disease mechanism of ALS is the spontaneous pathologic 
degeneration of motor neurons (MNs). Understanding the molecular mechanisms underlying 
spontaneous and selective MN demise is critical to the development of rational therapeutic 
strategies. In the current work, utilizing established in vitro models of ALS, I demonstrate that 
necroptosis, a form of caspase-independent programmed cell death (PCD), drives MN death. 
Pharmacologic inhibition and/or genetic silencing of receptor interacting protein kinase-1 
(RIPK1), receptor interacting protein kinase-3 (RIPK3), and mixed lineage kinase domain-like-
protein (MLKL) rescued MN death in vitro. While this core machinery was conserved, the 
requirement of nuclear factor kappa-B (NF-κB) and Bcl-2-associated X protein (Bax) deviated 
from known models of necroptosis. This divergence led me to consider that there may be a MN-
specific program of necroptosis. Thus, I then used unbiased approaches, by meta-analyzing a gene 
expression signature captured from MNs undergoing cell death in vitro, to explore MN cell death 
drivers that may be engaged upstream or downstream to RIPK1/RIPK3/MLKL. I also explored 
the relevance of necroptosis to MN disease in vivo, in part by deleting RIPK3 from a genetic mouse 
model of familial ALS. Overall this approach did not rescue motor neuron loss, and there was no 
improvement in motor function, disease onset, or survival in these animals. I conclude that while 
necroptosis machinery drives motor neuron death in in vitro models of ALS, more work needs to 
be done to (1) assess the motor neuron-specific cell death program, and (2) evaluate the 
relationship, if any, of necroptosis to motor neuron disease in vivo. 
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Chapter 1: Introduction 
 
As a biologist, I have always been struck by the elegance of complex signaling systems 
between cells of a multicellular organism, which integrate to create a working machine, e.g., the 
human body. One process that is imperative for the normal development of a multicellular 
organism is developmental cell death. This programmed cell death is ordered, deliberate, selective, 
and accounts for errors in redundancy. For example, the mammalian nervous system creates many 
more neurons than will survive and mature, and selects to survive and mature those neurons that 
pattern the correct connections. Other developmental programs more directly result from 
evolution, as in the classic example of selective death of cells in the connective tissue of webbed 
hands that generate digits during human development.  
While this elegant, programmed and systematic process of selective cell death is so critical 
to normal development, the questions arise: What happens in diseases in which cell death itself is 
a consequence, such as in neurodegenerative disease? Is this cell death a controlled, deliberate 
process, as in normal development, or is it a passive result of a pathological insult that has acutely 
changed the surrounding environment to become unsupportive of cellular integrity? 
One cannot begin to discuss cell death without first introducing the historically-defined 
dichotomy between apoptosis, e.g., molecularly-controlled programmed cell death, that accounts 
for developmental programs, and necrosis, which occurs by a passive process in which cells are 
overcome by a stressful injurious event in their environment, such as sharp change in pH, which 
even if it were possible, would leave no opportunity to integrate a response through regulated 
signaling.  
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For decades, it was assumed that pathologic cell death, occurring as a result of disease, was 
a passive process resulting from necrosis and that only developmental cell death was molecularly-
controlled via apoptosis. In diseases in which cell death is a major consequence, such as in 
neurodegenerative diseases, this notion leaves little room for conventional treatment options that 
often target a key regulator involved in aberrant signaling.  
In recent years, significant advances in our understanding of cell death processes and 
mechanisms of neurodegenerative disease have been made. Starting about 20 years ago, there was 
growing emphasis on the idea that the mechanisms driving the death of neurons in 
neurodegeneration may not be passive as it was once thought, but rather the result of, at least in 
part, programmed cell death. Several previous works by my mentor, Dr. Serge Przedborski, were 
of critical influence in such discussions. Attempts to target classical apoptosis mechanisms showed 
marked but quite modest effects on disease models of neurodegeneration. While promising, it was 
clear that targeting apoptosis did not mitigate the disease to an extent that would be therapeutically 
relevant. Excitingly, in the past decade, advances in our understanding of cell death mechanisms 
have challenged the dichotomy between apoptosis and necrosis. Indeed, an explosion of 
intermediate, alternative mechanisms have recently been uncovered, which rely on signaling 
molecules that may, in part, conserve some elements of apoptosis, but do not follow classical 
execution mechanisms; these alternative mechanisms may have morphologic criteria more 
consistent with necrosis, which, before modern advances in molecular biology, would have been 
characterized as such. 
As I began my studies in the Pathobiology and Molecular Medicine program, I was struck 
by the sheer selective nature of cells affected by neurodegeneration. Indeed, in each condition, 
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only a discrete subset of neurons is affected, which defines how we categorize unique diseases and 
their pathological hallmarks. In joining the Przedborski lab, my goal was to embark on a series of 
studies, guided by our advances in the current understanding of cell death and neurodegenerative 
disease, to investigate the nature of neuronal cell death occurring in this curiously cell-type 
selective manner in neurodegeneration. I chose to focus my studies on Amyotrophic Lateral 
Sclerosis (ALS), a disease model for which many in vitro and in vivo experimental systems have 
been created, and numerous causative inheritable genetic mutations have been identified in recent 
years. Yet for ALS, the mechanism of selective neurodegeneration in this fatal disease still remains 
obscure.  
 
1.1. General Introduction to ALS 
As reviewed by Rowland and collaborators (2010), ALS is an adult-onset disorder that 
manifests clinically within the fifth to sixth decade of life and is characterized by progressive 
paralysis. There is currently no cure for ALS, and the disease is typically fatal within 3-5 years 
after symptom onset, with patients succumbing to respiratory failure. In fact, merely 10% of 
patients survive more than 10 years after diagnosis. Until recently, the only known pharmacologic 
agent approved to treat ALS patients is the drug riluzole, approved in the US in 1995, which only 
extends survival by 2-3 months. However, the mechanism of action for this drug in extending ALS 
patient survival remains unclear. Recently, edaravone (Ito et al., 2008, FDA press release; May 5, 
2017) was approved to treat ALS, which is again not curative, but clinical data demonstrated that 
the drug slows the progression of motor symptom decline.  
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ALS is a neurodegenerative disease of the central nervous system (CNS) in which the 
pathophysiology of the onset and progression is driven by retraction of motor neuron axons from 
nerve terminals at the neuromuscular junction and the subsequent loss of upper and lower motor 
neuron cell bodies in both the brain motor cortex, brainstem and spinal cord. As a result, the critical 
connections between the CNS and skeletal muscles are progressively lost, resulting in paralysis 
and eventual respiratory failure and death (Munsat et al., 1988; Schwartz and Swash, 1995).  
The overall incidence of ALS in the US is about 4 new cases per 100,000 people (Mehta 
et al., 2016). Because of the high mortality rate, the relative prevalence is close to the number of 
new cases each year; an estimated 15,000 people currently live with ALS in the US, which has a 
population of just over 300 million (Mehta et al., 2016).  
1.1.1. Clinical Features and Diagnosis of ALS 
The diagnosis of sporadic ALS, in which the cause 
is unknown, occurs as a diagnosis of exclusion 
when other possible causes of the observed 
symptoms are ruled out and monitoring detects 
progression of the disease (Swinnen and 
Robberecht, 2014). Most patients present with an 
asymmetric weakness in a limb in the fifth to sixth 
decade of life. One common initial presentation is 
weakness in fine motor skills in a finger, affecting 
the patient’s ability to perform an ordinary task, 
thus termed limb or spinal onset ALS (Figure 1.1, 
reproduced from Swinnen and Robberecht, 2014). 
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The majority of cases are spinal onset, where symptoms begin in the arms and the legs. However, 
bulbar onset, in which slurred speech and difficulty swallowing are some of the initial presenting 
symptoms, makes up fewer cases (20-25%) but is more progressive and more severe (Figure 1.1) 
(Al-Chalabi et al., 2016; Swinnen and Robberecht, 2014).  
Patient performance on neurological exams, EMG (electromyography) and nerve 
conduction studies are carefully monitored over time. A diagnosis of ALS can be determined by 
criteria that support both upper and lower motor neuron impairment and involvement of at least 
three regions of the body; the bulbar region and at least two spinal regions or in three spinal regions 
(de Carvalho et al., 2008). A summary of 
upper and lower motor neuron signs is 
detailed in Figure 1.2., reproduced from 
Swinnen and Robberecht (2014). Signs of 
upper motor neuron involvement include 
Babinski signs, hyperreflexia, spasticity, 
pseudobulbar affect and Hoffman signs. 
Signs of lower motor neuron involvement 
consist of muscle atrophy, weakness and 
fasciculations.  
ALS is progressive and most patients 
succumb to the disease within 3-5 years after 
initial presentation. While early symptoms 
manifest as muscle weakness and cramping, 
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fasciculations, spasticity, slurred speech and difficulty chewing or swallowing, these quickly 
progress into more pronounced weakness and atrophy, dysarthria, dysphagia, and hyperreflexia.  
It should be noted that the clinical features of sporadic and inherited ALS are 
indistinguishable. However, an earlier age of onset (by about 10 years) and/or family member with 
ALS typically warrants genetic testing for heritable ALS-linked genetic mutations, further 
elaborated on in section 1.1.2.  
It should also be noted that a subset of ALS patients also experience frontotemporal 
dementia (ALS-FTD). The co-occurrence of the two diseases in subsets of patients, which share 
common neuropathological features, is an area of ongoing exploration with the identification of 
shared genetic etiologies within families. The discussion of ALS and ALS-FTD co-occurrence is 
beyond the scope of the thesis but contributes greatly to our understanding of the mechanisms by 
which distinct neurologic diseases, in this case along an ALS-FTD axis, can result from shared 
genetic factors (Guerreiro et al., 2015). 
 
1.1.2. Genetic Mutations in Inherited and Sporadic ALS 
At least 90% of ALS cases are sporadic with no known familial inheritance pattern (Taylor 
et al., 2016). The other 10% of cases can be attributed to familial inheritance of a number of genetic 
mutations (Figure 1.3). Since the first mutation in families was identified in 1993 by sequencing 
of the SOD1 gene (Rosen et al., 1993), upwards of 20 genetic loci linked to ALS have been 
identified [Table 1.1, reproduced from (Kirby et al., 2016)]. Most notably, about a third of familial 
cases can be attributed to mutations in C9orf72, a hexanucleotide repeat expansion, and about one-
fifth of familial cases result from mutations in SOD1 (Figure 1.3) (Kirby et al., 2016; Taylor et al., 
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2016). Interestingly, the majority these mutations are inherited in an autosomal-dominant manner, 
in that only one inherited allele 
containing the mutation is 
sufficient for the development 
of ALS. 
Although most sporadic 
cases with no inheritance 
pattern remain of unknown 
etiology, recently it was found 
that in at least 12% of sporadic 
cases, de novo mutations in 
familial-associated genes can be 
linked to the disease, with 
mutations in C9orf72 
accounting for the vast majority 
of sporadic ALS cases (Kirby et 
al., 2016; Taylor et al., 2016). Figure 1.3 details the relative contributions of the more common 
genetic loci identified in both familial and sporadic ALS to date, and Table 1.1 [reproduced from 
Kirby et al. (2016)] shows the list of known mutations. 
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Table 1.1. Overview of key information available for ALS and FTDALS loci 
 
Table reproduced from Kirby et. al. (2016) Deg. Neurol. and Neuromus. Dis. 6: 49-64. 
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1.1.3. Neuropathology Observed in ALS 
1.1.3.1. Cell Types Showing Pathology in ALS 
ALS is characterized primarily by the degeneration of both upper motor neurons of the motor 
cortex, brainstem nuclei, and lower motor neurons of the spinal cord anterior horn, with loss of 
axons in the lateral columns of the spinal cord. Additionally, glial cells show observable signs of 
reactive gliosis (Schiffer et al., 1996), not as a primary cause but rather as an inflammatory 
response to the degeneration of the neighboring motor neurons, concomitant insults to the 
neurovascular unit and breakdown of the blood brain barrier (Burda and Sofroniew, 2014). 
 
1.1.3.2. Neuropathological Features of ALS 
A number of neuropathological features have been observed in the central nervous system tissue 
from ALS patients, the most common being cytoplasmic inclusions in motor neurons. These 
inclusions are subcategorized by their morphology, reaction with various histologic stains, and by 
immuno-reactivity for associated proteins. These include Bunina bodies and skein-like 
cytoplasmic inclusions (Saberi et al., 2015). 
 
1.1.3.2.a. Bunina bodies  
Bunina bodies, which are ubiquitin-
negative inclusions, are observed in at 
least 85% of all ALS cases and are most 
commonly found in motor neurons of 
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the spinal cord and in the brainstem 
nuclei. They appear as 3-5 µm 
eosinophilic ovals or in chain-like 
structures with hematoxylin and 
eosin staining and have shown 
immunoreactivity for cystatin c, 
transferrin, and peripherin proteins 
(Saberi et al., 2015) (Figure 1.4).  
1.1.3.2.b. Skein-like inclusions  
The other inclusions, called Skein-
like, are the most common 
inclusions observed in ALS 
occurring in at least 90% of patients. 
Skein-like inclusions are 
transactivation response DNA 
protein-43 (TDP-43)-positive 
(Saberi et al., 2015), but can be 
positive for fused in sarcoma 
protein (FUS) or SOD1. Skein-like 
inclusions are ubiquitin-positive 
cytoplasmic inclusions 15-20 nm in 
diameter that have a filamentous 
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appearance (Figure 1.5) (Saberi et al., 2015). TDP-43-positive and FUS-positive inclusions also 
occur in frontotemporal dementia, the discovery of which greatly contributed to the notion that a 
subset of patients can experience symptoms which occur along an ALS-FTD axis (Neumann et al., 
2006).  
 
1.1.4. Links Between ALS Genetics, Neuropathology, and Disease Mechanism 
The question as to whether differences in ALS genetics and pathology lead to distinct subclasses 
of the disease that involve distinct mechanisms is yet to be determined. Importantly, we have 
learned that the historic categorization between sporadically-inherited vs. familially-inherited ALS 
does not seem to delineate distinct mechanisms as there are no distinctions in patient presentation. 
Mutations in common genetic loci are shared between familial and sporadic ALS, due to de novo 
mutations in sporadic patients. 
Rather, subclasses of ALS can be differentiated by unique neuropathology, such as TDP-
43-positive neuropathology and FUS-positive neuropathology, which occur in both FTD and ALS. 
TDP-43-positive neuropathology is not seen in SOD1-related ALS that has not been linked to FTD 
(Mackenzie et al., 2007; Saberi et al., 2015). A majority of ALS cases show TDP-43 pathology 
(Mackenzie et al., 2007; Saberi et al., 2015). Additionally, some ALS-associated genetic mutations 
can be grouped categorically into subsets by similar proposed mechanisms, select examples of 
which are briefly summarized below.  
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1.1.4.1. RNA Transport and Metabolism 
One mechanism that has been proposed as the functional consequence of genetic mutations linked 
with ALS is the disruption of normal RNA transport and metabolism. ALS-linked mutations that 
may lead to this common mechanism include (1) TARDBP (encoding TDP43), (2) FUS, in which 
gene products are known RNA binding proteins, and (3) C9orf72 (DeJesus-Hernandez et al., 
2011), in which the RNA gene product resulting from the hexanucleotide repeat expansion has 
been shown to form RNA foci that could sequester RNA binding proteins and disrupt their normal 
functions. Indeed, motor neurons seem to be particularly susceptible to defects in RNA 
metabolism. In spinal muscular atrophy, for example, there is a gene dosage effect for survival 
motor neuron (SMN), an RNA binding protein with known roles in splicing, in relation to the 
severity of the disease (Burghes and Beattie, 2009; Gavrilina et al., 2008). There is evidence that 
motor neurons require higher levels of SMN compared to other cells in order to function. When 
SMN levels are mildly lowered, motor neurons are the predominantly affected cells. Only when 
SMN levels are severely lowered do other cell types also become impaired (Burghes and Beattie, 
2009; Gavrilina et al., 2008).  
The question remains whether ALS resulting from defects in RNA biology shares a 
common downstream mechanism with ALS for which there is yet no clear link with RNA biology, 
such as SOD1-ALS.  
 
1.1.4.2. Disruptions in Autophagy 
Another common mechanism that involves multiple ALS-linked genetic factors is autophagy. 
Autophagy is a mechanism critical to cellular homeostasis and is involved in normal recycling of 
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organelles and certain proteins through lysosomal degradation or, clearance of dysfunctional 
organelles or sequestered misfolded protein inclusions. Controlled levels of autophagy are 
important for normal cellular function. Increased levels of autophagy can promote cell death, while 
decreased levels can lead to accumulation of protein aggregates and organelle material that should 
normally be turned over, which can lead to cellular dysfunction (Majcher et al., 2015). Many ALS-
linked genes have roles associated with autophagy. These include autophagy regulators valosin-
containing protein (VCP) and tank binding protein kinase (TBK1), and receptors optineurin 
(OPTN), ubiquilin 2 (UBQLN2), and sequestosome 1 (SQSTM1, encodes p62 protein) (Majcher et 
al., 2015). In addition, hexanucleotide repeat expansions in C9orf72, which have been linked to 
ALS, could impair autophagy (Sellier et al., 2016; Sullivan et al., 2016). It remains to be 
determined whether enhancing or inhibiting autophagy would be therapeutically relevant in the 
context of motor neuron degeneration in ALS.  
 
1.1.4.3. ALS As a Proteinopathy 
A mechanism that involves common neuropathology, but not common genetics, is the notion that 
the inclusions found in motor neurons in ALS indicate that the disease, at least in part, is a 
proteinopathy. The propensity of mutated forms of SOD1 to misfold and the fact that wild-type 
SOD1 forms stable dimers, led early studies to investigate the notion that accumulation of 
misfolded mutant SOD1 could prime wild-type SOD1 to misfold as well, thus propagating the 
disease process (Bruijn et al., 1998; Kabashi et al., 2007). While this is not a proven mechanism 
of ALS, TDP-43 inclusions have also recently been suggested to have prion-like spread (Nonaka 
et al., 2013). The fact that motor neurons in ALS tissue contain inclusion bodies suggests that they 
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are either a consequence or a cause of dysfunction, or both. For example, the sequestration of key 
proteins into inclusions, due to defects in trafficking, autophagy, etc., could lead to further loss of 
important cellular functions.  
 
1.1.5. Links Between Observed Cellular Dysfunctions in ALS and Disease Mechanism 
1.1.5.1. Endoplasmic Reticulum (ER) Stress  
ER stress is a stress response in which misfolded proteins accumulate in the ER lumen, leading to 
activation of the Unfolded Protein Response (UPR). UPR activity is sustained until ER 
homeostasis is restored by the clearance of misfolded proteins from the ER lumen. However, 
sustained activation of ER stress can lead to apoptosis. It has been suggested that misfolded 
proteins such as mutated SOD1 can accumulate in the ER of motor neurons leading to sustained 
ER stress and eventual apoptosis. Indeed, in the mutant SOD1 mouse model of familial ALS, 
accumulation of misfolded SOD1 and increased ER stress-related genes in motor neurons has been 
reported (Kikuchi et al., 2006; Saxena et al., 2009). 
 
1.1.5.2. Mitochondrial Dysfunction 
Normal transport and function of mitochondria are essential for neuronal survival. Anterograde 
transportation and retrograde transport of the mitochondrial network to meet regional energetic 
demands are especially essential for motor neurons, which have some of the longest axons in the 
body. Experimental evidence in models of ALS has demonstrated a variety of defects in 
mitochondria that could contribute to the neurodegenerative pathology of motor neurons, including 
mitochondrial transport, bioenergetics, calcium buffering, and induction of mitochondrial-
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mediated apoptosis (reviewed by Cozzolino et al., 2013).  Magrané, et al. (2014) showed defects 
in mitochondrial transport in both SOD1- and TDP43-mutant mice that correlated with onset and 
progression of motor abnormalities (Magrané et al., 2014).  
 
1.1.5.3. Differential Degeneration Susceptibility of Motor Neurons in ALS 
Motor neurons are differentially susceptible to degeneration in ALS. For example, oculomotor 
neurons are spared in the disease and have been the focus of studies examining genetic and 
functional properties involved in differential susceptibility (Kaplan et al., 2014). Motor neurons 
can be subcategorized in a number of ways, one being their participation in motor units. Spinal 
motor neurons can be separated into three subtypes: alpha, innervating extrafusal muscle fibers; 
beta, and gamma motor neurons, innervating intrafusal muscle fibers. Alpha motor neurons are 
distinctly susceptible in ALS. The motor units innervated by alpha motor neurons can further be 
classified into three functional subtypes: fast-twitch fatigable (FF), fast-twitch fatigue-resistant 
(FR), and slow-twitch (S) (Burke and Tsairis, 1973). These motor units are characterized based on 
two properties: amount of force generated by the muscle, and fatigability. FF motor units generate 
the most force, but over a brief period of time as they fatigue quickly, whereas S motor units are 
required for sustained low-force movements and are more resistant to fatigue, and FR exhibit an 
intermediate ability to generate force and sustain contractions. Motor neurons participating in FF 
motor units, innervated by large alpha motor neurons, show the earliest signs of degeneration 
followed by FR. In contrast, S motor neurons, innervated by relatively smaller alpha motor 
neurons, are largely spared until the disease has significantly progressed (Fischer et al., 2004; 
Hegedus et al., 2007; Pun et al., 2006).   
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1.1.5.4. Motor Circuit Dysfunction in ALS 
One hypothesis for why distinct pools of motor neurons are selectively susceptible in ALS 
(Kanning et al., 2010) is through their inherent differences in electrophysiologic properties and 
connectivity within the motor circuit. Consequently, one of the alterations observed in ALS models 
is a change in electrophysiological properties of motor neurons correlating with disease 
progression (reviewed by Leroy and Zytnicki, 2015; Quinlan, 2011). So far, defects in the motor 
circuit have not been demonstrated to contribute to the degenerative process in motor neurons per 
se. In fact, rather compelling evidence in a mouse model of SMA would argue that failure of the 
circuit and the actual death process of motor neurons are two distinct mechanisms (Fletcher et al., 
2017).  
 
1.1.5.5 Axonal Retraction from Nerve Terminals and Motor Neuron Death in the Spinal Cord 
Occur via Distinct Mechanisms 
Motor neuron degeneration in ALS occurs by retraction of axons from the neuromuscular junction 
and axonal degeneration followed by loss of the motor neuron cell bodies residing in the spinal 
cord. These two events are temporally isolated, in that retraction precedes motor neuron cell death 
that is re-capitulated in the SOD1 mouse model of ALS, which are discussed in section 1.2.1. One 
demonstration that these two events occur via distinct mechanisms is that the homozygous 
germline deletion of Bcl-2-associated X protein (BAX), encoding a proapoptotic protein, fully 
rescues cell bodies of motor neurons but fails to rescue axonal degeneration in the SOD1 mouse 
model of ALS (Gould et al., 2006). If these two processes indeed occur via distinct molecular 
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events, the approach for therapeutic targeting of ALS pathogenesis will need to be adjusted. 
Therapies may need to be combinatorial in order to target both mechanisms, unless a common 
targetable molecular event is identified. Furthermore, given that motor circuit dysfunction also 
contributes to the disease as well as the degenerative process of motor neurons, even therapies 
targeted at preserving axons and cell bodies of motor neurons may not be sufficient to restore fully 
functional motor circuits. 
 
1.1.5.6. Interplay Between Proposed Mechanisms of Motor Neuron Degeneration  
None of these proposed mechanisms of cellular dysfunction in ALS are mutually exclusive. For 
example, C9orf72 mutations lead to expansions of a hexanucleotide repeat. The RNA resulting 
from this repeat has been shown to lead to intranuclear RNA foci that could disrupt the normal 
production of important proteins by impairing mRNA splicing and transport from the nucleus. 
This, in turn, could lead to dysfunction in any of the proposed pathways in which those sequestered 
proteins are normally involved. On the other hand, the C9orf72 intronic repeat expansion could 
also lead to haploinsufficiency of C9orf72, which may be inadequate for proper autophagy 
initiation. Therefore, haploinsufficiency of C9orf72 and defects in autophagy could lead to 
impaired clearance of ubiquitinated inclusions, which could damage the cell by sequestering 
critical proteins.  
 
1.1.5.7. Non-Cell Autonomous Mechanisms in ALS 
It is clear that many altered cellular pathways in ALS could lead to dysfunction within motor 
neurons and downstream degeneration. However, over the last 20 years, there has been a growing 
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body of evidence that not only do motor neuron cell-autonomous mechanisms contribute to the 
disease, but also non-cell-autonomous mechanisms. Toxicity to motor neurons conferred by non-
neuronal neighboring cells, such as from neighboring glia, e.g., astrocytes and microglia (Frakes 
et al., 2014; Haidet-Phillips et al., 2011; Nagai et al., 2007; Papadeas et al., 2011; Re et al., 2014; 
Tong et al., 2013) correlate with disease progression. As far as neuronal cells are concerned, 
defects in the motor circuit conferred by dysfunction in the recurrent inhibitory circuit with 
interneurons (Wootz et al., 2013), also can contribute to motor circuit dysfunction, but, as 
discussed in section 1.1.5.4., it is unclear whether this can directly drive the degenerative process.  
 
1.1.6. Astrocyte-Mediated Motor Neuron Cell Death 
Studies in chimeric and conditional mutant SOD1-expressing transgenic mice support the notion 
that mutated SOD1 (mSOD1), in both motor neurons and non-neuronal cells, and especially in 
glial cells, contribute to the disease process in vivo (Papadeas et al., 2011; Yamanaka et al., 2008). 
Consistent with this evidence of non-cell-autonomous effects of mSOD1, previous work utilizing 
a neuron/glial co-culture model in the Przedborski lab and by others have demonstrated that 
astrocytes expressing mSOD1 or media conditioned by these astrocytes trigger the selective death 
of primary spinal motor neurons, regardless of whether the motor neurons express mSOD1 (Di 
Giorgio et al., 2007; Nagai et al., 2007). Evidence suggests the selective death of motor neurons 
in response to mutant astrocytes in vitro is due to release of a toxic factor rather than the lack of 
beneficial effect (Nagai et al., 2007). Recent in vitro and in vivo studies also suggest that the 
contribution of astrocyte non-cell-autonomous toxicity to motor neurons is a mechanism also in 
sporadic ALS (Haidet-Phillips et al., 2011; Qian et al., 2017; Re et al., 2014; Tong et al., 2013).  
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My work in this thesis focuses specifically on a mechanism of motor neuron cell death, 
namely necroptosis. Necroptosis was first identified as downstream to non-cell-autonomous 
toxicity by astrocytes associated with familial and sporadic ALS in co-culture models, which are 
discussed in Chapter 2. Whether necroptosis contributes to or synergizes with proposed 
mechanisms of cell-autonomous mechanisms of motor neuron dysfunction preceding the 
degeneration are also discussed. 
 
1.2. Rodent Models of ALS 
Although much recent work has been carried out to generate new rodent models based on newly-
identified ALS-causing mutations in recent years, I discuss with emphasis only those mouse 
models relevant to the series of studies I conducted in this thesis, namely those related to SOD1 
and optineurin (OPTN). Indeed, of the attempts to generate rodent models that recapitulate the 
hallmarks of the ALS phenotype—namely the retraction of nerve terminals from the 
neuromuscular junction, motor neuron cell death, progressive paralysis and premature fatality—
few have succeeded in mimicking the severe pathophysiology of the human disease.  
 
1.2.1 Mouse Models of SOD1 Mutations 
The best and most enduring mouse models for the study of motor neuron cell death, mimicking 
the onset, progression, and severity of the human disease, are in those that grossly overexpress 
(15-20 copies) a human mutated SOD1 transgene with a guanine to alanine substitution at position 
93, abbreviated here as SOD1G93A (Gurney et al., 1994). These mice exhibit 40-50% motor neuron 
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loss in the lumbar spinal cord by end stage, preceded by extensive retraction of nerve terminals 
from the neuromuscular junction, especially those originating in lumbar L4 and L5 of the spinal 
cord, such as the tibialis anterior muscle. In contrast to the human disease, these mice do not mimic 
the extent of the disease along the corticospinal tract, as pathology is primarily limited to lower 
motor neuron involvement.  
The SOD1 gene encodes a ubiquitously expressed cytosolic protein superoxide dismutase-
1, an enzyme that neutralizes harmful superoxide radicals. In fact, over 150 mutations in SOD1 
have been linked to ALS, and interestingly can occur throughout the length of the protein, rather 
than being concentrated in a specific functional domain. The G93A mutation is not common and 
found in only a small number of families, but is important to the understanding of ALS in that 
SOD1 retains its known enzymatic activity. Therefore, the mouse model suggests that, in 
combination with the fact that mice lacking SOD1 do not develop motor neuron disease (Reaume 
et al., 1996), the role of SOD1 in ALS is less likely to be a loss of normal enzymatic function, but 
rather a gain of toxic function or property of the protein. Proposed mechanisms center around the 
propensity of mSOD1 to misfold and gain one or more toxic properties as a result, including 
catalyzing aberrant reactions or, as has been observed in ALS tissue, forming aggregates that 
associate with cytoplasmic inclusions in motor neurons as previously discussed in section 1.1.4.3. 
The toxicity of such aggregates is unknown, but there is some evidence of prion-like proteinopathy 
as a mechanism of SOD1 gain of function toxicity in ALS (Ayers et al., 2016; Lee and Kim, 2015). 
Other mouse models of SOD1 mutations lead to similar phenotypes, with varying lifespans, 
and depend greatly on transgene copy number and the background strain in which it is generated. 
The SOD1G93A transgenic mouse has been the subject of criticism, mainly because of the extreme 
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overexpression (15-20 copies) needed to recapitulate the disease, and the dearth of experimental 
findings in the model that have translated therapeutically to the human condition (Zwiegers and 
Shaw, 2015). Despite this, the SOD1G93A transgenic mouse remains one of the most well-
characterized and widely-used mouse models. In addition, for the purposes of my work, which is 
focused on motor neuron cell death, it was imperative that the mouse model recapitulated this 
aspect of the pathology of the disease. 
 Importantly, SOD1G93A transgenic mice have variable onset and end stage based on the 
background strain used and copy number of the transgene. When the transgene is expressed in a 
mixed background B6/SJL, the average lifespan is about 4 months, whereas when expressed in the 
C57Bl/6J background, it is about 5 months. Sex differences in survival have also been reported for 
the B6/SJL background, with female mice living slightly longer and with a later onset of ALS-like 
motor manifestations (Heiman-Patterson et al., 2005; Scott et al., 2008).  
 
1.2.1. Mouse Models of Optineurin Deficiency 
Recently, optineurin (OPTN) mutations, first identified in glaucoma, have been linked to familial 
ALS (Maruyama et al., 2010). Many of these mutations correlated with loss of function and 
haploinsufficiency; thus, it has been suggested that optineurin plays a neuroprotective role 
(reviewed by Markovinovic et al., 2017). In part, in order to dissect the relevance of OPTN loss to 
ALS, Ito et al. (2016) generated a homozygous germline deletion of optineurin (OPTN-/-) and 
found a very mild phenotype with some evidence of axon degeneration in the white matter of the 
spinal cord. This was attributed to non-cell-autonomous contributions of increased microglia 
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activation and white matter oligodendrocyte degeneration, having a mild degenerative effect on 
myelinated axons in the ventral spinal cord white matter.  
 
1.3. Exploring Molecular Determinants of Apoptosis in Experimental Mouse 
Models of ALS and In Vitro Models 
The downstream execution mechanisms owing to eventual neuronal demise in neurodegenerative 
diseases continue to be an area of open investigation. Motor neuron retraction from nerve terminals 
and cell death in ALS occur throughout the entire spinal cord and in the upper motor neurons of 
the cortex, while other cells and neuronal processes in the spinal cord and in the cortex, besides 
notably gray matter oligodendrocytes (Kang et al., 2013), remain largely intact. Regardless of the 
interesting areas of exploration regarding the initiators of this death, one important area to be 
explored for clinical intervention is the downstream effectors, e.g., the molecular mechanisms, if 
any, which execute motor neuron death. 
 
1.3.1. Targeting Apoptosis in Mouse Models of ALS 
1.3.1.1. Overexpression of Bcl-2 
Bcl-2 (B-cell lymphoma 2) is a negative regulator of proapoptotic proteins, and its overexpression 
has been shown to inhibit apoptosis. Kostic et al. (1997) overexpressed Bcl-2 in the nervous system 
including motor neurons in SOD1G93A mice and found a delay in onset of 
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Figure 1.6. Targeting Apoptosis in the SOD1G93A Mouse Models of ALS 
a. Kostic et al. (1997) overexpressed Bcl-2 in the nervous system, including motor neurons, in SOD1G93A mice and 
measured onset of motor symptoms (top) and survival (bottom). (circle=control, triangle=Bcl-2 overexpression) b. 
Li et al. (2000) used osmotic pumps to deliver zVAD-fmk to the cerebral ventricle of SOD1G93A mice and measured 
onset of motor symptoms (top) and survival (bottom). (dashed=vehicle, line=zVAD-fmk) c-e. Gould et al. (2006) 
generated SOD1G93A mice that were homozygous for the germline deletion of the proapoptotic protein Bax and 
measured onset of motor symptoms (c), survival (d), and lumbar spinal motor neuron number (e) at end stage.  
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motor symptoms in mice that correlated with a shift in overall survival of the mice and an 
improvement in the number of surviving motor neurons at end stage (Figure 1.6, a). However, time 
from onset to death, which one could think of as a measure of progression, was not changed (Figure 
1.6, a) (Kostic et al., 1997).  
 
1.3.1.2. Pharmacological Targeting of Caspases 
Li et al. (2000) used osmotic pumps to deliver N-benzyloxycarbonyl-Val-Asp-fluoromethylketone 
(zVAD.fmk) to the cerebral ventricle of SOD1G93A mice. ZVAD.fmk is a broad-spectrum inhibitor 
of caspases (Garcia-Calvo et al., 1998) whose use, in many models, is sufficient to inhibit 
apoptosis. Like overexpression of Bcl-2, there was a delay in onset of motor symptoms which 
correlated with an overall survival of the mice and better performance of the mice on motor ability 
tests. However, like in the overexpression of Bcl-2, time from onset to death was not changed (Li, 
2000) (Figure 1.6, b). 
 
1.3.1.3. Homozygous Germline Deletion of Bax 
Perhaps the most compelling evidence of the contribution of programmed cell death in SOD1G93A 
mice came from the studies of Gould et al. (2006) who generated SOD1G93A mice that were 
homozygous for the germline deletion of the gene encoding the proapoptotic protein Bax (Bax-/- 
mice). Bax-/- mice have an increased number of motor neurons, owing to the critical role of Bax in 
developmental motor neuron death (White et al., 1998). However, Bax-/-/SOD1G93A completely 
rescued motor neuron death even at end stage, having the same increased number of motor neurons 
as non-transgenic Bax-/- mice (Figure 1.6, e). Interestingly, although motor neuron number in the 
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lumbar spinal cord was completely rescued, there was no improvement in motor axonal 
degeneration or retraction from the neuromuscular junction, which, at least in part, supports the 
idea that these two events are mechanistically distinct in ALS as discussed in section 1.1.5.5. As 
in the studies of Li et al. (2000) and Kostic et al. (1997), there were very modest improvements in 
onset and survival in these mice (Figure 1.6, c-d), likely attributed to the lack of ability to mitigate 
axonal degeneration. 
There were very modest effects of targeting apoptosis in mouse models of ALS, except in 
the case of Bax. Indeed, Bax is critical for motor neuron death in response to the non-cell-
autonomous effects of familial and sporadic ALS astrocytes (Nagai et al., 2007; Re et al., 2014), 
which we recently attributed to a mechanism of nonapoptotic cell death (Re et al., 2014). This and 
the lack of apoptosis targeting to completely mitigate the disease in mice further suggests that 
caspase-mediated cell death does not contribute to the full extent of motor neuron death in the 
disease. Despite some evidence of caspase activation in ALS mouse models and even in human 
tissue (Inoue et al., 2003; Li, 2000; Pasinelli et al., 2000; Vukosavic et al., 2000), others have 
reported an inability to detect clear signs of apoptosis in the degenerating motor neurons in the 
mouse models (Migheli et al., 1999). More recently, as insights into characterization of 
programmed cell death (PCD) mechanisms have been gained, and a variety of nonapoptotic 
programmed cell death mechanisms have emerged (Table 1.2, reproduced from Vanden Berghe et 
al., 2015) which challenge the historical dichotomy between apoptosis and necrosis. One such 
mechanism is necroptosis, which are discussed in section 1.4.  
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Table 1.2 Schematic Overview of Nonapoptotic Genetically Regulated Cell Death 
 
Table reproduced from Vanden Berghe et al. (2015) Cell. Mol. Life Sci. 73, 2137–2152. 
 
1.4. Necroptosis is an Alternative Programmed Cell Death Pathway 
Necroptosis has emerged as an alternative form of PCD in a variety of disease contexts (Ofengeim 
et al., 2015; Weinlich et al., 2016). Necroptosis is a form of programmed cell death with distinct 
molecular regulation from that of apoptosis, most strikingly the independence from caspase 
activation. Cells display features of necrosis rather than apoptosis, such as early loss of plasma 
membrane integrity and swelling (oncosis). Cell death by necroptosis in vivo induces inflammation 
in tissues much like necrosis through membrane rupture and exposure of cellular components to 
the immune system (Vanden Berghe et al., 2015).  
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1.4.1 Molecular Characterization of Necroptosis 
Activation of necroptosis first occurs at the plasma membrane by ligation of a death receptor or 
toll-like receptor, canonically tumor necrosis factor receptor-1 (TNFR1) by tumor necrosis factor 
(TNF), but many other ligand-receptor interactions to activate necroptosis have been described 
(Vanden Berghe et al., 2016).  
Activation of TNFR1 can lead to a variety of downstream signaling, including induction 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-dependent transcription 
of proinflammatory and pro-survival genes, via formation of Complex I, FAS-associated via death 
domain (FADD)/caspase-8 mediated apoptosis, via formation of Complex II, and necroptosis 
signaling, via formation of the necrosome (Figure 1.7.) (Pasparakis and Vandenabeele, 2015).  
Necroptosis was first described using in vitro models as an alternative cell death to 
apoptosis when cells were treated with TNF and apoptosis was concomitantly inhibited using the 
pan-caspase inhibitor zVAD.fmk. It was first determined that the kinase activity of receptor-
interacting protein kinase-1 (RIPK1) is essential for necroptosis, as the discovery that necrostatin-
1, a potent allosteric inhibitor of RIPK1 kinase function, fully inhibits TNF/zVAD.fmk-induced 
necroptosis (Degterev et al., 2005, 2008). Subsequent biochemical in vitro studies identified that 
RIPK1 interacts with receptor-interacting protein kinase-3 (RIPK3) in a phosphorylation-
dependent manner, forming a stable complex via homotypic interactions in their RHIM domains 
(e.g., “necrosome”) necessary for necroptosis (Cho et al., 2009; He et al., 2009; Zhang et al., 2009). 
RIPK3 then acts as an adapter that recruits and phosphorylates downstream targets to the 
necrosome, notably the pseudokinase mixed lineage kinase domain-like-pseudokinase (MLKL) 
(Sun et al., 2012; Zhao et al., 2012). More recently, it has been shown that the execution of 
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necroptosis depends on MLKL translocation to the plasma membrane and assembly into 
oligomeric membrane-permeable pores (Cai et al., 2014; Chen et al., 2014; Su et al., 2014; Wang 
et al., 2014) with striking structural similarity to the pores formed by Bax on the mitochondrial 
outer membrane during apoptosis.  
 
1.4.2 Evidence for Roles of Necroptosis in Human Disease 
Since the characterization of necroptosis in vitro induced by stimulation with TNF and inhibition 
of necroptosis with zVAD.fmk, the contribution of necroptosis has been implicated in a number 
of cellular contexts and disease models. The most well-characterized role of necroptosis is in the 
field of immunology. One proposed evolutionary basis for necroptosis is that it acts as a defensive 
cell death mechanism against viruses that express anti-apoptotic proteins, with the resulting 
inflammation further propagating an immunological response (Newton and Manning, 2016). 
Studies using RIPK3 knockout mice have demonstrated the role of necroptosis in the cellular 
response to microbial infections, as well as in disease models that involve inflammation-induced 
tissue damage (Moriwaki and Chan, 2013; Newton, 2015). Disease models ameliorated by the 
genetic targeting of necroptosis are listed in Table 1.3 reproduced from Newton (2015). 
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Figure 1.7. Activation Pathways Downstream of TNFR1 Activation 
Reproduced from Pasparakis & Vandenabeele (2015), Nature 517, 311–320. 
Recently, in a study I participated in using in vitro models, necroptosis was implicated as 
the mechanism in ALS by which ALS astrocytes may confer non-cell-autonomous cell death to 
motor neurons (Re et al., 2014) (described in more detail in Chapter 2). More recently, Ito et al. 
(2016) described an alternative mechanism for the role of necroptosis in ALS, again in a non-cell-
autonomous mechanism in which necroptosis activation in microglia leads to oligodendrocyte loss, 
which leads to motor neuron myelination defects and the resulting axonopathy (Ito et al., 2016a), 
a study discussed further in Chapter 5 as it relates to the present work.  
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Table 1.3. Genetic Targeting of Necroptosis in Various Disease Models 
 
1.5. Specific Aims  
The overall goal of my studies has been to shed light on the role of necroptosis in a 
neurodegenerative disorder such as ALS and to assess whether necroptosis, if instrumental here, 
operates within motor neurons via the same core machinery as in other cell types, especially 
immune cells. 
To achieve these stated goals, my thesis comprises four experimental Chapters, namely 
Chapter 2 to 5:  
In Chapter 2, I establish the role of necroptosis as the mechanism of astrocyte-mediated 
motor neuron death in in vitro models of familial and sporadic ALS. I show that while motor 
neurons engage core components of necroptosis, a number of differences emerge between motor 
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neuron necroptosis and what has been reported in the literature. In addition, there is increasing 
evidence in the literature that cell death pathways are cell context specific.  
Building on these findings, in Chapter 3, I investigate the motor neuron-specific cell death 
machinery, which we now know is driven by core elements of necroptosis, by meta-analyzing a 
gene expression signature captured from motor neurons undergoing cell death that was previously 
generated in the lab by Ikiz et al. (2015).  
In Chapter 4, I explore the in vivo relevance of necroptosis in mouse models of ALS, by 
first validating immunoreagents that are mandatory for allowing the study of the core elements of 
necroptosis in mouse tissue, namely RIPK1, RIPK3, MLKL and phosphorylated MLKL. While I 
was able to identify several reliable immunoreagents for Western blotting of whole tissues, thus 
far I have not been able to identify immunoreagents that could detect necroptosis components at 
the single-cell level in mouse spinal cord using immunohistochemistry.  
Lastly in Chapter 5, I seek to more directly and mechanistically assess the contribution of 
necroptosis to the disease phenotype in a mouse model of ALS by deleting the RIPK3 gene in 
transgenic SOD1G93A mice. 
My overall conclusion of the work in Chapters 2-5 is that while the necroptosis machinery 
drives motor neuron death in in vitro models of ALS, more work needs to be done to (1) assess the 
motor neuron-specific cell death program, and (2) evaluate the relationship, if any, of necroptosis 
to motor neuron disease in vivo.  
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Chapter 2: Programed Cell Death and Motor Neuron Degeneration  
 
2.1. Introduction 
The observation that motor neurons die in response to co-culture with SOD1G93A-expressing 
astrocytes was documented previously in the Przedborski group and by others interested in non-
cell-autonomous mechanisms of neurodegeneration in ALS (Di Giorgio et al., 2007; Nagai et al., 
2007). To describe briefly the co-culture model, primary motor neurons (PMNs) are co-cultured 
with primary neonatal astrocytes from rodents overexpressing the human mutant transgene 
SOD1G93A, a rodent model of familial ALS (fALS) that recapitulates most hallmarks of ALS 
(Gurney et al., 1994). 
It was reported that after 7 days in culture, 50% of motor neurons selectively die in response 
to co-culture with SOD1G93A–expressing astrocytes compared to wild-type astrocytes (Figure 2.1 
a, b). In contrast, other neurons, such as spinal GABAergic, interneurons, or dorsal root ganglion 
neurons, showed no difference in survival in culture with SOD1G93A–expressing astrocytes (Figure 
2.1 a, b) (Nagai et al., 2007). These observations supported the claim that this in vitro model not 
only recapitulated a spontaneous neurodegenerative phenotype caused by a human ALS-relevant 
context, i.e., by mutated SOD1 (mSOD1), but also that it reproduced the characteristic feature of 
ALS that not every population of spinal neurons were equally susceptible to the disease process 
(Kanning et al., 2010).  
The Przedborski lab also provided evidence that this motor neuron death was not due to a 
loss of beneficial properties from the mutant astrocytes, but rather a deleterious gain of function 
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related to the release of a toxic factor by the mutant astrocytes.  Indeed, it was demonstrated that 
medium conditioned with mutant but not wild-type astrocytes and re-supplemented with growth 
factors and glucose conferred the same toxicity as co-culture (Nagai et al., 2007).   
______________________________________________________________________________ 
 
Figure 2.1. Establishment of the fALS Co-culture Model 
Figure reproduced from Nagai et al. (2007) Nat. Neurosci.  
a. Wild-type primary motor neurons isolated from E12.5 embryos, expressing GFP under the HB9 motor neuron-
specific promoter, were co-cultured on primary astrocyte monolayers from SOD1G93A or non-transgenic (NTg) rats. 
The percentage of surviving primary motor neurons (identified by immunostaining for GFP) on SOD1G93A at 7 days 
was lower (p<0.004) than at 1 day, whereas the number of surviving GABAergic neurons was identical at 1 day and 
7 days (P > 0.5) b. Mouse embryonic stem cell-derived cultures, containing motor neurons expressing GFP under the 
HB9 motor neuron-specific promoter, Lim1/2+ neurons negative for GFP (likely interneurons) and other neurons 
positive for pan-neuronal marker MAP2+ but not GFP, were plated on primary astrocyte monolayers from SOD1G93A 
or non-transgenic (NTg) rats. At five days in co-culture, the percentage of surviving motor neurons on SOD1G93A 
astrocytes was lower (P<0.01) than on NTg astrocytes, whereas the percentage of the Lim1/2+ interneurons (p=0.9) 
was not changed nor was the percentage of other neurons (P=0.8). 
_____________________________________________________________________________________________ 
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After the in vitro model of fALS was established, efforts were made to observe and 
characterize the mode of motor neuron cell death in response to mutant astrocytes, which indeed 
could be very different from cell-autonomous mechanisms that had been thus proposed 
downstream of endoplasmic reticulum stress (Kikuchi et al., 2006; Saxena et al., 2009) and 
mitochondrial dysfunction (Magrane et al., 2009, 2011). One of the first distinctions to make was 
whether motor neurons were dying via a molecularly-controlled mechanism, the most prevalent 
being classical apoptosis, or by a passive mechanism via necrosis. Signs that this was a 
molecularly-controlled event were that motor neurons undergoing cell death in this in vitro model 
displayed increased DNA fragmentation, a hallmark of PCD, observed by TUNEL positive 
staining, and that motor neurons had increased caspase-3 activation, a hallmark of apoptosis, 
observed by immunostaining for fractin, a cleavage product produced by activated caspase-3 
during apoptosis (Fig 2.2, a) (Nagai et al., 2007). In addition, primary motor neurons cultured from 
mice with homozygous germline deletion for Bax (Bcl-2-associated X), a protein with known 
function in PCD execution, were resistant to death in response to SOD1G93A–expressing astrocytes 
(Fig. 2.2, b).  
In light of these data, I embarked on the characterization of the form of PCD that drives 
the demise of motor neurons in response to mutant astrocytes. In this chapter, I provide evidence 
that motor neurons selectively die in co-culture with ALS-associated astrocytes in a molecularly-
regulated manner by the necroptosis pathway. Understanding the mechanism by which motor 
neurons die in ALS is of great importance to understanding the neurodegeneration that contributes 
to the disease pathology as well as identifying molecular targets for intervention. 
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____________________________________________________________________________ 
 
Figure 2.2. Motor Neurons Die by Programmed Cell Death in the fALS Co-culture Model 
Figure reproduced from (a) Nagai et al. (2007) Nat. Neurosci and (b) Re. et al. (2014) Neuron.  
 
a. Mouse embryonic stem cell-derived motor neurons (ES-MNs) were plated on primary astrocyte monolayers from 
SOD1G93A mice or non-transgenic (NTg) rats for 7 days. top: All ES-MNs immunopositive for fractin (red) also 
showed DNA condensation (blue), as evidenced by Hoechst 33342 bottom: all ES-MNs with Hoechst 33342–labeled 
chromatin clumps show DNA fragmentation, as evidenced by TUNEL. Scale bar, 20 um.TUNEL=terminal dUTP 
nick-end labeling. b. Wild-type or Bax knockout primary motor neurons isolated from E12.5 mouse embryos, were 
co-cultured on primary astrocyte monolayers from SOD1G93A or non-transgenic (NTg) mice for 7 days and surviving 
motor neurons were counted using SMI32+ immunolabeling to identify motor neurons. A two-way ANOVA revealed 
there is an interaction between the astrocyte genotype and the motor neuron genotype (p<0.001). Newman-Keuls post-
hoc analyses indicated there are fewer (p<0.001) wild-type motor neurons whereas there was no difference (p=0.939) 
in the number of surviving Bax KO motor neurons on SOD1G93A monolayers. 
Values express MN survival in percent of controls (i.e. MNs number cultured on NTg astrocytes) and represent means 
± SEM (n=3-4 per group). Bax KO= motor neurons from mice with homozygous germline deletion of Bax.  
______________________________________________________________________________ 
 
2.2. Results 
Over the past decade, a host of new forms of PCD have emerged, often linked to specific cell death 
paradigms and often with a high degree of cell-type specificity (Feoktistova and Leverkus, 2015; 
Fuchs and Steller, 2015). Thus, even if apoptosis is the most prevalent form of PCD, it is essential 
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to consider alternative forms of molecularly-controlled mechanisms of motor neuron degeneration. 
This view is particularly relevant to mSOD1-related motor neuron degeneration in ALS transgenic 
mice, in which morphological features of apoptosis are rather rare and targeting apoptosis in 
transgenic mSOD1 mice by inhibiting caspases has provided limited benefit (discussed in Chapter 
1, section 1.3).  
To begin my characterization of PCD in this in vitro model of ALS, I revisited the role of 
caspases, a family of cysteine proteases, which play key regulatory and execution roles in all forms 
of apoptosis (Budihardjo et al., 1999). Consistent with previous finding of this lab (Nagai et al., 
2007; Re et al., 2014), I found that when cells were treated with pan-caspase inhibitor zVAD-fmk 
(Nagai et al., 2007) as well as with inhibitors targeting individual caspases such as Ac-DNLD-
CHO for caspase 3/7 or zIETD for caspase-8, the magnitude of motor neuron loss between the 
cultures containing mutant or wild-type astrocytes did not differ (Fig 2.3, a).  
In striking contrast, while survival of motor neurons was not afforded by zVAD-fmk, this 
treatment did abrogate all features of apoptosis, such as fraction-positive cells in motor neurons 
incubated with mutant astrocyte-conditioned medium (Nagai et al., 2007). Cultured motor neurons 
were also not protected from mutant astrocytes using soluble Fas ligand antagonist (Nagai et al., 
2007), ruling out a Fas-dependent apoptosis mechanism of motor neuron cell death, which had 
been previously described (Raoul et al., 2002).  
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______________________________________________________________________________ 
    Figure 2.3. Motor Neuron Cell Death is Not 
Rescued by Caspase Inhibitors 
Wild-type primary motor neurons (MN) isolated from 
E12.5 embryos, expressing GFP under the HB9 motor 
neuron-specific promoter, were co-cultured on primary 
astrocyte monolayers from SOD1G93A or non-
transgenic (NTg) mice. The percentage of surviving 
primary motor neurons on SOD1G93A at 7 days 
compared to NTg was measured (identified by 
immunostaining for GFP to enhance the signal). 
Neither inhibition of caspase 3/7, nor caspase 8 
protected mouse primary spinal MNs from fALS 
astrocyte-mediated toxicity. A two-way ANOVA 
reveals that there was a main effect of the astrocyte 
genotype (p<0.001) but no effect of treatment 
(p=0.666): 10 µM of Ac-DNLD-CHO (caspase 3/7 
inhibitor) or 1 µM of zIETD-fmk (caspase-8 inhibitor). 
Values express MN survival in percent of controls (i.e., 
MNs number cultured on NTg astrocytes) and 
represent means ± SEM (n=3-4 per group). 
Figure reproduced from Re et al. (2014). 
______________________________________________________________________________ 
 
However, early evidence pointed toward a role of a nonapoptotic mechanism of PCD in 
motor neurons, in that motor neurons in co-culture with SOD1G93A–expressing astrocytes showed 
early loss of plasma membrane integrity, imaged by ethidium homodimer permeability assay, a 
feature of necrosis rather than apoptosis (Re et al., 2014). In apoptosis, plasma membrane integrity 
is lost much later in the cell death process rather than occuring as a primary event. Thus, the story 
unfolded of a caspase-independent motor neuron cell death mechanism with morphological 
features reminiscent of necrosis. In light of this, I sought to examine the role of oxygen and 
nitrogen reactive species by using SOD1 mimetics (Jung et al., 2001),  N-acetylcysteine (Ferrari 
et al., 1995) or nitric oxide synthase inhibitors (Moore and Handy, 1997; Watanabe et al., 2004), 
and none provided any protection. Likewise, PARP-1 inhibitors (Fatokun et al., 2013), ferostatin-
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1 (Dixon et al., 2012) or AMPA/Ka receptor antagonists (Nagai et al., 2007; Van et al., 2003) 
aimed at preventing ferroptosis, parthanatosis or excitotoxicity, respectively, did not attenuate the 
loss of motor neurons in response to mutant astrocyte-conditioned medium. 
However, when necrostatin-1 (Nec-1) was used there was near complete protection of 
motor neuron death (Re et al., 2014) (Figure 2.4). These results strongly argue for the death of 
motor neurons in response to mutant astrocytes being driven by necroptosis, a form of molecularly-
regulated necrosis introduced in detail in Chapter 1. 
______________________________________________________________________________ 
 Figure 2.4. Astrocyte-mediated Motor Neuron Death is 
Rescued by Inhibiting RIPK1 Kinase Function 
Wild-type primary motor neurons (MN) isolated from E12.5 
embryos, expressing GFP under the HB9 motor neuron-specific 
promoter, were co-cultured on primary astrocyte monolayers 
from SOD1G93A or non-transgenic (NTg) mice. The percentage 
of surviving primary motor neurons on SOD1G93A at 7 days 
compared to NTg was measured (identified by immunostaining 
for GFP). While vehicle (Veh) showed significant motor neuron 
loss (DMSO, p<0.001), the RIPK1 inhibitor necrostatin-1 (Nec1, 
5 µM) abrogated the MN loss (p=0.532). DMSO = 
dimethylsulfoxide. 
 
Figure reproduced from Re et al. (2014). 
______________________________________________________________________________ 
As indicated in Chapter 1, known core components of necroptosis include RIPK1, RIPK3 
and MLKL. Briefly, necroptosis signaling occurs downstream of ligand-mediated death receptor 
activation at the plasma membrane, leading to phosphorylation-dependent assembly of a key 
molecular complex containing RIPK1 and RIPK3, termed the necrosome (Cho et al., 2009; He et 
al., 2009; Zhang et al., 2009). This allows RIPK3 to form amyloid-like signaling oligomers (Li et 
al.), and recruit and phosphorylate downstream targets to execute cell death, most notably the 
pseudokinase MLKL, a protein with strikingly similarity in structure to Bax, which has been 
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shown to have oligomeric pore-forming ability at the plasma membrane (Cai et al., 2014; Chen et 
al., 2014; Su et al., 2014; Wang et al., 2014).  
My studies thus began at this exciting time in the Przedborski group. A robust, promising 
in vitro model of “ALS in a dish” had suggested for the first time that necroptosis may play an 
important role in motor neuron cell death in ALS. If true, this would have a number of implications 
for both the study of necroptosis in the context of neurodegeneration and for identifying new 
potential therapeutic avenues for ALS.  
My initial goal was to confirm targets and validate the initial findings. The small molecule 
drug used to inhibit cell death in our model, Nec-1, besides antagonizing the kinase function of 
RIPK1, also has known off-target interactions. Most notably, Nec-1 inhibits the 
immunomodulatory enzyme indoleamine-2,3-dioxygenase, which has known roles in innate and 
adaptive immunity as well as in neuroprotection (Vandenabeele et al., 2013). Therefore, protection 
against cell death using Nec-1 alone is not sufficient to confirm necroptosis. We first used genetic 
targeting of RIPK1 to confirm that the rescue observed in Nec-1 treatment was indeed due to 
RIPK1 involvement. When I started my project, knockdown of RIPK1 mRNA in motor neurons 
by shRNA-containing lentivirus had demonstrated motor neuron protection in the fALS co-culture 
model. To further confirm these findings, I infected cells with a lentivirus containing a second 
unique shRNA sequence against RIPK1, which decreased RIPK1 transcript in the motor neuron 
culture by 60% (Fig. 2.5, a). Knockdown of RIPK1 afforded full protection of motor neuron death 
on SOD1G93A–expressing astrocytes compared to motor neurons infected with non-mammalian 
targeting shRNA-containing control lentivirus (Fig. 2.5, b). These results demonstrated that 
silencing RIPK1 phenocopied the effects of Nec-1, which provided compelling evidence for the 
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involvement of RIPK1 in the death mechanism of motor neurons in our in vitro model of ALS. 
_____________________________________________________________________________ 
 
Figure 2.5. Astrocyte-mediated Motor Neuron Death is Rescued by RIPK1 Silencing 
Wild-type primary motor neurons (MN) isolated from E12.5 embryos, expressing GFP under the HB9 motor neuron-
specific promoter, were co-cultured on primary astrocyte monolayers from SOD1G93A or non-transgenic (NTg) mice. 
Before plating, cells were infected with shRNA-containing viral particles containing an empty vector (EV), non-
mammalian targeting vector (SC), or shRNA against RIPK1 by spinoculation at MOI 20 as described in (Re et al. 
2014). a. After 4 days, an average of 60% reduction in endogenous RIPK1 transcript was measured by qPCR b. After 
7 days, there were fewer (p<0.001) motor neurons transduced with SC on SOD1G93A astrocytes than NTg astrocytes 
but motor neurons with 60% reduction in RIPK1 transcript were at equal numbers at day 7 on SOD1G93A astrocytes 
and NTg astrocytes (p>0.1). Data represent means ± SEM (n=3) MOI=multiplicity of infection (For more detailed 
methods, see Experimental Procedures). Motor neurons identified by immunostaining for GFP. 
____________________________________________________________________________________________ 
Although the above results provided strong support to the idea that motor neurons in our 
in vitro model of ALS were dying by necroptosis, it is important to emphasize that RIPK1 is also 
known to operate outside of necroptosis (Festjens et al., 2007; Newton, 2015; Ofengeim and Yuan, 
2013). Thus far, however, RIPK3 has no known functions outside of cell death and specifically 
necroptosis. Thus, to further support the hypothesis of necroptosis, I decided to then test the 
involvement of RIPK3. At the time of this work, unlike for RIPK1, there were no validated small 
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molecules available to inhibit RIPK3, and therefore, I decided to use constitutive knockout mice 
deficient in this kinase (Newton et al., 2004), kindly provided by Genentech. These mice develop 
normally to adulthood without any observed defects in weight gain or fertility, and histological 
analysis does not show defects in major organs (Newton et al., 2004). I thus cultured primary motor 
neurons from mice with homozygous germline deletion for RIPK3 (RIPK3KO) and from their 
wild-type counterparts. Quantitative RT-PCR showed no expression of RIPK3 mRNA transcript 
in the embryo at day 12.5 compared to control, in neither the head nor the spinal cord from which 
these cultures are derived (Fig. 2.7, a). First, I demonstrated that primary RIPK3KO spinal motor 
neurons have normal morphology of cell bodies and axons in culture (Fig. 2.6), because, to my 
knowledge, this is the first time primary neurons from these animals had been cultured. I then 
assessed the effect of mutant astrocytes on RIPK3-deficient motor neurons as done before in the 
lab for other mutant mouse lines (Nagai et al., 2007; Re et al., 2014). I found that counts of 
RIPK3KO motor neurons co-cultured with mutant astrocytes for 7 days did not differ from those 
of RIPK3KO motor neurons co-cultured with wild-type astrocytes (Student’s t-test, p=0.075) (Fig. 
2.7, b). Conversely, within the same experiment, I found that counts of wild-type motor neurons 
co-cultured with mutant astrocytes were ~40% lower than those of wild-type motor neurons co-
cultured with wild-type astrocytes (Student’s t-test, p=0.0002) (Fig. 2.7, b). These results indicated 
that the constitutive lack of RIPK3 also provided protection to motor neurons from the deleterious 
effects of SOD1G93A–expressing astrocytes. Accordingly, it seemed that the case for necroptosis, 
being a driver of motor neuron degeneration in this in vitro model of ALS, was becoming very 
strong. I could also conclude that, because both RIPK1 and RIPK3 are necessary for motor neuron 
death in this model of ALS, it was likely that this was a necroptosis-dependent mechanism 
resulting from the formation of the necrosome assembly and ensuing signaling. 
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______________________________________________________________________________ 
 
Figure 2.6. Cultured RIPK3-/- Motor Neurons Have Typical Morphology in Culture 
RIPK3 knockout spinal motor neurons were isolated from E12.5 mouse embryos and plated on wild-type astrocyte 
monolayers as has been described (Nagai et al., 2007). After 7 days, SMI32 immunostaining (green) labeled motor 
neurons were observed with typical axonal and cell body morphology indistinguishable from wild-type motor neurons 
in cultured prepared under comparable conditions. DAPI counterstained nuclei (blue) and MAP2 staining (red) labeled 
all neurons in culture.  
_____________________________________________________________________________________________ 
  
 Notably, at the same time as the non-cell-autonomous astrocyte-mediated mechanism of 
motor neuron death in the model of familial-associated mutation in mouse was being elucidated, a 
fully humanized sporadic ALS (sALS) model co-culture system was being established. For this, 
postmortem astrocytes from sporadic ALS patients and age-matched donor control astrocytes were 
co-cultured with human embryonic stem cell-derived motor neurons. I actively participated in the 
culture of postmortem human astrocytes from patients and controls to aid in the study of this new 
culture model that provided us, for the first time, the ability to test our pathogenic hypothesis in a 
human cell system and in absence of mutant SOD1 overexpression. Furthermore, to assure that the 
astrocytes were from sALS patients, each sample was genotyped and none of the known mutations 
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linked to ALS was identified. None of the samples used in the lab and particularly in my studies 
carried pathological C9orf72 expansion (Re et al., 2014). Strikingly, this fully humanized in vitro 
model of sALS demonstrated the same non-cell autonomous and selective motor neuron death in 
response to sALS-associated astrocytes (Re, 2014). Targeting of RIPK1 by shRNA-mediated 
knockdown or Nec-1 treatment was protective against the selective motor neuron death (Re et al., 
2014). This model system also provided us with a unique opportunity to test for the involvement 
of MLKL at the level of its activation by using a small molecule drug called necrosulfonamide 
(NSA) (Sun et al., 2012). NSA operates by binding to a human-specific cysteine that is not 
conserved in mice and thus, the only chance to test the effect of using NSA for this work was in 
the humanized model that now was available to me. Accordingly, human ES-MNs were cultured 
with human sALS astrocytes in the presence and absence of NSA. This experiment showed that 
counts of human ES-MNs co-cultured with human sALS astrocytes for 7 days in the presence of 
0.25 µM NSA did not differ from those of human ES-MNs co-cultured with human control 
astrocytes (post-ANOVA Newman-Keuls test, p>0.12) (Fig. 2.8). Conversely, within the same 
experiment, I found that the counts of human ES-MNs co-cultured with human sALS astrocytes 
in absence of NSA were ~50% lower than those of human ES-MNs co-cultured with human control 
astrocytes (post-ANOVA Newman-Keuls test p<0.001) (Fig. 2.8). Although these results were 
derived from the use of a small molecule that could have unexpected off-target effects, they suggest 
that MLKL is also instrumental in the demise of motor neurons. Thus, taken together, these two 
models of both familial and sporadic ALS suggested, for the first time, necroptosis as a generalized 
mechanism of motor neuron death.  
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Figure 2.7. RIPK3-/- motor neurons are protected from SOD1G93A astrocytes 
a. Mouse E12.5 embryos from wild-type (WT) or RIPK3-/- mice (Newton et al., 2004) were dissected to remove the 
whole spinal cord (sc) or whole head and RNA was extracted and prepared for RT-qPCR to detect RIPK3 mRNA 
transcript (n=1-3 samples per condition, error bars represent SEM of biological replicates). Quantification showed 
relative levels of RIPK3 were undetectable in all RIP3-/- samples. b. Wild-type or RIPK3 knockout primary motor 
neurons (MN) isolated from E12.5 mouse embryos, were co-cultured on primary astrocyte monolayers from SOD1G93A 
or non-transgenic (NTg) mice for 7 days, and surviving motor neurons were counted using SMI32+ immunolabeling 
to identify motor neurons. RIPK3-/- motor neurons did not differ in counts between NTg or SOD1G93 astrocytes 
(Student’s t-test, p=0.075), whereas WT motor neurons co-cultured with mutant astrocytes were ~40% lower on 
SOD1G93 astrocytes (Student’s t-test, p=0.0002). Error bars represent SEM. n=3 biological replicates. 
_____________________________________________________________________________________________  
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______________________________________________________________________________ 
 
Figure 2.8. Human Astrocyte-mediated Motor Neuron Death is Protected by MLKL Inhibition 
Reproduced from Re et al. (2014).  
Human primary astrocytes/purified GFP+ human ES-derived motor neuron cultures were prepared as described in Re 
et al. (2014). In the presence of vehicle (Veh, DMSO), there were fewer (p<0.001) motor neurons on sporadic ALS 
patient astrocytes compared to non-diseased control astrocytes. 250 nM of the MLKL inhibitor necrosulfonamide 
(NSA) prevented the loss of human motor neurons co-cultured for 7 d on sporadic ALS astrocytes as hES-MN numbers 
no longer differed (p>0.123). Data are expressed as percent of MN number on Ctrs astro. Mean and error bars represent 
± SEM (n=3–5 per group). Ctrs = astrocytes from age-matched control patients with no neurologic disease. Motor 
neurons identified by immunostaining for GFP. 
______________________________________________________________________________ 
 
2.3. Discussion 
Our results indicated that astrocyte-mediated motor neuron death in both familial and sporadic in 
vitro models of ALS occured by a programmed cell death pathway that involveed RIPK1, RIPK3, 
MLKL, and Bax, and did not involve caspases. Both inhibition of RIPK1 kinase function and 
silencing of RIPK1 protected motor neurons from ALS astrocyte-induced death. Motor neurons 
lacking RIPK3 were protected from cell death. Furthermore, in the human sporadic ALS co-culture 
model, motor neurons were protected from astrocyte-mediated cell death in co-culture by 
pharmacologic inhibition of MLKL activation. This provided strong evidence that motor neurons 
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respond to ALS-associated astrocyte toxicity by engaging necroptosis machinery leading to their 
demise. These results however raise two important questions that are explored in the following 
chapters: 
First, while the dependence on RIPK1 kinase function and RIPK3 are clearly demonstrated, 
what is the mechanism of motor neuron death downstream of RIPK1/RIPK3 activation? Second, 
what is the dependence, if any, on necroptosis in the development of motor neuron disease and 
could this pathway be a good target for therapeutic intervention? I explore these questions in 
Chapters 3-5.  
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Chapter 3. Unbiased Approach to Study Motor Neuron Death in ALS 
 
3.1. Introduction 
Over the past few years, efforts have been made to decipher the molecular makeup of necroptosis, 
and a great deal has already been discovered, at least in the context of the immune system and in 
response to TNF-α and/or the pan-cascape inhibitor zVAD-fmk in cultured cells (Degterev et al., 
2008; He et al., 2009; Newton and Manning, 2016). From the work done in the Przedborski lab to 
which I have contributed (discussed in the previous chapters), it is clear that spinal motor neurons 
succumb to the deleterious effects of both mouse familial (i.e., expressing mSOD1) and human 
sporadic ALS astrocytes via the engagement of core components of necroptosis (Re et al., 2014). 
However, we also discovered that while some elements were conserved, namely the dependence 
on RIPK1, the involvement of RIPK3, and the activity of MLKL, a number of striking differences 
emerged from the results. For instance, motor neuron necroptosis in the in vitro ALS models I 
studied in my work:  
a. occurred in the absence of caspase-inhibition,  
b. was dependent on the pro-cell death Bax protein, 
c. was dependent on the canonical pathway of NF-κB, and 
d. was equally rescued by RIPK1 inhibition and silencing. 
These differences from previous publications in the literature, elaborated below, led me to 
hypothesize that some aspects of the necroptosis mechanism may be cell specific.  
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3.1.1. Necroptosis Activation in ALS. 
Almost all studies that have been performed to elucidate the biochemistry and molecular 
mechanisms of necroptosis relied thus far on protein overexpression and immortalized cancer cell 
lines (Cho et al., 2009; Degterev et al., 2005, 2008). Additionally, in most of these studies, 
necroptosis is observed only when cell death is induced and apoptosis is concomitantly inhibited 
(Degterev et al., 2008; He et al., 2009; Newton and Manning, 2016). The evolutionary role for 
necroptosis as an alternative death pathway of apoptosis when the latter is inhibited is proposed as 
a mechanism related to innate immunity. Indeed, some pathogens such as viruses and bacteria 
express anti-apoptotic proteins, hence preventing the engagement of apoptosis (Jorgensen et al., 
2017; Newton and Manning, 2016). While elimination of the host cell by programmed cell death 
was once thought to be beneficial in the fight of the host against the infecting pathogen, there is 
increasing interest in the notion that programmed cell death also plays a role in the innate immune 
defense against pathogens (Jorgensen et al., 2017). Necroptosis, unlike apoptosis, leads the dying 
cell to leave behind damage-associated molecular patterns (DAMPs) that further activate the 
immune system to respond to the pathogen (Jorgensen et al., 2017; Newton and Manning, 2016). 
Necroptosis is regarded as the optimal form of molecularly-controlled cell death when an 
inflammatory/immunological response is required as found in pathological situations related to the 
presence of foreign invaders; a similar view was previously proposed for necrosis, before 
necroptosis was discovered. 
Although one may envision that necroptosis would be instrumental in virtually all cell 
types, thus far it has been demonstrated as an alternative cell death pathway to apoptosis almost 
exclusively in immune cells such as macrophages and T-cells, and also microglia, endothelial cells 
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and fibroblasts (Newton and Manning, 2016; Weinlich et al., 2016). Moreover, in these cells, 
especially when caspase-8 activation or recruitment is impaired, necroptosis is known to be 
engaged downstream of ligation of death and toll-like receptors with ligands such as TNF-α, Fas 
ligand (FasL), TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma (IFNγ), LPS 
(lipopolysaccharide produced by Gram-negative bacteria), cluster of differentiation 3/28 (CD3, 
CD28) and TNF-related weak inducer of apoptosis (TWEAK) (Figure 3.1) (Chan et al., 2003; 
Degterev et al., 2005; Holler et al., 2000; Matsumura et al., 2000). 
______________________________________________________________________________ 
 
Figure 3.1. Activation of Necroptosis by Engagement of a Variety of Ligands and Receptors 
Necroptosis activation occurs especially under conditions of impaired caspase-8 recruitment or activation, 
downstream of ligation of death receptors and toll-like receptors by ligands such as Tumor necrosis factor-α (TNF-α), 
Fas ligand (FasL), TNF-related weak inducer of apoptosis (TWEAK), TNF-related apoptosis-inducing ligand 
(TRAIL), LPS (lipopolysaccharide produced by Gram-negative bacteria), cluster of differentiation 3/28 (CD3, CD28), 
and interferon gamma (IFNγ). Figure reproduced from Vandenabeele et al. (2014) Path. Hum. Dis. p.153-161. 
_____________________________________________________________________________________________ 
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However, none of the proposed agonists of necroptosis are responsible for the toxicity of either 
mouse mSOD1 or sALS astrocyte-conditioned media, discussed below.  
 
3.1.1.1. Tumor Necrosis Factor-α (TNF-α) 
Given the importance of this ligand to my topic, concentration of TNF-α was measured by enzyme-
linked immunosorbent assay (ELISA) in astrocyte-conditioned media (ACM). Strikingly, TNF-α, 
which engages tumor necrosis factor receptor (TNFR1/2), was detected in the same low levels in 
wild-type and mSOD1 mouse ACM (Figure 3.2, a) (Nagai et al., 2007). In addition, I performed 
another ELISA for 31 human cytokines using ACM from primary sALS astrocytes and control 
astrocytes and did not detect TNF-α (Figure 3.2, d, OD <0.01, below the detection limit of the 
plate reader/assay). In same assay, I did detect granulocyte macrophage colony-stimulating factor 
(GM-CSF) (Figure 3.2, d, OD = 0.15-0.2) which is known to be secreted from human astrocytes 
in primary culture (Choi et al., 2014). Of note, this specific ELISA was meant to compare levels 
between samples, not to provide absolute values. However the limit of detection of most ELISA 
reactions are between 0.01 pg/mL to 100 ng/mL (Zhang et al., 2014). Thus, I can conclude that if 
present, TNF-α might be at least below 100 ng/mL, and GM-CSF is at least above 0.01 pg/mL. 
Lastly, I noted that spinal motor neurons grown from TNFR1/2 double knockout mice were as 
susceptible to mSOD1 astrocytes as their wild-type counterparts (Figure 3.2, c). Thus, collectively, 
I did not have any evidence to implicate either TNF-α or TNFR1/2 in ALS astrocyte-mediated 
motor neurons death in my studied in vitro models of ALS.  
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______________________________________________________________________________ 
 
Figure 3.2. Evaluating Ligands and Receptors Associated with Necroptosis Activation 
a. ELISA detected the same levels of TNF-α in wild-type (non-transgenic) and SOD1G93A ACM b-c Wild-type primary 
motor neurons (MNs) from E12.5 embryos were co-cultured on astrocyte monolayers from wild-type (non-transgenic 
NTg) or SOD1G93A astrocytes and MN survival was measured after 7 days with or without treatment with 1µg/mL Fas 
inhibitor Fas-Fc or DR5-neutralizing antibody and no improvement in MN survival was measured. MNs identified by 
immunostaining for GFP. c. MNs from mice with germline deletion of TNFR1/2 also showed no protection compared 
to wild-type MNs. MNs identified by SMI32+ immunostaining d-e. ELISA against human cytokines on ACM from 
sALS astrocytes and non-diseased control (NDC) astrocytes showed undetectable levels of TNF-α and no change in 
IFNγ levels (absorbance 450nm ~0.05, 2-way ANOVA, p= 0.94 ALS vs. NDC). COPD= chronic obstructive pulmonary 
disorder AD= Alzheimer’s disease. n=3 biological replicates per condition for all experiments (a-e). 
______________________________________________________________________________ 
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3.1.1.2. Fas ligand (FasL) 
Although activation of Fas by FasL is a known inducer of motor neuron programmed cell death 
involving FADD-caspase-8 (Raoul et al., 1999, 2002), in our astrocyte co-culture we have 
consistently found that Fas inhibition does not rescue motor neuron death from mSOD1 astrocytes 
(Nagai et al., 2007). Indeed, Fas inhibitor Fas-Fc, which is sufficient to block Fas activation by 
FasL (Raoul et al., 1999), does not rescue motor neuron death in co-culture with mSOD1 astrocytes 
(Figure 3.2, b).  
 
3.1.1.3. TNF-related weak inducer of apoptosis (TWEAK) 
TWEAK has been shown to be produced by astrocytes and can induce apoptosis in primary motor 
neurons via a CD163 receptor and caspase-3 dependent mechanism (Bowerman et al., 2015). 
However, Bowerman et al. (2015) report comparable low levels of TWEAK in the media of wild-
type and SOD1G93A astrocyte cultures, and comparable increased levels after stimulation with IFNγ 
between the two genotypes (Bowerman et al., 2015). Therefore, I postulated that if TWEAK is 
related to the astrocyte toxicity in our co-culture model via a necroptosis-dependent mechanism, 
it would likely be as a “priming factor” that would require action of at least a second toxic factor 
that is differentially produced by SOD1G93A-expressing astrocytes. However, antagonizing this 
mechanism through genetic deletion of TWEAK or through treatment with antagonistic anti-
TWEAK antibody did not improve motor neuron loss in SOD1G93A mice (Bowerman et al., 2015). 
It is unclear whether TWEAK contributes to a necroptosis-dependent mechanism of motor neuron 
death. We did not yet look for soluble TWEAK in mSOD1 or sALS astrocytes in our co-culture 
models.  
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3.1.1.4. TNF-related apoptosis-inducing ligand (TRAIL) 
Two death receptors (DR) respond to TRAIL ligand: DR4, which was not detected in mouse ES-
MN by RNA sequencing, and DR5. When the co-culture was treated with DR5-neutralizing 
antibody, there was no protection from mSOD1 astrocyte induced motor neuron cell death (Figure 
3.2, c). ELISA for TRAIL was performed on control and sALS ACM, and there was no significant 
difference between control and sALS ACM in levels of TRAIL, which was measured by Dr. V. 
LeVerche, an Associate Research Scientist in the lab. TRAIL was found to be at low levels (10 
pg/ml), approaching the detection limits of the assay. 
 
3.1.1.5. Lipopolysaccharide (LPS) 
LPS is specifically produced by Gram-negative bacteria and activates TLR4 (Toll-like receptor 4), 
which leads to necroptosis. As LPS is not produced by astrocytes, it is not a relevant agonist to 
explore in ACM. However, TLR4 is expressed in mouse ES-MN, determined by RNA sequencing, 
so engagement of the receptor by other means is possible. While LPS is the most well-studied, in 
some instances TLR4 has been shown to be activated by other endogenous ligands such as β-
defensins, heat shock proteins, fibrinogen cleavage products, and modified forms of low-density 
lipoprotein (Brubaker et al., 2015, Millien et al., 2013). We did not yet explore TLR4 in the context 
of motor neurons. 
 
3.1.1.6. Cluster of differentiation (CD)3/CD28 
Activation of T-cell receptors (TCR) by CD3 or CD28 engages necroptosis in T-cells. However, 
TCR (encoded by TRA, TRB, TRG, TRB genes) was not found to be expressed in mouse ES-MN 
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as determined by RNA sequencing, and therefore I did not consider this mechanism in our study 
of motor neuron death.  
 
3.1.1.7. Interferon gamma (IFNγ) 
IFNγ was undetectable by ELISA in wild-type or mSOD1 ACM (Nagai et al., 2007). In addition, 
I performed an ELISA on conditioned media from primary sALS astrocytes and non-diseased 
control (NDC) astrocytes and found no significant difference in levels between NDC and sALS 
astrocytes (Figure 3.2, e, absorbance at 450 nm ~0.05, 2-way ANOVA, p= 0.94). 
Thus, the above data strongly argue that, in the case of our primary motor neuron cultures, 
necroptosis is the primary driver of motor neuron cell death in response to ALS-associated 
astrocytes and takes place without stimulation by any known exogenous ligands, ligation of any 
known receptors, or by first suppressing apoptosis using pan-caspase inhibitors such as 
zVAD.fmk. 
 
3.1.2. Motor Neuron Cell Death in Response to fALS Astrocytes Is Dependent on Bax Protein  
Another unique feature of our model of motor neuron death is the dependence of this process on 
Bax protein, as shown in Chapter 2. In other cells so far, any generalized mitochondrial-dependent 
execution mechanism of necroptosis, suggested by some studies (Wang et al., 2012), has not been 
confirmed by others (Tait et al., 2013). There have been few if any studies evaluating the role of 
Bax directly in necroptosis. However, downstream execution of necroptosis may be cell-type 
specific (Vanden Berghe et al., 2015; Morioka et al., 2014; Newton and Manning, 2016; Thornton 
and Hagberg, 2014) 
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3.1.3. Role of NF-κB in Motor Neuron Death 
A recent study from Przedborski lab (Ikiz et al., 2015), to which I contributed, showed that motor 
neuron death in response to SOD1G93A-expressing astrocytes was dependent on the canonical 
pathway of NF-κB. In this work, we showed that not only does the silencing of NF-κB	subunit p50 
protect motor neurons, but also that NF-κB subunits P50 and P65 bind to DNA in motor neurons 
upon exposure to media conditioned by ALS astrocytes (Ikiz et al., 2015). Conversely in other 
necroptosis-competent cells, NF-κB signaling (typically upon TNFR1 activation by TNF-α) is pro-
survival; proinflammatory signaling downstream of formation of Complex I requires ubiquitinated 
RIPK1 and recruitment of NF-kappa-B essential modulator (NEMO), and IκB kinase (IKK) 
complex components IKK-α and IKK-β (Festjens et al., 2007; Walczak, 2013) (Figure 3.3). Cell 
death via Complex II formation, which leads to apoptosis or necroptosis depending on the activity 
of caspase-8, occurs only under conditions where NF-κB signaling is impaired (Walczak, 2013) 
(Figure 3.3).  
One of the first demonstrations of the critical pro-survival role of NF-κB signaling 
downstream of TNF-α stimulation was in mice with homozygous germline deletion of NF-κB 
subunit RelA. Deletion of RelA resulted in embryonic lethality and liver degeneration resulting 
from apoptosis in liver cells (Beg et al., 1995). In addition, embryonic fibroblasts cultured from 
these mice had decreased viability in response to TNF-α treatment compared to control cells (Beg 
and Baltimore, 1996). 
In contrast, in Ikiz et al. (2015) we have demonstrated that targeting the activation of the 
canonical pathway of NF-κB that occurs in motor neurons undergoing cell death in response to 
fALS astrocytes by genetic or pharmacologic inhibition protected motor neurons, which argues 
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for NF-κB having the opposite effect in our cell models of ALS. 
______________________________________________________________________________ 
 
Figure 3.3. Differential Activation of NF-κB Pathway, Apoptosis, and Necroptosis Downstream of 
Receptor Activation 
Figure reproduced from Liu W and Xia Y. (2016) Necroptosis in Acute Kidney Injury. Austin J Nephrol Hypertens. 
3(2): 1059. (Liu W, Xia, 2016) 
Upon activation of TNFR1, TRADD and RIPK1 are recruited to the death domain of the receptor to begin formation 
of Complex I. TRADD recruits TRAF2 and in turn cIAP1/2 is recruited and ubiquitinates various components of 
Complex I dependent for LUBAC recruitment. LUBAC is responsible for ubiquitination of linear chains on RIPK1 
and NEMO, which in turn lead to recruitment and activation of IKK and TAB1/TAK1 complexes required for NF-κB 
activation and translocation to the nucleus. When RIPK1 is deubiquitinated, Complex II forms and depending on 
whether caspase-8 is active in the cells, leads to caspase-8/FADD-dependent apoptosis or RIPK3/MLKL-dependent 
necroptosis.  
_____________________________________________________________________________________________ 
3.1.4. RIPK1 Did Not Seem to Play a Pro-Survival Role in Motor Neurons  
Another feature of our motor neuron necroptosis incongruent with the literature is the fact that 
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RIPK1 does not have a pro-survival role in addition to its role in necroptosis signaling that has 
been documented by others (Vanden Berghe et al., 2015; Festjens et al., 2007). Indeed, in other 
models, RNA interference (RNAi) against RIPK1 potentiates death rather than protecting from 
cell death (Dillon et al., 2014; Kearney et al., 2014). This occurs via loss of pro-survival RIPK1 
signaling that is independent of RIPK1 kinase function, but rather dependent on its ubiquitination, 
which promotes NF-κB pro-survival signaling (Festjens et al., 2007; Newton, 2015) (Figure 3.3). 
In the case of motor neurons, surprisingly both the kinase inhibition via necrostatin-1 and RNAi 
silencing of RIPK1 were protective against motor neuron death (Nagai et al., 2007). 
Given these differences between our co-culture model of motor neuron death and canonical 
necroptosis defined in the literature, the specific program invoked by motor neurons in response 
to SOD1G93A-expressing astrocytes may conserve some elements but also differ in a number of 
ways. In addition, even in the literature, studies of the downstream mechanisms executing cell 
death downstream of the necrosome remain elusive. For instance, targeted approaches have 
revealed the importance of MLKL in necroptosis downstream of RIPK3. Upon activation, MLKL 
assembles into cation-permeable pores at the plasma membrane and is thought to drive necroptosis 
by disrupting intracellular ion homeostasis (Cai et al., 2014; Wang et al., 2014; Xia et al., 2016). 
Whereas MLKL is a critical element downstream of RIPK3 in necroptosis signaling, the RIPK3-
dependent phosphoproteome is quite extensive, as one study suggested (Zhong et al., 2014), and 
downstream signaling elements and are still being uncovered beyond MLKL (Zhong et al., 2014). 
In addition, it is quite possible that MLKL pores lead to ion disturbances that then act as second-
messengers to activate downstream execution elements (Xia et al., 2016). Compared to apoptosis, 
plasma membrane permeability occurs early in necroptosis, so this certainly could be the case.  
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Often, we conceptualize that cells execute molecular programs linearly. In reality, a given 
cellular response reflects the integration of numerous signaling pathways converging. Thus, in 
light of the previous work from the Przedborski lab in collaboration with the Department of System 
Biology, I sought to use a bioinformatics meta-analysis of motor neuron RNA-Seq data to gain 
insights into the molecular network of motor neuron death in response to ALS astrocytes and to 
determine if motor neuron-specific information about necroptosis could be obtained. 
 
3.2. Results 
3.2.1. Reverse Gene Engineering to Decipher the Motor Neuron Death Pathway 
In an in vitro model, mouse ES-MN undergo cell death when exposed to ACM from transgenic 
mice expressing SOD1G93A, a mouse model of ALS (Chapter 2). In Chapter 2, I determined that 
the mechanism of the motor neuron loss, which occurs between day 3 and day 7 in in vitro culture, 
conserved core elements of necroptosis. Since mouse ES-MN behave like primary cells (Miles et 
al., 2004), can be produced in high quantities, and can be purified (Ikiz et al., 2015), they are an 
optimal system to study the molecular basis of necroptosis.  
Ikiz et al. (2015) exposed purified mouse ES-MN to either non-transgenic ACM, ACM 
from wild-type SOD1 overexpressing astrocytes (a control for overexpression but does not induce 
motor neuron loss), or ACM from SOD1G93A-expressing astrocytes (Figure 3.4). A time point of 
3 days exposure to ACM was selected because it is the point at which SOD1G93A-specific motor 
neuron loss commences in vitro, and the motor neurons are committed to cell death in response to 
SOD1G93A ACM, as replacing the media with fresh motor neuron media fails to rescue the motor 
neuron death (Ikiz et al., 2015). Furthermore, the number of differentially-expressed genes was the 
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highest at this time point between wild-type and mSOD1 ACM exposure (Ikiz et al., 2015).  
______________________________________________________________________________ 
 
Figure 3.4 Graphical Abstract from Ikiz et. al. (2015) Cell. Rep.  
Purified healthy mouse ES-MN were exposed to ACM from transgenic (Tg) SOD1G93A, wild-type SOD1 
overexpressing, or wild-type (non-Tg) astrocytes. After 3 days exposure, RNA was extracted and quantified 
using RNA sequencing. By interrogating the mouse brain interactome with the gene expression signatures 
built from RNA sequencing, candidate master regulators were identified. Candidate genes were then 
assessed in vitro on the ability of their silencing to protect against SOD1G93A specific astrocyte toxicity to 
motor neurons.  
______________________________________________________________________________ 
The approach taken by Ikiz et al. (2015) did not use gene expression profiling to look at 
altered expression in selected target genes among conditions. Instead, using RNA-Seq data 
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obtained at 3 days in vitro, relative levels of all expressed transcripts for each condition were 
quantified to generate a gene expression signature (3d-GES). Then, the entire set of transcriptional 
changes was used to infer changes in transcriptional regulators, specifically "master regulators,” 
or the transcription factors that are necessary and sufficient to explain the studied phenotype. This 
was achieved using a large dataset of known cell-specific interactions: the mouse brain interactome 
(reverse-engineered from mouse whole-brain gene expression profiles) and the Master Regulator 
Interference algorithm (MARINa) (Lefebvre et al., 2010).
 
MARINa interfaces between the 
transcriptional data and the mouse brain interactome to infer the set of master regulators that is 
statistically most likely to explain the 3d-GES. This systems approach has been validated in a 
number of cell types and contexts (Carro et al., 2010; Ikiz et al., 2015; Lefebvre et al., 2010). 
While Ikiz et al. (2015) generated and validated a number of candidate master regulators 
(MRs) of motor neuron cell death utilizing this approach, their analysis addressed a different set 
of questions than those in my current study. Here, in light of our findings using targeted approaches 
involving necroptosis machinery, I sought to determine whether there was evidence of necroptosis 
in the signature generated by Ikiz et al. (2015). 
3.2.2. The Signature Was Enriched for an Available Necroptosis Signature 
Hitomi et al. (2008) induced necroptosis in a mouse fibrosarcoma cell line (L929), and used an 
siRNA-based repressor screen to identify positive regulators of necroptosis in those cells, e.g., 
those genes that when downregulated in expression were sufficient to protect cells from zVAD-
induced necroptosis. Using the list of necroptosis drivers generated by Hitomi et al., and 
specifically those 40 genes that have neuronal expression, I discovered that the motor neuron death 
signature generated (3d-GES) by Ikiz et al. (2015) was significantly enriched for neuronal drivers 
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of necroptosis (Figure 3.5, normalized enrichment score [NES]= 6.89, p= 2.7x10-12). Importantly, 
Hitomi et al. did not perform their experiments in neurons, but rather derived the 432 genes they 
identified as zVAD-induced necroptosis drivers from L929 cells, and identified those that also are 
expressed in neurons. Despite the limitations of the list in that it may not indeed reflect the 
signaling specific to neurons undergoing necroptosis because it was derived from a cancer cell 
line, my enrichment was promising. Table 3.1 details the list of genes driving the positive 
enrichment.  
______________________________________________________________________________ 
 
Figure 3.5. The 3d-GES is Enriched for a Neuronal Necroptosis Gene Set 
Gene Set Enrichment Analysis for 40 neuron-specific necroptosis genes from Hitomi et al. (2008) on the 3d-GES. The 
maximum value of the curve determines the enrichment score. The vertical lines indicate the projection of the neuron-
specific necroptosis genes on the sorted GES. The normalized enrichment score (NES) and associated p-value is 
shown. 
______________________________________________________________________________  
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 _____________________________________________________________________________________________ 
Table 3.1 Gene Set Enrichment Analysis for 3d GES Against Known Necroptosis Drivers 
 
Legend: 40 neuron-specific necroptosis genes from Hitomi et al. (2008) indicating their differential 
expression at 3-days after mSOD1 ACM treatment (Z-score, p-value and FDR). The Ledge column 
indicates the fraction of the necroptosis genes that are in the leading-edge when their enrichment on the 
3d-GES was computed by gene set enrichment analysis. Table reproduced from Ikiz et al. (2015). 
______________________________________________________________________________ 
The genes driving the positive enrichment in the gene set in this analysis were candidates 
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for drivers of necroptosis in our model. However, I also wanted to consider in our 3d-GES the 
entire list of 432 genes Hitomi et al. identified as zVAD-induced necroptosis drivers in mouse 
L929 cells. I wanted to expand beyond the list of 40 “neuronal” drivers to also consider the 432-
gene list because I wanted to remove the database-derived bias of assuming the genes were 
expressed in neurons. Databases considering expression levels usually rely on basal conditions 
rather than what could be happening in pathological situation. In addition, the Hitomi et al. study 
was performed in 2008 and improved annotations could have been made since then. 
To expand the gene set for analysis, I filtered the list of genes in the 3d-GES that were 
increased in expression in the mSOD1 ACM condition (positive two-tail Student’s t-test statistic 
in this case), because the Hitomi et al. screen was biased for positive regulators of necroptosis 
and my assumption was that these would increase in expression in our signature. I used cutoff 
values of p<0.005 and false discovery rate (FDR)<0.05, which from consulting with colleagues 
are commonly-accepted cutoffs for this type of analysis. This generated 689 genes upregulated 
genes in the 3d-GES mSOD1 ACM condition. I then determined which genes coincided with the 
list of 432 genes Hitomi et al. identified as necroptosis drivers. Indeed, of the 26 genes that 
overlapped the Hitomi et al. screen and Ikiz et al. (2015) mSOD1-ACM responsive (increased) 
gene expression signature, 11 were not originally deemed neuronally expressed by Hitomi et al. 
(Table 3.2, indicated by “N"). An annotated table of these 26 genes is in Table 3.2.  
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Table 3.2 Necroptosis Genes Enriched in Motor Neurons Exposed to mSOD1 ACM
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Of the list, only zfp451 was a master regulator of motor neuron cell death identified by Ikiz 
et al. (2015) with FDR <0.05, and it was ranked #117 (NES= 2.86, p= 0.00423, FDR= 0.0486) 
with a predicted increase in activity (positive NES). Also, only zfp451 and jun have known roles 
as transcription factors, and nap1l3 is a nucleosome assembly factor that could be involved in 
transcriptional regulation.  
 Zfp451 (zinc finger protein 451), stood out as a transcription factor that was increased in 
the motor neuron death signature, identified as a necroptosis driver in mouse fibrosarcoma cells 
(Hitomi et al., 2008), and was identified as a master regulator of motor neuron cell death (Ikiz et 
al., 2015). In addition, the regulon of zfp451 contains inpp4a (inositol polhyphosphate-4-
phosphatase type 1), which was indeed increased in our signature and was also identified as a 
necroptosis driver by Hitomi et al. (Table 3.2). While not much is known about zfp451, its regulon, 
which contains 204 genes, was enriched in functional pathways that could be related to 
neurodegeneration and to necroptosis. Inpp4a was interesting in its own right because mutations 
in or silencing of inpp4a lead to neurodegeneration in mice, establishing a role of inpp4a in 
neuroprotection (Nystuen et al., 2001; Sasaki et al., 2010). Inpp4a protein is a phosphatase 
regulating phosphatidylinositol-3,4-bisphosphate (PTdIns(3,4)P2) that may mediate 
neuroprotection through suppression of NMDAR (N-methyl-D-aspartate-type glutamate receptor) 
mediated excitotoxicity by negatively regulating NMDAR density at the synapse (Sasaki et al., 
2010).  Furthermore, when I performed analysis using String software, among the top five Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways enriched in the zfp451 regulon were 
Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease (Table 3.3). As these are also 
neurodegenerative disorders, experimental validation is warranted to determine what relevance, if 
any, an increase in activity zfp451 could play in ALS and these other diseases. In addition, non-
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alcoholic fatty liver disease (NAFLD) was also in the top five KEGG pathways enriched in the 
regulon of zfp451 (Table 3.3). Interestingly, necroptosis has also been linked in mechanisms of 
NAFLD (Afonso et al., 2015). One clue into the mechanisms represented by the regulon of zfp451 
was the enrichment for biological process, including mechanisms involving the mitochondria and 
responses to cellular stress in the top five KEGG pathways (Table 3.4). Taken together, 
experimental validation of zfp451 in in vitro and in vivo models of ALS and necroptosis could 
provide more clues as to the link between this transcription factor and motor neuron death in ALS. 
______________________________________________________________________________ 
Table 3.3. KEGG Pathways Enriched in the zfp451 Regulon 
______________________________________________________________________________ 
Table 3.4. Biological Processes Represented in zfp451 Regulon 
______________________________________________________________________________ 
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Of those directly related to cell death, one gene of particular interest was jun, which in 
some contexts is anti-apoptotic. While jun—which encodes c-Jun, a subunit of transcription factor 
AP-1—has roles in cell cycle progression in G1, it is also involved in anti-apoptotic signaling 
through a distinct mechanism (Wisdom et al., 1999). Interestingly, in a study from Kostic et al., 
(1997), the authors used c-Jun as a cell stress marker in transgenic SOD1G93A mice and found that, 
at symptomatic stage, many spinal motor neurons exhibited a strong nuclear c-Jun 
immunoreactivity. Several years later, as a post-doctoral researcher in our lab, Diane Re infected 
cultured motor neurons with an adenovirus expressing a shRNA against c-Jun and found that 
silencing this gene target dramatically enhanced motor neuron susceptibility to astrocyte ACM; 
however, this study was never pursued in greater detail. In other settings, it has been shown that 
c-jun-deficient fibroblasts showed enhanced sensitivity to UV-induced apoptosis, and TNF-α-
induced apoptosis (when pro-survival NF-κB was also inactivated) suggesting a protective role 
(Wisdom et al., 1999). Also, c-Jun is increased in neuronal response to injury and is involved in 
promoting survival of axotomized neuronal cell bodies and axonal regeneration in facial motor 
neurons following injury (Ruff et al., 2012).  
The other genes, while not driving transcription, were predicted to be response elements. 
Cellular component analysis of the 26-gene list using String-db software identified an enrichment 
for synapse-associated proteins (cnih3, glra2, stx1a, dnm3, gabrg2, atp6v1g2, nmnat2, FDR = 
0.0063) and membrane-associated proteins (cnih3, gng2, glra2, dpp10, grb2, gabrg2, atp6v1g2, 
FDR= 0.0454).  
Whereas generating a list using transcriptionally-responsive genes as I have done could 
lead to interesting insights when compared to a known list of necroptosis drivers from the 
 
68 
 
literature, in general using transcriptionally-responsive genes is not typically very useful to identify 
true drivers of a given cellular phenotype (e.g., “master regulators”). Using the gene expression 
signature and powerful systems based techniques, the activity of key transcriptional drivers of cell 
fate changes could be inferred due to large scale changes in those responsive genes that they 
regulate (e.g., their regulon). In many cases, these key drivers themselves might not be the most 
differentially expressed genes in the signature and might be regulated through post-translational 
modifications, so their involvement could be missed in traditional screens.  
I thus quickly turned my attention to the master regulator analysis in order to gain insights 
into the drivers of the motor neuron death phenotype in our model. This analysis allowed me to 
better predict global changes mediated by master regulators, rather than comparing signatures at 
the individual transcript level, which could result in a bias toward nonspecific responsive elements 
owing to secondary effects and biological noise.   
 
3.2.3 Re-Analysis of the moto neuron signature 3d-GES  
In the time since Ikiz et al. (2015) published their report, there have been several improvements in 
the methods used to infer key transcriptional regulators based on RNA-sequencing data and a cell 
context-specific interactome. The updated virtual inference of protein activity by enriched regulon 
analysis (msVIPER) method (compared to MARINa) interrogates the mouse brain interactome 
using the RNA-sequencing data (Alvarez et al., 2016). Importantly, improvements have been made 
in the strength of the protein activity inference and the generation of a null model to infer 
candidates. The null model is an assumption of the null hypothesis that is computed using random 
shuffling of the sample labels. This takes into account variability (e.g., experimental noise) that 
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occurs from running the computational analysis itself by making multiple permutations of the data. 
By running an enrichment against the null model, if the variance between control and experimental 
is above the threshold set by the null model, e.g., the noise created from the permutations of 
randomly-shuffled data, the significance can be inferred with reduced likelihood of a false-positive 
and false-negative. Therefore, I decided rather than exploring master regulators generated by Ikiz 
et al. (2015), to re-analyze the RNA-seq data using the most updated and robust methods available. 
Additionally, it should be noted that Ikiz et al. (2015) ran an updated version of MARINa (a beta 
version of msVIPER) and thus generated a null model by permuting the samples uniformly at 
random 1,000 times in order to infer statistical significance. However, the robustness of this 
analysis was never explored. Therefore, by re-analyzing the data, I could also answer the question 
as to the reproducibility of the analysis by independent generation of the null model. 
In collaboration with Alessandro Vasciaveo, Mariano Alvarez and Andrea Califano, the 
2015 RNA-sequencing data were re-analyzed using the updated methods. All 23 of Ikiz et al. 
(2015) MRs occurred in the top 50 MRs of the re-analysis with the same predicted directionality 
of the change, but with slightly different rankings (Figure 3.6, highlighted in yellow). However, 
despite the coherence with the previous analysis, a number of novel predicted MRs of astrocyte-
mediated motor neuron cell death were identified in the new analysis that warranted consideration, 
discussed below. 
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______________________________________________________________________________ 
 
Figure 3.6. Inferred Drivers of mSOD1 Astrocyte-Induced Motor Neuron Death  
Top 50 statistically significant master regulators (MRs) (p<0.001, FDR<0.05) inferred by msVIPER analysis of the 
mouse brain interactome, using the 3-day signature of MNs exposed to mSOD1 ACM. X-axis represents all genes, 
sorted from the largest decrease to the largest increase in expression. For each MR, activated and repressed ARACNe-
inferred targets are shown as red and blue bars, respectively, to indicate that msVIPER considered them separately to 
compute MR significance. MRs are sorted from those with greatest predicted increase in activity (top) to those with 
greatest predicted increase in activity (bottom). Top 10 MRs with increase in activity were zfp697, sox5, epas1, 
zdhhc2, app, zfp235, npas2, zc3h13, prdm15, camta1. Top 10 MRs with decrease in activity were tgif2, hoxc6, zcchc3, 
nfkb1, zfp646, irx5, tcf3, hmgb2, tgif1, and gfi1. Highlighted (yellow) values indicate the previously inferred top 23 
MRs most significant by Ikiz et al. (2015). Act= activity inferred by msVIPER by absolute normalized enrichment 
score (heatmap: red=increase blue=decrease). Exp= expression of TF (z-score) expressed as heat map (red= increase, 
blue=decrease, white=no change). 
_____________________________________________________________________________________________ 
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3.2.3.1. Master Regulators with Predicted Increases in Activity  
Of the top 10 MRs that had predicted increases in activity from the new analysis, zfp697, sox5, 
npas2, zc3h13, and prdm15, were not ranked as such in Ikiz et al. (2015); therefore, their 
contributions to driving the motor neuron cell death signature were not previously discussed or 
validated. Of the top 10 MRs from the new analysis, Ikiz et al. (2015) validated epas1 and 
zdhhc2 as astrocyte-specific motor neuron death drivers, and app, zfp235, and camta1 were not 
confirmed as astrocyte-specific motor neuron death drivers.  
3.2.3.1.a. Novel master regulators with predicted increases in activity in the MN death signature 
zfp697: Not much is known about zinc finger protease-697 (zfp697), but according to the 
Allen Brain Atlas, this gene is expressed in neurons in the spinal cord of adult mice. 
sox5: SRY-related HMG-box-5 (Sox5) has known roles in nervous system development 
and affects the proliferative capacity of neuronal progenitors. It is involved in cell fate and 
promotes terminal differentiation, e.g., cell cycle exit, of neurons in the chick spinal cord, and was 
found to be expressed by islet 1/2+ dorsal interneurons and a small subpopulation of the islet 1/2+ 
motor neurons (Martinez-Morales et al., 2010). 
npas2: Neuronal PAS Domain Protein 2 (Npas2) positively regulates cell survival in cancer 
cells by leading to a cascade of events that inhibit apoptosis through transcriptional upregulation 
of CDC25A, a phosphatase that dephosphorylates CDK2/4/6 and Bcl-2 (Yuan et al., 2017). Npas2 
has been shown to positively regulate cell cycle and DNA repair genes in the context of cancer 
(Hoffman et al., 2008). According to the Allen Brain Atlas, there is a neuronal pattern of expression 
in adult mouse brain, and it is present in the spinal cord at low levels in neurons. In neurons it has 
been shown to be a circadian clock responsive element (Reick, 2001). 
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zc3h13: Zinc Finger CCCH-Type Containing 13 (Zc3h13) positively regulates NF-κB 
activation, as knockdown of zc3h13 inhibited NF-κB activation following LMP1, TNF-α and IL-
1β stimulation in HEK293 cells. In addition, MLKL was important for NF-κB activation 
downstream of LMP1 and IL-1β activation (Gewurz et al., 2012). According to genecards 
databbase zc3h13 is expressed in the spinal cord.  
prdm15: PR/SET Domain 15 (Prdm15) has an unknown function but is expressed in the 
mouse spinal cord in neurons according to the Allen Brain Atlas. 
3.2.3.2. Master Regulators with Predicted Decreases in Activity 
Of the top 10 MRs from the new analysis that had predicted decreases in activity, tgif2, hoxc6, 
zcchc3 and gfi1 were not ranked as such in Ikiz et al. (2015), and therefore their contribution to 
driving the motor neuron cell death signature was not discussed or validated. However, of the same 
top 10 MRs, Ikiz et al. (2015) validated nfkb1, tcf3, and tgif1 as astrocyte-specific motor neuron 
death drivers, and zfp646, irx5, and hmgb2 were not confirmed as astrocyte-specific motor neuron 
death drivers. 
 
3.2.3.2.a. Novel master regulators with predicted decreases in activity in the MN death signature 
tgif2: Loss of both TGF-β Induced Factor Homeobox 1 (Tgif1), previously validated by 
Ikiz et al. (2015) as a master regulator of astrocyte-specific motor neuron death, and Tgif2 in mice 
is lethal on some backgrounds (Melhuish et al., 2016). Tgif1/Tgif2 are transcriptional repressors 
of TGF-β signaling, so if the activity of Tgif1/Tgif2 was predicted to decrease, which could mean 
that TGF- β signaling is active in motor neurons undergoing cell death.  
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hoxc6: Homeobox C6 (Hoxc6) is a determinant of motor neuron pool diversity within the 
LMC of the spinal cord during development (Lacombe et al., 2013).  
zcchc3: Not much is known about Zinc Finger CCHC-Type Containing 3 (Zcchc3), but it 
is neuronally expressed in mouse spinal cord according to the Allen Brain Atlas. 
gfi1: Gfi-1 inhibits NLRP3 inflammasome activation and proinflammatory signaling in 
macrophages. NLRP3 inflammasome activation is an intrinsic signal upstream of RIPK3 that 
mediates the proinflammatory role of RIPK3 rather than cell death through extrinsic activation of 
necroptosis through a death receptor (Lawlor et al., 2015). Downregulation of gfi1 was shown to 
promote inflammation-linked metastasis of colorectal cancer (Xing et al., 2017). Gfi-1 was also 
shown to inhibit apoptosis and inflammation in a Bax-dependent manner (Grimes et al., 1996). 
During TGF-β signaling, Gfi-1 is downregulated (Chalmin et al., 2012). The transcript is not 
highly expressed in mouse spinal cord neurons according to the Allen Brain Atlas. 
 
3.2.3.3. Emerging Themes in the Astrocyte-Mediated Motor Neuron Cell Death Signature 
3.2.3.3.a. NF-κB activity  
Besides NFkB1 itself (one of the NF-κB subunits) predicted as being a driver of the motor neuron 
death signature, validated by Ikiz et al., zc3h13 may also positively regulate the NF-κB signaling 
pathway (Gewurz et al., 2012). There have been links to NF-κB signaling in neurodegeneration, 
but namely in a protective role of activation rather than a deleterious role (Mattson and Meffert, 
2006). It remains unclear why experimental validation showed that reducing levels of NF-κB or 
inhibiting its activity was neuroprotective in this case. However, some evidence has accumulated 
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that under conditions of cellular stress, NF-κB could promote cell death. One mechanism proposed 
is that under stress conditions, the RelA subunit of NF-κB translocates to the nucleolus and 
promotes apoptosis through promoting nucleophosmin (Npm) translocation to the cytoplasm, 
which in turn mediates mitochondrial accumulation of Bax (Khandelwal et al., 2011). Given that 
Bax was instrumental in our model, this was an interesting avenue to explore. 
3.2.3.3.b. TGF-β signaling  
Three of the top predicted drivers of motor neuron cell death were involved in TGF-β signaling 
according to the literature, namely Gfi1, and Tgif1/Tgif2. The predicted decreased activity of these 
three elements was consistent with an increase in TGF-β signaling based on their roles, as I 
discussed, in that tgif1/tgif2 both repress TGF-β signaling, and Gfi-1 is downregulated in response 
to TGF-β signaling. Furthermore smad3, which was in the top 11 MRs with increased activity in 
mSOD1 condition, was indeed activated by TGF-β signaling (Derynck and Zhang, 2003).  
Despite much of this evidence in the signature pointing toward TGF-β activation, I did not, 
however, detect TGF-β in sALS astrocyte-conditioned medium by ELISA (absorbance450<0.01). 
So if there was evidence of increased TGF-β signaling in response to astrocytes in our model, it 
might be due to ligand-independent increase in activity. TGF-β signaling downstream of receptor 
activation is highly regulated by SMAD proteins binding to microtubules; one study showed 
activated TGF-β transcriptional pathways independent of treatment with exogenous TGF-β when 
microtubules were destabilized (Dong et al., 2000).  
TGF-β signaling has a number of cellular functions, including promoting neurogenesis 
during development. There has been some evidence that reduced TGF-β signaling in neurons 
contributes to age-dependent neurodegeneration in a model of Alzheimer’s disease (Tesseur et al., 
 
75 
 
2006). There is also a degree of crosstalk between TGF-β signaling and NF-κB, mediated by TAK1 
kinase (TGF-β activated kinase 1) and SMAD7 (Bitzer et al., 2000; Freudlsperger et al., 2013).  
3.2.3.3.c. Motor neuron development and maturation 
A number of predicted drivers of motor neuron cell death were involved in motor neuron 
development and diversity, including Hoxc6, Sox5. In addition, Hoxa9 was not in the top 10 but 
was in the top 50 predicted MRs of motor neuron death, and it also functions in motor neuron 
differentiation during development. In addition, although the link to motor neurons is less clear, 
tgif1 and tgif2 are also known homeobox proteins with roles in development. It is unclear what 
role, if any these factors may play post-development. One proposed mechanism of neuronal death 
is that paradoxical re-activation of cell cycle machinery in neurons may act as a cell death signal 
(Greene et al., 2004, 2007). 
There is a notion that under conditions of normal stress, mitotic cells have a tendency to 
re-enter the cell cycle. However, in neurons, which are post-mitotic, this attempt at re-entry is a 
failed event and one possible mechanism of neurodegeneration. This is just one example whereby 
a tightly-controlled developmental physiological mechanism could by a pathological process 
become re-activated and detrimental. 
Pathological reactivation could also tie in the involvement of Npas2, which has known 
roles in cell cycle regulation, although it is not a homeobox protein. Indeed, as NPAS2 has been 
shown to regulate the cell cycle in mitotic cells via a CDC25A-dependent mechanism (Yuan et al., 
2017), CDC25A was indicated in neurons as a response element to genotoxic stress, and 
expression of CDC25A was shown to promote cortical neuron cell death even in the absence of 
DNA damage (Zhang et al., 2006).  
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Another similar yet independent possibility is that neurons under stress conditions start to 
reduce levels of mature markers of differentiation in order to conserve energy from transcription 
and translation. Mature neurons may be more resistant to cell death than immature neurons (Kole 
et al., 2013). This transition in turn could re-activate elements involved in cell fate and maturation 
and explain that what we were seeing was a consequence of the cells under stress that eventually 
succumb to cell death.  
 
3.3. Discussion 
3.3.1. Summary of Key Findings 
3.3.1.1. Necroptosis Activation in ALS Differs from Other Models of Necroptosis 
While motor neuron death in response to ALS-associated astrocytes may involve necroptosis core 
machinery such as RIPK1, RIPK3, and MLKL, upstream activators or downstream executioners 
of cell death may be specific to motor neurons compared to other cellular models. In looking for 
known ligands and receptors at the plasma membrane that have been known to engage necroptosis 
downstream machinery in some conditions, none of the conserved elements including TNF-α, Fas, 
TRAIL, or IFNγ seemed to be involved in our co-culture model. We have yet to explore TWEAK 
in our model, but others have shown that there is some level of TWEAK expressed by both wild-
type and mSOD1 astrocytes. However, it did not seem to be necessary for the death of motor 
neurons in vivo as pharmacologic or genetic inhibition of TWEAK did not rescue motor neuron 
loss in SOD1G93A animals (Bowerman et al., 2015). Other key differences with canonical 
necroptosis activation was that Bax was instrumental in our model of motor neuron death, NF-κB 
 
77 
 
signaling led to cell death rather than survival or inflammation, and RIPK1 was not necessary for 
motor neuron cell survival in addition to having a role in cell death. 
 
3.3.1.2. Reverse Gene Engineering to Decipher Motor Neuron Death Pathway 
At the transcriptional level, the motor neuron death signature generated (3d-GES) by Ikiz et al. 
was significantly enriched for neuronal drivers of necroptosis. I also generated a list of genes that 
are both upregulated in the motor neurons after exposure to mSOD1 ACM and were identified as 
drivers of necroptosis in L929 cells by Hitomi et al. (2008). Using updated techniques, I re-
analyzed the 3d-GES by Ikiz et al. (2015) by reverse gene engineering and identified new candidate 
master regulators that could be driving motor neuron cell death. Three themes emerged from the 
list of motor neuron death drivers: NF-κB was activated, TGF-β signaling seemed to be activated, 
and genes involved with motor neuron development and activation were activated. The role of 
these mechanisms, whether they were activated as a neuroprotective response, or indeed driving 
death, will need to be explored in future studies. 
Determining the activation status of TAK1 during motor neuron death could be another 
interesting lead to follow. TAK1 activation can follow both TGF-β and TNF-α activation of 
surface receptors (Freudlsperger et al., 2013). Following TNF-α activation, TAK1 could lead to 
NF-κB activation through phosphorylation of IKK in a RIPK1-dependent manner (Ea et al., 2006). 
TAK1 activation can also play a role in RIPK3-mediated necroptosis after TNF receptor 
stimulation depending on the cellular context (Morioka et al., 2014). Given that we saw evidence 
of NF-κB and TGF-β signaling and necroptosis activation in our model, and TAK1 was involved 
in the activation of all three of these pathways, evaluating the status of and/or requirement for 
activation of TAK1 kinase during ALS astrocyte-mediated motor neuron death could provide 
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another clue into the mechanism.  
 
3.3.2. Validation of Candidates and Exploration of Themes 
The candidates I have identified were inferential and require biological validation in future studies 
to determine relevance. Candidates will first be validated for their effects on motor neuron death 
markers and survival using pharmacologic approaches (when available), and genetic approaches 
such as viral-mediated shRNA knockdown. If the candidate activity is known to be regulated by 
enzymatic modifications (phosphorylation, cleavage, ubiquitination, etc.), their activation state 
will be verified during the time course of mSOD1 astrocyte-mediated motor neuron death. Then, 
the most promising candidates will be validated in vivo using knock out animal breeding or viral 
infection of motor neuron pools with shRNA in SOD1G93A mice. Together, these results will 
educate future studies on motor neuron cell death in ALS.  
 
3.3.3. Are Developmental Cell Death Programs at Play in ALS?  
A number of motor neuron cell death drivers were identified that are involved in neuronal 
patterning during development. What role, if any, could these factors play in ALS 
neurodegeneration? Whether these are a consequence of cellular stress or actual drivers of the 
motor neuron death would need to be explored. Another clue comes from Bax. Motor neurons 
undergo natural developmental death (~40% loss) during development and patterning of the spinal 
cord (Hamburger, 1992). Whereas targeting necroptosis or apoptosis alone does not prevent the 
developmental cell death of motor neurons in the spinal cord as in mouse models (Kanungo et al., 
2008; Oppenheim et al., 2001), there are no increases in the number of motor neurons observed, 
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and in Bax knockout mice the developmental death of motor neurons is prevented (White et al., 
1998). Perhaps Bax is necessary for more than one mode of motor neuron cell death. In many 
cellular contexts, when apoptosis is blocked, necroptosis occurs as a backup mechanism. If Bax is 
a common element in both apoptosis and necroptosis, then its elimination would be sufficient. It 
is interesting that in both the context of development and in pathologic motor neuron cell death 
(Gould et al., 2006), Bax is the most potent inhibitor of motor neuron cell death, meaning that it is 
likely not involved in canonical apoptosis alone.  
 
3.3.4. Exploiting the Motor Neuron Cell Death Signature in the Context of Necroptosis 
These studies also raise the question: If knocking down NFkB1 phenocopies blocking RIPK1 
kinase, what is the link between RIPK1 and NFkB1 regulation? By analyzing a motor neuron death 
transcriptome, Ikiz et al. (2015) identified potential drivers of motor neuron death. However, any 
response to ALS astrocyte-conditioned medium would be reflected in the signature, even a 
protective response rather than a driver of death. Experimental validation could eliminate those 
false leads. However, by first fully enriching the signature only for those elements that respond in 
a necroptosis-dependent manner (e.g., a “necroptosis-dependent gene expression signature”), this 
could be a more optimal approach. Given what we know about necroptosis in motor neurons and 
the differences that exist between our model of motor neuron death and classical apoptosis, and 
the limited models of the necroptosis transcriptome in the literature, such an analysis would greatly 
contribute both to our knowledge of motor neuron cell death and to identify new downstream 
mechanisms of necroptosis that have not been explored. 
In order to elucidate the necroptosis-dependent gene expression signature of motor neuron 
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cell death, I would perform the same experiment as Ikiz et al. (2015) by exposing purified mouse 
ES-MN to ACM from mSOD1-expressing astrocytes, but with or without the inhibition of 
necroptosis via pharmacologic targeting of RIPK1 or genetic targeting of RIPK3. Then using a 
similar rationale, we could extract only those motor neuron death drivers enriched in the 3 day 
ACM signature that are reverted by inhibition of necroptosis.  
The proposed study would identify motor neuron drivers of necroptosis and could be a 
useful approach to both answer the question as to the motor neuron-specific death program 
downstream of RIPK1 and tie together our data on Bax and NF-κB involvement. The proposed 
study could also generate new leads relevant for both motor neuron cell death and necroptosis 
mechanisms downstream of the necrosome. One attempt was made to generate the necroptosis-
dependent gene expression signature of motor neuron cell death during my thesis, but too many 
samples failed to meet quality control criteria, and thus could not be used.  
A second limitation to this work was using the whole brain interactome to study 
necroptosis. Unless this interactome was subjected to a necroptosis-relevant perturbation during 
its assembly, I cannot be sure that it captured the actual network of necroptosis. In addition, 
because the interactome was whole mouse brain and not specific to motor neurons, it might not be 
the most optimal interactome to fit the data in a cell-specific manner. Future studies would use a 
motor neuron-specific interactome if one becomes available. In addition, this motor neuron-
specific interactome would ideally include exposure to a necroptosis-relevant perturbation during 
its assembly. The same RNA-seq data generated by Ikiz et al. (2015) could be rerun using the 
motor neuron-specific interactome, as well as the new RNA-seq data generated by the 
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aforementioned proposed experiment to generate a necroptosis-dependent gene expression 
signature of motor neuron cell death after exposure to ALS astrocytes.  
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Chapter 4: Immunoreagents to Study Necroptosis 
 
4.1. Introduction 
Necroptosis is a newly-recognized form of necrosis that is molecularly controlled (Degterev et al., 
2005, 2008). Thus far it has been primarily studied in the field of immunology, in which it was 
discovered (Holler et al., 2000) by inducing cell death in in vitro systems with TNFα and using 
pan-caspase inhibitors such as zVAD-fmk, which has a high affinity for caspase-8 (Garcia-Calvo 
et al., 1998). Through these model systems, it was discovered that three key modular factors, 
namely RIPK1, RIPK3 and MLKL were driving the death process following a stereotypical 
cascade of events that can be summarized as follows. Upon death signal, RIPK1 becomes 
phosphorylated, which in turn recruits and phosphorylates RIPK3. RIPK3 then recruits and 
phosphorylates MLKL, which is believed the be the actual death effector of necroptosis by 
anchoring within the cell plasma membrane where it forms permeable pores leading to cell 
destruction (Cai et al., 2014; Chen et al., 2014; Su et al., 2014; Wang et al., 2014). While these 
deleterious events seem quite well documented, at least in vitro and in non-neuronal cells, I 
participated in a series of in vitro investigations, reported in the previous chapters, that provided 
compelling evidence supporting the notion that at least some of the core components of necroptosis 
may be conserved in neurons, and specifically motor neurons. While quite promising, a major 
limitation of the data presented in the previous chapters was that they all provided insight into a 
mode of cell death in an in vitro model system that was developed to emulate ALS in which the 
key cellular element, i.e., motor neurons, were immature (Ikiz et al., 2015; Re et al., 2014). Thus, 
a main outstanding question is whether necroptosis is a cell death mechanism by which mature 
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motor neurons die in vivo in the context of ALS. Relevant to this question is the recent study from 
Ito et al. (2016) in which the authors provided a host of immunoblot and immunocytochemical 
data consistent with necroptosis being involved in ALS pathogenesis. However, this study focused 
on the role of necroptosis in the activation of microglial inflammation, death of oligodendrocytes 
and ensuing axonopathy in two mouse models of ALS, but surprisingly failed to examine the 
potential role of this form of programmed necrosis in the demise of motor neurons, which has been 
the focus of my work. Accordingly, the goal of this chapter, built on the previous data generated 
by the Przedborski laboratory on neuronal necroptosis (see previous chapters) and on the Ito et al. 
study (2016), was to study the expression and status of RIPK1, RIPK3, and MLKL in a mouse 
model of ALS with emphasis on spinal cord and, more specifically, motor neurons. 
 
4.2. Results 
In Chapter 4, I focused my efforts on determining the status of the three key molecular 
determinants of necroptosis, at least as known in the immunological field, namely RIPK1, RIPK3 
and MLKL. The studies were conducted primarily in transgenic SOD1G93A mice, which represent, 
up to now, the most extensively-validated and recognized mouse model of ALS. I began Chapter 
4 by quantifying mRNAs for each of the aforementioned factors in the spinal cord of transgenic 
SOD1G93A mice. I then extended my work to their respective proteins to confirm that these core 
elements of necroptosis were expressed and detectable in the mouse spinal cord and to determine 
if the ALS-related disease process did alter their expression. I chose the spinal cord rather than the 
motor cortex, which also has motor neuron death in ALS, because lumbar spinal cord is the most 
well-studied and most affected area in the SOD1G93A mouse model.  
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4.2.1. Necroptosis mRNA Levels  
Although expression of RIPK1, RIPK3 and MLKL in peripheral blood cells and other organ 
systems been well established (Newton and Manning, 2016), their expression in whole tissue of 
the CNS has been scarcely studied (Degterev et al., 2005; Ito et al., 2016; Kanno et al., 2015; 
Ofengeim et al., 2015). Indeed, recently, Fagerberg et al. (2014) used quantitative transcriptomics 
to analyze relative levels of protein coding transcripts across human tissues. While they did not 
test spinal cord, they did use brain, and indeed while present, mRNA levels of RIPK1, RIPK3, and 
MLKL were relatively low compared to other organs (Fagerberg et al., 2014). In addition, Wang 
et al. (2016)  looked at relative levels of RIPK3 mRNA and protein in various wild-type mouse 
tissues, and found the lowest levels in brain tissue compared to other organs (Wang et al., 2016). 
Wu and collaborators (2013) surveyed MLKL protein levels in various mouse tissues, and found 
undetectable levels in several organs including the brain (Wu et al., 2013).   
Thus, I wanted to determine whether I could detect RIPK1, RIPK3, or MLKL mRNA 
transcript levels in the spinal cord of wild-type mice and, if this was the case, compare levels with 
those assessed in symptomatic transgenic SOD1G93A mice to determine whether the mutant SOD1-
induced disease process, which affects most severely the spinal cord in this model, might be 
associated with changes in the expression of these specific factors.  
 For these proposed experiments, I used RT-qPCR, which can detect as little as 1-10 copies 
of a given mRNA, so that if there were very low levels of transcripts and/or small magnitude of 
changes, in a small subset of cells in the spinal cord, I might be in an optimal position to detect 
them; I understood though that if I detected such small changes, the challenge would be to 
demonstrate their pathological significance.  
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To do these experiments, I extracted RNA from the lumbar spinal cords of symptomatic 
SOD1G93A mice and age and strain-matched controls at 15 weeks. After generating cDNA by 
reverse transcription, I ran quantitative PCR using primers against RIPK1, RIPK3 and MLKL and 
used the transcript for the housekeeping GAPDH gene as a normalization control. 
 
4.2.1.1. RIPK1, RIPK3, and MLKL mRNAs were detected in the mouse spinal cord 
In whole spinal cord extracts from wild-type mice, the presence of RIPK1, RIPK3 and MLKL 
transcripts were consistently detected with average CT values of 26.05, 32.17, and 29.94, 
respectively, with average ΔCT of 9.08, 15.05, and 12.82 compared to GAPDH, respectively. 
Transcripts detected with CT values below 30 were generally accepted to be expressed, while those 
above 30 and especially above 35 were low abundance and easily affected by contamination of 
samples or reaction side-products. Although CT values for RIPK3 and MLKL were high, 
amplification curves showed product was being produced, and melting curves showed specificity 
of the primers to a single product (Figure 4.1, a-c). One confirmation that the CT value for RIPK3, 
although high, was reflecting specific signal was the use of the same primer against spinal cord 
sample from RIPK3KO mice with homozygous germline deletion of RIPK3 gene. Indeed, the CT 
value for RIPK3 in those mice was 35.26 and the ΔCT compared to GAPDH was 18.08, indicating 
a 6.6-fold reduction compared to wild-type mice and that at least part of the signal detected in 
wild-type spinal cord was specific for RIPK3. This was consistent with my findings in in vitro 
studies using spinal cord primary cultures; whereas CT values were consistently high for RIPK3 
and MLKL, when using targeted shRNA lentiviral vectors to reduce the transcript I would 
consistently see higher CT values and relative fold reductions in RIPK3 and MLKL (data not 
shown). This led me to conclude that, although low, some specificity of signal was being detected.  
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For comparison, using the same RT-qPCR conditions and methods, expression of RIPK3 
in wild-type spleen had a CT of 25.4, with a ΔCT compared to GAPDH of 6. Assuming GAPDH 
was similarly expressed in spinal cord and spleen, this would suggest that RIPK3 was more than 
500-fold less abundantly expressed in wild-type spinal cord compared to spleen. This was very 
approximate because a more optimal comparison would typically use multiple housekeeping genes 
and run the RT-qPCR in parallel “within run” for both tissues, if not an unbiased and absolute 
quantitative RNA-seq method. Nonetheless this approximate fold difference demonstrated that the 
levels of RIPK3 in wild-type mouse spinal cord were quite low and approaching the detection 
limits of the reaction.  
For comparison of MLKL, expression of MLKL in L929 cells, which are known to express 
high levels of MLKL and readily undergo necroptosis, had a CT of 24.3 for MLKL and 6.98 ΔCT 
compared to GAPDH. This suggested, again by rough approximation, that in the spinal cord MLKL 
was more than 50-fold less abundantly expressed.  
4.2.1.2. RIPK1, RIPK3, and MLKL mRNAs were increased in the spinal cord of symptomatic 
SOD1G93A mice 
In whole spinal cord extracts from 12-week-old, early symptomatic transgenic SOD1G93A 
mice, the presence of RIPK1, RIPK3 and MLKL transcripts were consistently detected with CT 
values of 31.51, 32.11, and 28.82, respectively, and ΔCT compared to GAPDH of 14.01, 14.61, 
and 11.32, respectively. Transcripts in age-matched controls were detected at CT of 31.34, 33.30, 
and 28.95 and ΔCT compared to GAPDH of 13.84, 11.45, and 15.80, respectively.  
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Figure 4.1 qPCR Amplification and Melting Curves for RIPK1 RIPK3 and MLKL 
Male mice aged 12 weeks were perfused with ice-cold PBS and their spinal cords were dissected. RNA was extracted 
from the tissue and 1 µg of RNA was used per reaction to reverse-transcribe into cDNA for qPCR. Individual lines 
represent individual reactions. Graphs show aggregate data from three replicate reactions of all samples used in the 
12 weeks analysis (NTg n=2, SOD1G93A n=3). a-b. Real-time quantitative qPCR amplification curve (x-axis= time in 
cycles, y-axis= fluorescence) using SYBR-green detection methods and primers against RIPK1, RIPK3, MLKL and 
GAPDH. c. Melting curve analysis shows a single peak for RIPK1, RIPK3 and MLKL primed reactions [x = 
temperature, y= decrease in fluorescence/time (top) or fluorescence (bottom)] 
 
These values indicate that RIPK1 mRNA levels were not changed the spinal cord of 12-
week-old symptomatic SOD1G93A mice as compared to age-matched wild-type controls (two-tailed 
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Student’s t-test, df=4, p= 0.14, Figure 4.2, a). Likewise, MLKL mRNA levels were not changed 
(two-tailed Student’s t-test, df=4, p=0.8, Figure 4.2, c). As for RIPK3 mRNA levels, they were 
2.15-fold higher in the spinal cord of symptomatic SOD1G93A mice as compared to age-matched 
wild-type controls (two-tailed Student’s t-test, df=4, p= 0.4, Figure 4.2, b). 
In whole spinal cord extracts from 15-week-old symptomatic transgenic SOD1G93A mice, 
the presence of RIPK1, RIPK3 and MLKL transcripts were consistently detected with CT values 
of 25.68, 31.73, and 29.72, respectively, and ΔCT compared to GAPDH of 8.45, 14.31, and 12.29, 
respectively. Age-matched controls were detected at CT of 27.76, 32.1675 and 29.935 and ΔCT 
compared to GAPDH of 9.085, 15.05 and 12.82, respectively.  
These values indicated that RIPK1 mRNA levels were 1.55-fold greater in the spinal cord 
of symptomatic SOD1G93A mice as compared to age-matched wild-type controls (Figure 4.2, d). 
Likewise, RIPK3 mRNA levels were 1.67-fold greater in the spinal cord of symptomatic 
SOD1G93A mice as compared to age-matched wild-type controls (Figure 4.2, e). As for MLKL 
mRNA levels, they were 1.45-fold greater in the spinal cord of symptomatic SOD1G93A mice as 
compared to age-matched wild-type controls (Figure 4.2, f). Unfortunately, I did not have enough 
wild-type control tissue at this time point to have n=3 for each condition, so I could not determine 
statistical analysis. However, I could conclude that the RT-qPCR results suggested that spinal 
cords of symptomatic SOD1G93A mice showed either unchanged or higher transcript levels for the 
three core components of necroptosis, not lower. Such modest increases in mRNA transcript may 
not be biologically relevant. I explore this question in part II and III to look at whether the protein 
products of these three genes were in fact increased as a result.  
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______________________________________________________________________________ 
 
Figure 4.2 Increases in mRNA of Core Necroptosis Components RIPK1, RIP3, and MLKL in 
Symptomatic Mouse SOD1G93A Spinal Cord 
Male mice at 12 (n=3 NTg, n=3 SOD1G93A) or 15 (n=2 NTg, n=3 SOD1G93A) weeks postnatal age were perfused with 
ice-cold PBS and lumbar spinal cords were dissected out and used for RNA extraction, preparation of cDNA, and 
qPCR. Using primers against RIPK1, RIPK3, and MLKL and housekeeping gene GAPDH, the results were the 
following: In the SOD1G93A spinal cord at 12 weeks, there was no change in levels of RIPK1 (a, p= 0.14) or MLKL (c, 
p=0.80) mRNA, but there was a 2.15-fold increase of RIPK3 (b, p=0.04). In the SOD1G93A spinal cord at 15 weeks 
(symptomatic) d. RIPK1 mRNA was increased 1.55-fold, e. RIPK3 mRNA was increased 1.67-fold, and f. MLKL 
mRNA increased 1.45-fold. Two-tailed Student’s t-tests were performed).  
______________________________________________________________________________ 
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Therefore, in this section I showed that RIPK1, RIPK3, and MLKL transcript were detected in 
mouse spinal cord, however the levels of RIPK3 and MLKL transcript were quite low. I also 
showed modest increases for RIPK1, RIPK3, and MLKL transcript in the spinal cord of 15 weeks 
symptomatic SOD1G93A mice, but only RIPK3 was increased at an earlier time point of 12 weeks.  
 
4.2.2. Validation of Antibodies Against Necroptosis Proteins for Immunoblot 
Now that I determined that RIPK1, RIPK3 and MLKL mRNAs were expressed in mouse spinal 
cord, even if they were at low levels, I decided to examine whether their respective products could 
be detected in the mouse spinal cord by using available immunoreagents that have been used in 
several published studies (Ito et al., 2016; Miao and Degterev, 2009; Ofengeim et al., 2015; Orozco 
et al., 2014).  
However, in reviewing these different papers, I was struck by the fact that few, even as part 
of supplementary data, included any validation of these different antibodies for western blot, 
except in the case of RIPK1 (Moujalled et al., 2013; Orozco et al., 2014), but not 
immunocytochemistry, leaving me with only the material provided by the commercial vendors. 
Though I selected the antibodies based on extensive use in publications, it thus appeared essential 
to me to formally validate the selected antibodies (see Table 4.1) for their use in both immunoblot 
and immunohisto-/immunocyto-chemistry prior to embarking on the actual studies in ALS mice.  
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______________________________________________________________________________ 
Table 4.1 Antibodies Against Necroptosis Core Elements Selected for Validation 
Legend: “Validation (in house)” = for western blotting 
______________________________________________________________________________ 
Before validation, and because I had in hand commercially-available lysate for use as 
positive controls for western blotting, I ran some of the antibodies against this lysate in order to 
ensure I was using optimal detection methods to reveal my bands of interest, and more importantly, 
to determine whether the antibodies cleanly detected a single band or detected many bands of 
various weights, as can occur when antibodies recognize proteins other than those against which 
they were raised. I had mouse NIH3T3 lysate, which is known to express RIPK1 and MLKL, but 
not RIPK3 (He et al., 2011; Sun et al., 2012). I ran two MLKL and two RIPK1 antibodies against 
the NIH3T3 lysate (Figure 4.3, a-d). I also ran RIPK1 antibodies against human Jurkat cell lysate 
(Figure 4.3, c-d), as these two antibodies were raised against a fragment of human RIPK1 protein 
(Table 4.1), and although there is sequence similarity between mouse and human RIPK1, I wanted 
to be certain that if I did not see a band in mouse, it was not because the antibody failed to recognize 
mouse RIPK1. I did not use MLKL antibodies or RIPK3 antibodies against the Jurkat lysate 
because both were raised against mouse protein (Table 4.1), the product sheets did not indicate 
their use in human, and in all future experiments I would be using these antibodies against mouse 
tissue. The results were the following: both MLKL antibodies detected just one prominent band at 
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the expected molecular weight of MLKL at 54 kD (Figure 4.3, a-b), and both RIPK1 antibodies 
detected just one prominent band at 74 (mouse NIH3T3) or 76 (human Jurkat) corresponding to 
the predicted molecular weight of RIPK1 protein (Figure 4.3, c-d). Assuming these bands were 
specific, I concluded I was using optimal detection methods for both RIPK1 and MLKL proteins 
via western blot. In addition, these four antibodies did not recognize other proteins in the control 
lysate (Figure 4.3, a-d). Therefore, I confidently continued with further validations using negative 
controls to ensure specificity of the prominent band for each antibody. 
 
4.2.2.1. Validation of RIPK1-Specific Antibody for Western Blot   
I chose two RIPK1 antibodies to validate. One was chosen based on its validation in the literature 
for western blot (He et al., 2009; Orozco et al., 2014) and the other because of its previous use in 
mouse spinal cord samples for western blot (Ito et al., 2016). However, it had not been validated 
with positive and negative controls. In order to validate RIPK1 antibodies for immunoblot, I 
decided to silence RIPK1 in E12.5 primary spinal culture from a wild-type mouse using a lentiviral 
vector expressing a validated RIPK1 shRNA. Cells were isolated, infected by spinoculation as I 
have done before (Re et al., 2014), and cultured. Four days post-infection, RNA was extracted and 
used for RT-qPCR. With this approach, I found that this silencing procedure produced a 78% 
knockdown of RIPK1 transcript (Figure 4.4, c), which I thought should be sufficient to detect a 
change in RIPK1 protein. From the same cells, protein lysate was extracted and used for 
immunoblot, using two different antibodies, which both revealed one prominent band 
corresponding to ~74 kDa in both cells infected with RIPK1 shRNA and non-mammalian control 
shRNA (Figure 4.4, a-b, 4.4, d-e). In the immunoblot loaded with proteins from the former, I 
noticed a 51% reduction of the band that corresponded to ~74 kDa using the first antibody (Figure 
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4.4 a, b), and 66% reduction using the second antibody (Figure 4.4, a-b) which is consistent with 
the molecular weight of RIPK1 protein.  
______________________________________________________________________________ 
 
Figure 4.3 Using Control Cell Lysates as Positive Controls to Test Antibodies Against RIPK1 and 
MLKL 
a-d: 20 ug per lane of protein extract from mouse NIH3T3 cells or human Jurkat cells (whole cell lysates in sample 
buffer purchased from Abgent, Inc. San Diego, CA) was separated by SDS-PAGE and transferred to nitrocellulose 
membrane. After blocking with blocking buffer for fluorescent western blotting (Rockland Immunochemicals, 
Limerick, PA) membranes were probed overnight at 4°C in blocking buffer with the indicated primary antibodies 
against MLKL and RIPK1. The next day, membranes were washed 3x with 0.1% Pbst and probed with infrared probe-
conjugated secondary antibodies, washed 3x with 0.1% Pbst, and were imaged by the Li-cor Odyssey Imaging System.  
______________________________________________________________________________ 
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Figure 4.4 RIPK1 Antibodies were Validated for Western Blot Using Spinal Cord Primary 
Cultures  
Primary neuronal cultures from mouse embryo E12.5 were prepared infected with lentivirus containing shRNA against 
RIPK1 by spinoculation exactly as previously described (s et al., 2014) and plated for 4 days in culture, after which 
RNA and protein was extracted a. Western blot for RIPK1 (BD Biosciences, Clone 38/RIP) comparing lysate from 
control (CTL) or cells infected with shRNA-containing virus against RIPK1 (RNAi) shows a 51% decrease in intensity 
in the 74 kD band quantified in b. c. qPCR quantification of RIPK1 RNAi shows 78% reduction in RIPK1 mRNA d. 
Western blot for RIPK1 (Cell Signaling, clone D49C12) shows a 66% reduction in the 74 kD band intensity quantified 
in e. 30 ug of protein was used per lane. 
______________________________________________________________________________ 
 
4.2.2.2. Validation of RIPK3-Specific Antibody for Western blot 
Thus, I followed a similar approach to identify and validate a RIPK3 antibody that was recently 
used to detect RIPK3 protein in mouse spinal cord for immunoblot (Ito et al., 2016). Given the low 
levels of RIPK3 transcript in the spinal cord, as I saw in part I, I turned my attention to the spleen, 
a known organ with high levels of RIPK3 mRNA and protein. Using spleen from adult wild-type 
or mice with homozygous germline deletion of RIPK3 (RIPK3KO), which are known to not 
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express RIPK3 (Newton et al., 2004), I tested the specificity of the antibody for western blot. Some 
of these RIPK3KO mice were perfused with ice-cold phosphate buffered saline (PBS) to remove 
the blood prior to extracting RNA from the spleen, and this material was used to confirm by RT-
qPCR the lack of RIPK3 transcript (Figure 4.5, c).  
Upon running immunoblots with spleen proteins from both wild-type and RIPK3KO mice 
using ECL detection methods, I observed two prominent bands, one at 47 kD and one at 55 kD, 
and a smear between 47 and 55 kD (Figure 4.5, a). The prominent band around 55 kDa, which is 
consistent with RIPK3 known molecular weight, was markedly less visible in RIPK3KO using 
ECL detection methods (Figure 4.5, a) and even absent when using Li-cor detection (Figure 4.5, 
d). It is possible that the lower molecular weight bands seen below the 55 kD band were 
degradation or cleavage products, though the prominent 47 kD band was not consistent with the 
predicted (~36 kD) or observed (~39 kD) reported C-terminal RIPK3 cleavage product generated 
by caspase-8 at Asp328 of the RHIM domain (Feng et al., 2007). 
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Figure 4.5 A RIPK3 Antibody was Validated for Western Blot by Comparing Spleen Protein 
Extract from Wild-type or Mice with Germline Deletion in RIPK3 
Adult mice, either wild-type or with germline deletion of RIPK3 [RIPK3KO obtained from Genentech (Newton et al., 
2004)], were perfused with ice-cold PBS and the spleen was dissected. Protein was extracted and prepared for western 
blot under denaturing conditions, and RNA was extracted and prepared for qPCR. a. Western blot using RIPK3 
primary antibody (Cell Signaling, #15828) and ECL detection methods showed a marked reduction in a 55 kD band 
in RIPK3KO spleen tissue quantified in b. c. qPCR using primers against RIPK3 and housekeeping gene GAPDH 
showed a 100% reduction in RIPK3 mRNA d. Western blot using RIPK3 primary antibody (Cell Signaling, #15828) 
and the Li-cor Odyssey Imaging System showed undetectable levels in the 55 kD band in RIPK3KO spleen tissue. 
______________________________________________________________________________ 
 
mouse spleen 
mouse spleen 
 
97 
 
4.2.2.3. Validation of MLKL-specific Antibody for Western Blot 
Using a similar rationale, I identified two MLKL antibodies in the literature, one because of its use 
for multiple western blots in a recent publication showing a very clear high-intensity band (Yoon 
et al., 2016), and the other because it was used recently to detect MLKL in mouse spinal cord (Ito 
et al., 2016). Both MLKL antibodies that I identified had shown a clean band against mouse 
NIH3T3 lysate at expected molecular weight 54 kD (Figure 4.3). However, because both 
antibodies were rabbit polyclonal against mouse C-terminal MLKL (Table 4.1) and one was a 
product of Sigma, I suspected that they could be in fact the same, meaning generated from the 
same animal, because they are polyclonal, as Sigma is a purchasing partner of Abgent’s antibodies. 
Although I could not get a clear answer from Sigma, a representative at Abgent confirmed that 
these two products are likely the same based on product notes. Therefore, I continued with the 
validation of the antibody from Abgent, since the it likely originated from there, and the product 
page listed the specifics about the region of the protein used as an immunogen (Table 4.1), so I 
was more certain about what region of the protein I was detecting.  
Here, I knocked down MLKL transcript in mouse L929 cells, a necroptosis-sensitive 
fibrosarcoma cell line known to express high levels of MLKL protein, by using a lentiviral vector 
expressing shRNA against MLKL. As above, after 4 days, RNA was extracted and used for RT-
qPCR for MLKL transcript. Although I found that my silencing strategy gave only a 65% reduction 
of MLKL transcript (Figure 4.6, c), I decided to pursue my validation with this reagent as I thought 
that this moderate reduction in MLKL mRNA may suffice to have a meaningful impact on the 
expression of its product. Consistent with my assumption, I found that there was a 48% reduction 
in the intensity of a band localized on the immunoblot at around 54 kDa (Figure 4.6, a-b), which 
is consistent with the known MLKL molecular weight. No other bands were observed on the 
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immunoblot, providing encouragement that this antibody may be suitable for the planned 
experiments.  
______________________________________________________________________________ 
 
Figure 4.6 An MLKL Antibody and a P-MLKL Antibody were Validated for Western Blot Using 
Mouse L929 Cultures 
a-c. Mouse L929 cell line cultures were plated and 24 hours later lentivirus containing shRNA against MLKL (Sigma 
Mission # 360819) was applied for 4 days at MOI 100, after which RNA and protein was extracted a. Western blot 
using MLKL primary antibody (Abgent, Inc.) showed a 48% reduction in band intensity in a 54 kD band quantified 
in b. c. qPCR quantification of MLKL RNAi showed 65% reduction in MLKL mRNA  
d-e. L929 cells were treated with human recombinant TNF-α (30 ng/mL), smac mimetic (TL-32711) (100 nM) and 
zVAD-fmk (20 µM) (TSZ) for 1 hour and protein was extracted. d. Western blot showed a 6-fold increase in a 54 kD 
band in the TSZ-treated cells quantified in e.  
______________________________________________________________________________ 
 
4.2.2.4. Validation of phospho-MLKL-Specific Antibody for Western Blot 
Lastly, I validated the only commercially-available mouse MLKL phospho-serine 345 antibody 
(Table 4.1), a site that is phosphorylated during necroptosis signaling. Thus, to induce necroptosis 
β-actin 43 kD 
β-actin 43 kD 
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in mouse L929 cells, I exposed these cells to TNFα, smac mimetic (TL-32711), and caspase 
inhibitor zVAD-fmk treatment (TSZ), a treatment known to induce necroptosis in L929 cells (He 
et al., 2009) the kinetics of which were recently further characterized by Ros et al. (Ros et al., 
2017). I predicted that the phosphorylated MLKL band would be more intense in the immunoblot 
following necroptosis induction compared to control cells. First, to confirm necroptosis induction 
using this method, cells were live-imaged at 8 hr post-treatment using Hoescht (blue) to count the 
number of cells present in the dish as well as propidium iodide (PI) (red) to quantify the number 
of dying cells that have lost plasma membrane integrity and therefore would readily take up the 
dye (Figure 4.7). After 8 hr, no live cells remained on the plate in the TSZ-treated group compared 
to control (Figure 4.7). Necroptosis was confirmed as the cell death mechanism by using 
necrostatin-1, as indeed, at 8 hr post co-treatment with necrostatin-1 and TSZ, the number of 
Hoescht positive nuclei were close to that of the control condition, although there were some PI 
positive cells (Figure 4.7). Because all of the cells were dead in the TSZ alone condition, in order 
to extract protein, I used an earlier time point, i.e., 1 hr after TSZ addition. Indeed, this is similar 
to the kinetics recently reported by Ros et al. (Ros et al., 2017) that showed necroptosis induction 
at 1-hour post TSZ treatment in L929 cells. L929 control cell protein extract and 1-hr TSZ-treated 
were used for immunoblot. A band at 54 kDa consistent with phospho-MLKL protein molecular 
weight was observed to be increased 6-fold in TSZ-treated cells (Figure 4.6, d-e). Other less 
prominent bands were observed on the blot as well, but none were increased in the TSZ condition 
(data not shown). These results support the usefulness of this immuno-reagent even if given the 
other bands detected, its value for immunohisto/immunocytochemistry is uncertain. Therefore, I 
successfully validated antibodies against mouse RIPK1, RIPK3, MLKL, and phosphorylated 
MLKL for use in western blot. 
 
100 
 
______________________________________________________________________________ 
 
Figure 4.7 Necroptosis Induction in L929 Cells 
L929 cells were treated with human recombinant TNF-α (30 ng/mL), smac mimetic (TL-32711) (100 nM) and zVAD-
fmk (20 µM) (TSZ) with or without necrostatin-1 (20 µM) for 8 hours and incubated with propidium iodide (red) and 
hoescht (blue) for 15 minutes at 37°C, washed, and live imaged using fluorescent microscopy. 
______________________________________________________________________________ 
 
4.2.3. Signs of Core Necroptosis Factors Activation in the Spinal Cord of SOD1G93A Mice 
Using the immunoblot-validated antibodies discussed above, I wanted to now see whether I could 
find evidence of necroptosis protein activation in the spinal cord of symptomatic SOD1G93A mice. 
A reasonable assumption would be that if necroptosis was ongoing, protein levels of the core 
necroptosis proteins RIPK1, RIPK3, and MLKL would increase as a result of their stabilization 
due to their assembly in the necroptosome complex (Li et al., 2012) and based on what others have 
reported (Ito et al., 2016; Ofengeim et al., 2015). In order to better assess activation of necroptosis, 
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rather than simple upregulation of protein levels, I also looked for signs of increased MLKL 
phosphorylation using the phosphoserine 345 specific antibody validated in Part I. For the 
following studies, lumbar spinal cord protein extract from adult symptomatic SOD1G93A (15 
weeks) and age-matched, background strain-matched controls were used to assess necroptosis 
protein levels and activation by immunoblot.  
 
4.2.3.1. RIPK1 Levels Increase in the Spinal Cord of Symptomatic SOD1G93A Mice 
Consistently, I detected the validated RIPK1 band in the wild-type spinal cord extracts (Figure 
4.8). Interestingly, there was a two-fold increase in RIPK1 band intensity in the symptomatic 
SOD1G93A mice compared to wild-type mice (two-tailed Student’s t-test, df=4, p=0.0037) (Figure 
4.8, a-b).  
______________________________________________________________________________ 
Figure 4.8 RIPK1 Protein Levels are 
Increased in Symptomatic SOD1G93A 
Mouse Spinal Cord 
Male B6/SJL mice at 15 weeks postnatal age (n=3 
NTg, n=3 SOD1G93A) were perfused with ice-cold 
PBS and lumbar spinal cords were dissected out and 
protein was extracted in RIPA lysis buffer (150 mM 
NaCl, 25 mM Tris pH 8.0,1% Triton X-100, 0.5% 
sodium deoxycholate, 1 mM ETDA, 0.1 % SDS, 
protease inhibitor cocktail and phosphatase inhibitor 
(Sigma, cOmplete™, PhosSTOP™)). a. western blot 
using RIPK1 antibody (BD Biosciences, Clone 
38/RIP) and b. quantification showed a two-fold 
increase in intensity of the RIPK1 band at 74 kD in 
the SOD1G93A spinal cord lysate (two-tailed Student’s 
t-test, df=4, p=0.0037) 60 ug of protein per lane of 
protein was loaded. 
______________________________________________________________________________  
 
β-actin 43 kD 
 
102 
 
4.2.3.2. RIPK3 is Undetectable in the Mouse Spinal Cord 
In contrast to RIPK1, I did not detect RIPK3 protein in wild-type nor in symptomatic SOD1G93A 
mice even by loading 50-60 µg of protein per lane and by using the most sensitive technical 
available to me, i.e., ECL detection method (Figure 4.9, a-c). I identified the most prominent band 
observed, at 52 kD, as nonspecific as it is much lower than any predicted molecular weight for 
RIPK3 and did not run at the same level as the positive control (Figure 4.9, a-c). The nonspecific 
nature of this band was confirmed by using spinal cord extract from RIPK3KO mice (Figure 4.9, 
b-c).  
I also know that this negative result was not attributable to my protein preparation as I tried 
a variety of lysing conditions, ranging from commercially-available tissue lysis buffer, RIPA 
buffer, to urea-containing lysis buffers, and based on published protocols (Afonso et al., 2015; Ito 
et al., 2016; Miao and Degterev, 2009) used for the study of necroptosis. Using lysis buffer 
containing 6 M urea, the most stringent that I tried, again detected RIPK1 in the spinal cord of 
both wild-type and SOD1G93A mice (Figure 4.10, a). Because I did not observe the increase that I 
saw at 15 weeks, I re-affirmed these findings using RIPA lysis buffer to extract protein at 12 weeks, 
and found similar results, with no quantified increase in RIPK1 protein (Figure 4.10, b-c). As this 
tissue was taken at 12 weeks, and I did not see an increase in RIPK1, it suggested that the increase 
I observe at 15 weeks might be concomitant with disease progression. These results correlated 
with observed mRNA expression, in that in part 4.2.1.2. I observed an increase in RIPK1 mRNA 
at 15 weeks but not 12 weeks. This suggested that the observed increase in RIPK1 protein could 
in part be due to transcriptional upregulation. More protein samples, at 12 weeks, and at additional 
time points during disease progression, would be needed to confirm this, but it was interesting to 
note that the increase in RIPK1 I observed at 15 weeks could be a result of a more advanced 
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pathology at that age. Nonetheless, this further validated that the 6 M urea-containing lysates I 
prepared were suitable to detect the proteins of interest. When I ran the RIPK3 antibody I validated 
in part 4.2.2.2. using the sensitive ECL method and 50 ug of protein per lane against the wild-type 
and 12 weeks SOD1G93A samples, I saw a prominent band around 52 kD, and a fainter band at ~70 
kD, neither of which disappear in lysate from RIPK3KO mice, so I concluded that both were 
nonspecific (Figure 4.10, d). 
As the last recourse, I could try to enhance the RIPK3 signal if its spinal cord content is so 
low by subjecting the extracts first to an immunoprecipitation step and then run the immunoblot. 
However, I did not pursue this option as I was doubtful that even if positive, such a low amount of 
RIPK3 protein could be sufficient to have a meaningful pathological significance, and notably, 
immunoprecipitation is not as amenable to quantifying differences in protein levels between 
individual samples. Instead, I thought that a more fruitful approach would be to cross the 
RIPK3KO mice with the transgenic mSOD1 mice and see if the absence of RIPK3 would have a 
disease-modifying effect; this experiment is presented in Chapter 5. 
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Figure 4.9. RIPK3, MLKL, and P-MLKL Protein Levels Were Undetectable in Symptomatic 
SOD1G93A Mouse Spinal Cord 
a, d-e: Male B6/SJL mice at 15 weeks postnatal age (n=3 NTg, n=3 SOD1G93A) were perfused with ice-cold PBS and 
lumbar spinal cords were dissected out. Protein was extracted in RIPA lysis buffer [150 mM NaCl, 25 mM Tris pH 
8.0,1% Triton X-100, 0.5% sodium deoxycholate, 1 mM ETDA, 0.1 % SDS, protease inhibitor cocktail and 
phosphatase inhibitor (Sigma, cOmplete™, PhosSTOP™)]. a. Western blot using RIPK3 antibody (Cell Sig. Clone 
D8J3L) showed no signal at 55 kD compared to wild-type spleen control. d. Western blot using MLKL antibody 
(Abgent) showed no signal at 55 kD compared to NIH3T3 cell lysate control. e. Western blot using P-MLKL antibody 
(Abcam, #196436) showed no signal at 55 kD compared to TSZ-treated L929 cell lysate control. b-c: Protein from 
male C57Bl/6 mice at 19 weeks age (n=1 SOD1G93A, n=1 RIPK3KO/SOD1G93A) was extracted as in a. b. Western blot 
using RIPK3 antibody (Cell Sig. Clone D8J3L) showed no signal at 55 kD compared to wild-type spleen control and 
nonspecific band at 50 kD did not change in intensity in RIPK3KO/SOD1G93A. c. Higher exposure of b. showed similar 
results. 60 ug of protein per lane was loaded of the spinal cord lysate, 25 ug of protein was loaded for the spleen tissue 
lysate, NIH3T3 lysate, and TSZ-treated L929 lysate.  
______________________________________________________________________________ 
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Figure 4.10. RIPK3, MLKL, and P-MLKL Protein Levels Were Undetectable in Early 
Symptomatic SOD1G93A Mouse Spinal Cord 
Male B6/SJL mice at 12 weeks postnatal age (n=1 NTg, n=1 SOD1G93A) were perfused with ice-cold PBS and lumbar 
spinal cords were dissected out. Protein was extracted in urea lysis buffer [6 M urea, 50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 1% NP-40, 1 mM EGTA, 50 mM NaF, 10 mM b-glycerophosphate, 5 mM sodium pyrophosphate, 1 mM 
sodium orthovanadate, 1 mM benzamidine, 1 mM PMSF, 5 mM N-ethylmaleimide, 1 mM DTT, protease inhibitor 
cocktail and phosphatase inhibitor (Sigma, cOmplete™, PhosSTOP™)] according to Ito et al. (2016). a-b. Western 
blot of spinal cord (a) RIPA (b) urea lysate using the indicated RIPK1 antibodies and c. quantification of b. d-e. 
Western blot of spinal cord urea lysate using the indicated antibodies and RIPK3KO (RIPK3 negative control) and 
NIH3T3 lysate (MLKL positive control). 50 ug of protein per lane was loaded of the spinal cord lysate 25 ug per lane 
of NIH3T3 lysate. 
______________________________________________________________________________ 
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4.2.3.3. MLKL Was Likewise Undetectable in the Mouse Spinal Cord 
I encountered a similar situation for MLKL as for RIPK3 in that I did not detect MLKL protein in 
wild-type nor symptomatic SOD1G93A mice, even when loading 50-60 ug of protein per lane. 
Lysate from NIH3T3 cells, which are known to express high levels of MLKL, was run as an in-
run positive control and showed high signal at 54 kDA using the same antibody validated in Part 
I (Figure 4.9, d). No other bands of different sizes were detected on the blot. (Figure 4.9, d). This 
again, as for RIPK3, raised the same question as to whether the protein levels of MLKL in the 
spinal cord were very low and under the detection limit of the validated immunoreagent.  
Again, I tried running using several other published protein preparations, the most stringent 
of which was 6 M urea-containing lysis buffer, using sensitive ECL detection methods, and using 
both MLKL antibodies that showed me a clean band at the expected molecular weight in the 
NIH3T3 lysate (Figure 4.10, e). Again, I saw a nonspecific band at 52 kD that was much less 
prominent and ran below the very prominent 54 kD band in the NIH3T3 lysate (Figure 4.10, e). In 
fact, using the urea lysis buffer and ECL detection methods, for whatever reason, I often saw this 
nonspecific band at 52 kD, as well as a faint band at ~70kD, both of which were also observed in 
the RIPK1 and RIPK3 immunoblot from the same lysate (Figure 4.10, a, d, e). This further led me 
to conclude that these two bands were not specific.  
 
4.2.3.4. Phosphorylated MLKL Levels Were Undetectable in the Mouse Spinal Cord 
Although in the absence of MLKL protein detection cited above, I could have omitted the study 
of phospho-MLKL in our mouse spinal cord extracts. However, I thought it may still be worth 
exploring as the phospho-MLKL antibody may be more sensitive than the c-terminal MLKL 
antibody and that detection of a small trace of phospho-MLKL would still be highly significant. 
 
107 
 
I did not detect phosphorylated MLKL protein in wild-type nor symptomatic SOD1G93A 
mice (Figure 4.9, e). A band that ran lower than 52 kD, at around 50 kD, was observed but 
concluded to be nonspecific as it ran slightly lower than the positive control band in the lysate 
from necroptosis-induced L929 cells (Figure 4.9, e). This was not surprising because I also could 
not detect total MLKL in the spinal cord as even a faint band. The antibody against total MLKL 
did not detect a region that contains the phosphorylation site (see Table 4.1) so the likelihood that 
there would be inhibition of this antibody to detect a subset of phosphorylated MLKL was low, so 
if there was a subset of phosphorylated MLKL it could theoretically also be detected in the total 
MLKL blot and it was not.  
In this section, using the reagents I validated for western blotting, RIPK1 showed a modest 
but significant increase in protein levels in the spinal cord of symptomatic SOD1G93A mice 
compared to controls. However, RIPK3 and MLKL levels were undetectable by western blotting 
in the same samples, even loading high levels of protein per lane and using high stringency buffers.  
 
4.2.4. Detecting Necroptosis Proteins in Human ALS Patient Samples  
In light of the increase in RIPK1 in the spinal cord of SOD1G93A, I was curious to see if similar 
RIPK1 alteration could be detected in postmortem tissue from sporadic and SOD1 ALS patients. 
While I did not have readily-available patient spinal cord tissue, I was kindly provided with brain 
homogenate from Broadmann’s area 4, which contains the motor cortex, from patients with 
sporadic ALS, SOD1 ALS, and age-matched control patients. The samples were a gift from and 
previously prepared as described by Erin Conlon (Conlon et al., 2016) in collaboration with the 
Shneider Lab at Columbia University. I prepared protein extracts under denaturing conditions 
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using equivalent amounts of sample. Patient history, when available, is described for each sample 
in Table 4.2. 
______________________________________________________________________________ 
Table 4.2 ALS Patient Samples History 
______________________________________________________________________________ 
4.2.4.1. RIPK1 in Human Samples  
Using two different antibodies against RIPK1, one validated in part II that also recognizes human 
RIPK1 (recall Jurkat extracts), and one that has been extensively validated in the literature for 
human RIPK1 (Luan et al., 2015)(Miao and Degterev, 2009), I looked for changes in RIPK1 
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protein between the samples. Both antibodies detected a band at 76 kD, consistent with RIPK1, 
and a slightly higher and much fainter band (not shown) at 80-85 kD, the identity of which is 
unknown (Figure 4.11, a,b). While I found consistent results between the two antibodies (Figure 
4.11, a-c), what I found was that levels of RIPK1 were variable across all samples, with no clear 
trend among patients. For example, there was no correlation with higher levels in the ALS patient 
samples compared to controls, as high and low expressers were seen in both pools (Figure 4.11, a-
c). I also did not see an obvious correlation with patient history; those patients with higher levels 
of RIPK1 did not necessarily have a more aggressive disease (Table 4.2, Figure 4.11 a-c).  
However, because these samples were taken postmortem, and because RIPK1 has roles in 
necrosis and necroptosis in response to ischemia, it is possible that the samples had baseline levels 
of necrosis and or necroptosis, from the exposure to ischemic conditions in the tissue at the time 
of death (Degterev et al., 2005; Vieira et al., 2014). Therefore, even in the control patients the 
protein profile may not reflect the status of the tissue before losing blood supply. Postmortem 
samples may not be ideal to detect changes between patients in these particular proteins involved 
in cell death for this reason. Interestingly, it was recently found that significant transcriptional 
upregulation can occur postmortem, especially in the brain (Pozhitkov et al., 2017), and that many 
of the transcripts upregulated during the first hour encode proteins that are involved in cell death 
and inflammation.  
The RIPK3 and MLKL antibodies which I validated in part II were not optimal for use 
against the human proteins as they recognized mouse epitopes (Table 4.1). In the future, I could 
obtain and validate human RIPK3 and human MLKL-specific antibodies to test their levels in 
these samples. What would be even better would be to obtain a phosphorylation-specific human 
MLKL antibody, which is commercially available and has been used by other groups, as this would 
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reflect an activation state rather than simply upregulation of the protein. However, given the 
aforementioned caveats of using postmortem samples, and the lack of detection of these proteins 
in the mouse tissue, this was not explored in the current work.  
______________________________________________________________________________ 
 
Figure 4.11. Measuring RIPK1 Levels in Postmortem Brain Cortex (Broadmann’s Area 4) 
Protein lysate was prepared as described in (Conlon et al., 2016) from pulverized human brain from motor cortex 
(Broadmann’s area 4) in lysis buffer (0.1 M MES (pH 7), 1 mM EDTA, 0.5 mM MgSO4, 1 M sucrose, 50 mM N-
ethylmaleimide, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF and 10 µg/ml each of aprotinin, leupeptin and pepstatin) at 
18 ul/ mg of tissue. ~4 uL of soluble homogenate was loaded per lane. Samples lanes are labeled as according to Table 
4.2. a-b Western blot on samples was performed using the indicated RIPK1 antibodies and c. quantification of relative 
band intensity between samples. 
______________________________________________________________________________ 
β-actin (43 kD) 
β-actin (43 kD) 
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I did, however have an antibody against human phosphorylated-RIPK3, kindly provided 
by Jiahuai Han at Xiamen University, China, whose group previously validated the antibody (Chen 
et al., 2013) against phosphorylated threonine 231/serine 232, a site which promotes MLKL 
interaction and necroptosis (Chen et al., 2013, 2015; McQuade et al., 2013). Using this antibody, 
I did get a band at 55 kD corresponding to the molecular weight of phosphorylated RIPK3, but the 
levels of that band, if specific, were the same across all samples (Figure 4.12).  
______________________________________________________________________________ 
 
Figure 4.12. Measuring p-RIPK3 Levels in Postmortem Brain Cortex (Broadmann’s Area 4) 
Protein lysate was prepared as described in (Conlon et al., 2016) from pulverized human brain from motor cortex 
(Broadmann’s area 4) in lysis buffer (0.1 M MES (pH 7), 1 mM EDTA, 0.5 mM MgSO4, 1 M sucrose, 50 mM N-
ethylmaleimide, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF and 10 µg/ml each of aprotinin, leupeptin and pepstatin) at 
18 ul/ mg of tissue. ~4 uL of soluble homogenate was loaded per lane. Samples lanes are labeled as according to Table 
4.2. a-b Western blot on samples was performed using anti=human phospho-RIPK3 (threonine 231/serine 232) 
antibodies generated by (Chen et al., 2013) and c. quantification of relative band intensity between samples.  
______________________________________________________________________________ 
β-actin (43 kD) 
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4.2.5. No Antibodies Against Necroptosis Were yet Identified as Suitable for Immunostaining 
I was very curious to see which cell types were responsible for the mRNA and protein expression 
patterns in the mouse wild-type and symptomatic SOD1G93A spinal cord. Given the increase on 
whole spinal cord tissue I observed in RIPK1 protein in symptomatic SOD1G93A, I was curious to 
see, as per my original hypothesis from the conclusions of Chapters 2 and 3 in vitro studies, 
whether necroptosis proteins were indeed increased in motor neurons in vivo in the context of 
motor neuron degeneration. I could not exclude the possibility that the increased RIPK1 content 
in the whole spinal cord tissue of symptomatic transgenic SOD1G93A mice I observed did not reflect 
changes in other cells, such as glial cells rather than in motor neurons.  
 I focused my studies on the expression of RIPK1, in particular, because it is the only one 
of the three core factors I was able to detect in mouse spinal cord tissue at reasonable levels by 
western blot. Thus, I first sought to confirm whether the two antibodies validated for western 
blotting were indeed suitable for detection using immunohistochemistry. Then, I would use the 
antibodies to stain tissue sections of spinal cord from wild-type and symptomatic SOD1G93A mice. 
 
4.2.5.1. Western Blot-Validated RIPK1 Antibodies Did Not Show Specific Signal for 
Immunostaining in Same Cell Culture used for Western Blot and qPCR 
First, in order to identify antibodies that may be suitable for immunostaining against RIPK1, cells 
from the same spinal cord primary culture that was used to validate RIPK1 antibody specificity on 
western blot (Figure 4.4) were also fixed on coverslips and stained with the two antibodies against 
RIPK1 that showed specificity via western blot in Figure 4.4. The product sheets available for 
these antibodies indicated they could be suitable for use in immunostaining. While there was some 
faint signal present for both antibodies that required relatively high exposure via fluorescent 
 
113 
 
microscopy to capture (in the seconds rather than milliseconds), by taking pictures at the same 
exposure time, there was no change in this signal between control cells and cells with 50% 
reduction in the western blot band, 78% reduction in RIPK1 transcript (Figure 4.13, a-b). I 
confirmed that the cells were prepared properly for immunostaining by co-staining with anti-GFP 
antibody, which labels motor neurons in this culture as they are from a motor neuron promoter 
(HB9) GFP reporter line. Representative images are shown of motor neurons stained with anti-
GFP antibody in the same culture (Figure 4.13, c). Therefore, I did not conclude that these 
antibodies could be used with confidence, and so I did not identify a suitable antibody to detect 
RIPK1 protein via immunostaining. Since I did not have the advantage of having a negative control 
for RIPK1 in vivo in the spinal cord, as germline deletion of RIPK1 is early postnatal lethal, even 
if I stained spinal cord, I would not know with certainty that the staining was specific based on this 
experiment.  
 
4.2.5.2. No RIPK3-Specific Antibody Was Identified as Suitable for Immunohistochemistry to 
Detect RIPK3 in the Spinal Cord of Wild-type and Symptomatic SOD1G93A mice 
Even though I did not detect RIPK3 in whole spinal cord protein lysate, it was possible that a small 
number of cells expressed RIPK3 and therefore did not enrich enough in the pooled sample to 
detect. Therefore, I was very interested to see if I could detect RIPK3 in the spinal cord of animals, 
especially in symptomatic SOD1G93A mice. As for identifying a suitable antibody, I had the 
advantage of having mice with homozygous germline deletion for RIPK3, which I further 
confirmed do not express RIPK3 in previous sections II and III, which served as a negative control. 
I also had the advantage of a recent study demonstrating an increase in RIPK3 immunostaining in  
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______________________________________________________________________________ 
 
 
Figure 4.13 RIPK1 Antibodies Did Not Show Specific Signal for Immunostaining in Mouse Primary 
Spinal Cord Cultures  
Primary neuronal cultures from mouse embryo E12.5 were prepared infected with lentivirus containing shRNA against 
RIPK1 by spinoculation exactly as previously described (Re et al., 2014) and plated for 4 days in culture, after which 
RIPK1 knockdown was validated by western blot and qPCR (Figure 4.3), and cells were fixed on coverslips and a-b 
immunostained for RIPK1 using the indicated antibodies or c. GFP, which labels motor neurons in this culture (GFP 
reporter under HB9 promoter). No change in RIPK1 immunostaining was observed by fluorescence microscopy.  
______________________________________________________________________________ 
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the mouse spinal cord in a spinal cord injury model (Kanno et al., 2015). This study indicated no 
or little RIPK3 immunostaining in wild-type mouse spinal cord, but an increase in signal following 
spinal cord hemi-transection compared to sham surgery. They reference a rabbit RIPK3 antibody 
from Sigma, and, I concluded that this was #2283 as it was the only mouse-specific RIPK3 
antibody offered by Sigma that was suggested for use for immunostaining. Sigma purchases this 
antibody clone from ProSci, and so I used the ProSci #2283 product for my experiment. Based on 
the results generated by Kanno et al. (2015), I assumed that I might not detect RIPK3 in adult wild-
type mouse spinal cord using this antibody. Therefore, I decided to compare levels of RIPK3 
immunostaining in the spinal cord of symptomatic SOD1G93A mice either on a wild-type 
background or a RIPK3KO background. My assumption was that, if RIPK3 protein did increase 
in this model in a subset of cells, as suggested by the modest increase in RIPK3 transcript I 
measured, I would be in optimal conditions to detect the signal, and should see no signal in the 
RIPK3KO tissue. I also did compare wild-type mice to RIPK3KO mice, with the assumption that 
if I did see a signal in wild-type mice it might not be specific for RIPK3 based on Kanno et al. 
study not measuring RIPK3 signal in wild-type animals. Using the same antibody and similar 
tissue preparation and staining protocol reported by Kanno et al. (2015), I did see faint signal in 
all four of these conditions, mostly labeling neurons based on their morphology and nuclei, but 
there was no change in this signal between wild-type background or RIPK3KO background, in 
neither the non-transgenic or SOD1G93A-expressing animals, indicating that this staining I observed 
was not specific for RIPK3 (Figure 4.14, a-h).  
Based on these results, and identifying off-target signal using this antibody, I had the idea 
to run an immunoblot with this new antibody using NIH3T3 lysate, which as I mentioned in section 
II, should not express RIPK3 (He et al., 2011; Sun et al., 2012). Indeed, while the validated RIPK3 
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antibody from section II (Cell Sig. D8J3L), showed no signal, the new RIPK3 ProSci #2283 
antibody used by Kanno et al. (2015) showed many prominent bands in the same lysate and using 
the same immunoblotting conditions, which should be nonspecific due to the reported lack of 
RIPK3 in this lysate (Figure 4.15, a). This further indicated to me that this antibody was not 
suitable for western blotting, nor was it suitable for immunostaining due to many off-target 
interactions.  
Unfortunately, the RIPK3 antibody I validated for western blot (Cell Sig. D8J3L) was not 
indicated on the product sheet as suitable for immunostaining, so I did not try this, although I could 
in a future study. One additional experiment I could do to be absolutely certain of my results would 
be to induce the spinal cord injury in mice as Kanno et al. (2015) have done, to have an optimal 
positive control. Nonetheless, I concluded so far that I have not yet identified an antibody that 
shows specific immunostaining for RIPK3 in vivo.  
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______________________________________________________________________________ 
 
Figure 4.14 No RIPK3-Specific Immunohistochemistry Labeling in the Ventral Horn 
Male B6/SJL mice at 17 weeks postnatal age, NTg, SOD1G93, RIPK3KO/NTg, RIPK3KO/ SOD1G93 perfused with 
PBS followed by 4% paraformaldehyde and lumbar spinal cord was dissected and post-fixed overnight at 4°C. 
Samples were embedded in 10% sucrose/gelatin and flash frozen and 20 micron sections were cut at the cryostat and 
mounted on slides. Sections were immunostained with RIPK3 antibody (ProSci #2283) and choline acetyltransferase 
(ChAT) antibody (Millipore, AB144P). 
______________________________________________________________________________ 
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Figure 4.15 RIPK3 Antibody Recognizes Many Nonspecific Bands on Western Blot 
a. 20 ug per lane of protein extract from mouse NIH3T3 cells (whole cell lysate in sample buffer purchased from 
Abgent, Inc. San Diego, CA) was separated by SDS-PAGE and transferred to nitrocellulose membrane. After blocking 
with blocking buffer for fluorescent western blotting (Rockland Immunochemicals, Limerick, PA) membranes were 
probed overnight at 4°C in blocking buffer with the indicated primary antibodies against the indicated RIPK3 
antibodies. The next day membranes were washed 3x with 0.1% Pbst and probed with infrared probe-conjugated 
secondary antibodies, washed 3x with 0.1% Pbst and membranes were imaged by the Li-cor Odyssey Imaging System. 
______________________________________________________________________________ 
 
4.3. Discussion 
In this chapter, I performed an extensive validation of immunoreagents raised against core factors 
of necroptosis. This task was prompted by the realization that a growing number of publications 
are reporting quite convincing immunoblot and immunohistochemical and immunocytochemical 
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data in a variety of pathological situations including non-neurological such as steatohepatitis 
(Afonso et al., 2015b) and neurological such as multiple sclerosis (Ofengeim et al., 2015) and more 
recently ALS (Ito et al., 2016). In light of these studies, it was quite tantalizing to try to use these 
reagents to study necroptosis in ALS, but by focusing at the protein and cellular levels in both 
animal models and even postmortem samples from ALS patients. While Ito et al. (2016) proposed 
a role for necroptosis in ALS by showing activation in oligodendrocytes and microglia (Ito et al., 
2016), surprisingly there was no report on whether necroptosis is activated in motor neurons to 
drive cell death, as my previous in vitro data suggests.  
 Here, I showed that RIPK1, RIPK3, and MLKL transcripts were detected in mouse spinal 
cord, however the levels of RIPK3 and MLKL transcript were quite low. I also showed modest but 
significant increases for RIPK1, RIPK3, and an increasing trend in MLKL transcript in the spinal 
cord of symptomatic SOD1G93A mice, the site of motor neuron neurodegeneration in these animals.  
I then validated immunoreagents to study levels of RIPK1, RIPK3, and MLKL in the spinal 
cord of symptomatic SOD1G93A mice. While I found suitable reagents and conditions for 
immunoblotting of RIPK1, RIPK3, MLKL and necroptosis-specific phosphorylated MLKL, I did 
not yet identify suitable immunoreagents to study necroptosis at the cellular level in vivo in mouse 
tissue, despite the reports of others.  
Using the reagents, I validated for western blotting, RIPK1 showed a modest but significant 
increase in protein levels in the spinal cord of symptomatic SOD1G93A mice compared to controls. 
However, RIPK3 and MLKL levels were undetectable by western blotting in the same samples, 
even loading high levels of protein per lane and using high stringency buffers. I cannot exclude 
that RIPK3 and MLKL were indeed present but below the level of detection by western blotting. 
This was not entirely surprising, as in the case for RIPK3, I estimated that based on my qPCR 
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results the mRNA was enriched in spinal cord at 500-fold less than in the spleen, where it is 
abundantly expressed. Likewise, for MLKL, the mRNA was expressed 50-fold less than in L929 
cells where it is abundantly expressed. If RIPK3 and MLKL proteins were indeed present, they 
were likely expressed in a small number of cells that did not enrich the whole spinal cord extract 
enough to detect on western blotting, and/or were expressed at low levels throughout the tissue. 
My finding that RIPK3 and MLKL transcript and protein levels were low in the mouse 
spinal cord in part support the findings of Kanno et al. (2015) whereby there was no detection of 
RIPK3 protein in the spinal cord of adult wild-type mice by immuno labeling. These findings were 
also supported by Wang et al. (Wang et al., 2016), who by studying relative levels of RIPK3 
mRNA and protein in various wild-type mouse tissues, found the lowest levels in brain tissue 
compared to other organs. In addition, Wu et al. (Wu et al., 2013) surveyed MLKL protein levels 
in various mouse tissues, and found undetectable levels in several organs including the brain (Wu 
et al., 2013).  This directly calls into question the abundant signal observed by Ito et al. (2016) for 
RIPK3, MLKL, and phospho-MLKL in the spinal cord of both wild-type and early-symptomatic 
SOD1G93A mice.  
My results led me to question whether, given such low levels of RIPK3 and MLKL protein, 
necroptosis could play a meaningful role in the mechanism of motor neuron death in SOD1G93A 
mice. However, this conclusion is fraught with assumptions. First, assuming that necroptosis does 
indeed play a role in motor neuron death in ALS, one important point to make is that motor neuron 
death is not synchronous in this model. The degeneration and death occurs over a period of time, 
so that at any one given time, only a subset of motor neurons in the spinal cord are in the same 
window of cell death. Second, it is only an assumption, based on what others have shown, that 
levels of necroptosis proteins would increase based on necroptosis activation, rather than signaling 
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through post-translational modifications alone, e.g., phosphorylation-mediated signal 
transduction. Third, there is evidence that increasing protein levels of RIPK3 and MLKL by 
overexpression alone promotes necroptosis signaling, regardless of RIPK1 activation, due to 
homodimerization/self-associated activation (Dondelinger et al., 2014; Geserick et al., 2015; 
Moujalled et al., 2013; Zhao et al., 2012), meaning that there would be an advantage for cells to 
keep baseline levels of RIPK3 and MLKL protein low to minimize aberrant necroptosis activation, 
especially in post-mitotic neurons that are not regularly turning as in other tissues. Supporting this 
notion is the work of Kanno et al. (2015) showing undetectable RIPK3 protein at baseline in the 
spinal cord but rapidly increasing in protein expression following spinal cord injury specific to the 
injury site. 
Still, I am intrigued by the increase in RIPK1 mRNA and protein levels I observed. As 
RIPK1 has roles in pro-survival, apoptotic, and necroptotic signaling (Festjens et al., 2007; 
Newton, 2015; Newton and Manning, 2016), I would be curious to identify the specific role RIPK1 
could be playing here given the significant increase in spinal cord in symptomatic SOD1G93A mice, 
and, if suitable immunoreagents become available, to study which cell types show this increase in 
RIPK1. I would also be curious to observe whether the increasing RIPK1 fraction contained post-
translational modifications, such as ubiquitination and phosphorylation, that could give me a clue 
as to which downstream mechanism of RIPK1 could be resulting from the increase. A recent study 
rather elegantly demonstrated the coordinated phosphorylation and site-specific ubiquitination 
events during RIPK1-mediated necroptosis signaling (de Almagro et al., 2016), and by mass 
spectrometry identified K115 as a necroptosis-specific ubiquitination site on human RIPK1. De 
Almagro et al. also suggested this site, which is evolutionarily-conserved, may be functionally 
conserved in mouse RIPK1 protein. Therefore, I could use a similar approach to identify whether 
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this site is preferentially ubiquitinated in RIPK1 from the in spinal cord of symptomatic SOD1G93A 
mice compared to wild-type mice. 
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Chapter 5: Genetic Deletion of RIPK3 as Disease-Modifying Strategy in ALS 
 
5.1 Introduction 
As mentioned in the previous chapter, we have collected a series of compelling data supporting 
the notion that necroptosis can kill motor neurons in in vitro models of both familial and sporadic 
ALS (Re et al., 2014). To further support the involvement of necroptosis in ALS, I tried to use a 
series of published immunoreagents to examine by immunoblot the tissue content and by 
immunohistochemistry the cellular expression of the three core factors of necroptosis, namely 
RIPK1, RIPK3 and MLKL. However, since using the immunoreagents, at least in my hands, did 
not prove useful to study necroptosis in vivo, I thought of an alternative strategy and perhaps one 
that is more mechanistic. I thus posited that one way to assess the contribution, if any, of the 
necroptosis pathway to the ALS-like pathology in the SOD1G93A mice might be to target obligate 
mediators of necroptosis and assess any measurable improvement of the ALS-like phenotype. The 
way I tested this idea was through genetic means by crossing mice with homozygous germline 
deletion of RIPK3 (RIPK3-/-, kindly provided by Genentech) with transgenic SOD1G93A mice. I 
had three reasons to choose this model. The first was that RIPK3-/- mice had already been shown 
to be resistant to a variety of necroptosis stimuli. The second was that while RIPK3-/- mice are 
healthy, RIPK1-/- die soon after birth. The third, related to this and previously discussed in other 
chapters, while RIPK3 has few non-redundant roles outside of necroptosis, RIPK1 as a scaffold is 
a critical mediator NF-κB pro-survival and inflammation pathways independent of its role in 
necroptosis.  
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Newton et al. (2004) generated these RIPK1-/- mice by using a targeting vector to remove 
the first 3 exons of RIPK3 gene, which encode amino acids 1-158 of the protein, and confirmed 
that RIPK3 protein was not produced in various cells and organs. Whereas RIPK1-deficient mice 
die soon after birth, RIPK3-/- mice survive to adulthood without health or fertility defects, ripk3-/- 
homozygotes occur in litters at the expected Mendelian frequency, and histological analysis does 
not show defects in major organs (Newton et al., 2004). In my hands, I observed the RIPK3-/- mice 
also survived, bred and gained weight in a normal manner (Figure 5.1). In chapters 2 and 4, I 
further confirmed that I did not detect RIPK3 transcript in various tissues relevant to the present 
study such as embryonic and adult spinal cord, in adult spleen, nor RIPK3 protein in adult spleen 
of these RIPK3-/- mice.  
______________________________________________________________________________ 
 
Figure 5.1 RIPK3-/- Mice Had Normal Weight Gain   
Mice (C57Bl/6N, n=1 for each condition m=male, f=female, RIPK3WT= wild-type littermates, RIPK3KO=RIPK3-/- 
littermates) were weighed at the given time points and weights (in grams) were plotted over time. Slopes of the lines 
are similar showing weight gain over time is equivalent in the genotypes, even though there can be variation in 
individual mouse weight. 
______________________________________________________________________________ 
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5.2 Results 
5.2.1 Male, But Not Female, Transgenic SOD1G93A/RIPK3-/- Mice Showed Delayed Onset and 
Prolonged Survival  
5.2.1.1 Onset in SOD1G93A/RIPK3-/- mice  
Mice of each genotype were weighed 2-3 times per week, and onset was defined in this case as the 
age (postnatal day) at which a mouse lost 10% of its peak weight. Given that much of a mouse’s 
weight is determined by muscle mass, this correlated with loss of muscle mass related to the 
denervation and atrophy in this model. Using this parameter, I found no difference overall between 
SOD1G93A/RIPK3-/- mice (median=155) and SOD1G93A/RIPK3+/+ mice (median=152) (Figure 5.2, 
a, Log-rank Mantel-Cox test, p= 0.108).   
Likewise, when I stratified the data per sex, age at onset was not different between 
transgenic SOD1G93A male (median=152) and female (median=155) mice (Figure 5.2, b, Log-rank 
Mantel-Cox test, P=0.168). However, SOD1G93A/RIPK3-/- male mice showed a significantly longer 
time to end-stage onset (median=155) as compared to SOD1G93A/RIPK3+/+ male (median=152) 
(Figure 5.2, c, Log-rank Mantel-Cox test, P= 0.0050). Even though the medians were similar, the 
curve comparison through statistical testing indicated a shift in onset. Strikingly, this genotypic 
difference was only seen in males as it was not observed in female mice, which had no significantly 
different age at end-stage onset (Figure 5.2, d, Log-rank Mantel-Cox test, P=0.8356), even though 
the medians were quite different (SOD1G93A/RIPK3+/+ female = 155, SOD1G93A/RIPK3-/- female = 
147.5).  
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Lastly, improvement in the male mice did not extend onset past the point of the typical 
female transgenic SOD1G93A mice, with the medians both at 155 (Log-rank Mantel-Cox test, 
P=0.281).  
_____________________________________________________________________________ 
 
Figure 5.2. Onset in SOD1G93ARIPK3-/- Mice 
SOD1G93A mice of each genotype were weighed 2-3 times per week, and onset was defined as the age (postnatal day) 
at which a mouse lost 10% of its weight from its peak weight during the study. a. Onset was not different overall 
between SOD1G93A/RIPK3-/- mice (median=155) and SOD1G93A/RIPK3+/+ mice (median=152) (n=8-9 mice per 
condition). (Log-rank Mantel-Cox test, p= 0.108) b. Age at onset was not different between transgenic SOD1G93A male 
(median=152) and female (median=155) mice (Log-rank Mantel-Cox test, P=0.168) c. Onset in SOD1G93A/RIPK3-/- 
male mice showed a significantly longer time to onset (median=155) as compared to SOD1G93A/RIPK3+/+ males 
(median=152) (Log-rank Mantel-Cox test, p= 0.0050) d. Onset in SOD1G93A/RIPK3-/- female mice (median=147.5) 
was not significantly different age than SOD1G93A/RIPK3+/+ females (median=155) (Log-rank Mantel-Cox test, 
P=0.8356) (for b-d, n=4-5 mice per condition). 
______________________________________________________________________________ 
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5.2.1.2 Survival of SOD1G93A/RIPK3-/- Mice 
At end stage, muscle wasting and weakness had progressed and spread rapidly, and mice were thus 
sacrificed humanely when they were no longer able to right themselves from supine position after 
30 seconds. In each mouse, survival time was recorded as postnatal day from birth to loss of 
righting ability. Again, there was no overall difference in survival between transgenic 
SOD1G93A/RIPK3-/- mice (median=168.5) and SOD1G93A/RIPK3+/+ mice (median=162.5) (Figure 
5.3, a, Log-rank Mantel-Cox test, p= 0.0678).   
_____________________________________________________________________________________________ 
 
Figure 5.3. Survival of SOD1G93ARIPK3-/- Mice 
Survival age was recorded as postnatal day from birth to loss of righting ability, within 30 seconds from being placed 
in a supine position, SOD1G93A mice of each genotype. a. No difference in survival was found between transgenic 
SOD1G93A/RIPK3-/- mice (median=168.5) and SOD1G93A/RIPK3+/+ mice (median=162.5) (Log-rank Mantel-Cox test, 
p= 0.0678). b. Transgenic SOD1G93A female mice did survive longer than male mice (medians=170, 157, respectively) 
(Log-rank Mantel-Cox test, P= 0.0256). c. SOD1G93A/RIPK3-/- male mice survived significantly longer than 
SOD1G93A/RIPK3+/+ male mice (medians=178, 157, respectively) (Log-rank Mantel-Cox test, P=0.0170). d. Survival 
was not significantly different between the SOD1G93A/RIPK3-/- and the SOD1G93A/RIPK3+/+ female mice 
(medians=163, 170 respectively) (Log-rank Mantel-Cox test, P=0.7205). n=10-12 mice per group in a, and 5-6 mice 
per group in b-d. 
______________________________________________________________________________ 
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When I stratified the data by sex, transgenic SOD1G93A female mice survived longer than 
male mice (medians=170, 157, respectively) (Figure 5.3, b, Log-rank Mantel-Cox test, P= 0.0256). 
Furthermore, I found that SOD1G93A/RIPK3-/- male mice survived significantly longer than 
SOD1G93A/RIPK3+/+ male mice (medians=178, 157, respectively) (Figure 5.3, c, Log-rank Mantel-
Cox test, P=0.0170). Conversely, likewise to the age of onset, survival was not significantly 
different between the SOD1G93A/RIPK3-/- and the SOD1G93A/RIPK3+/+ female mice (medians=163, 
170 respectively) (Figure 5.3, d, Log-rank Mantel-Cox test, P=0.7205).  
Similar to onset of end stage, the improvement of survival of transgenic SOD1G93A/RIPK3-
/- male mice did not exceed the survival of the typical female transgenic SOD1G93A mice 
(medians=178, 170, respectively) (Log-rank Mantel-Cox test, P=0.1070).  
 
5.2.2 Sex-Specific Improvements in Onset and Survival Did Not Correlate with Functional 
Motor Tests 
A visual representation of functional motor tests is presented in Figure 5.4, and results are 
described below. 
 
5.2.2.1 Grip Strength Measured by Inverted Grid Test 
Starting at 9 weeks of age, mice were tested once per week by recording the maximum inverted 
hanging time on a grid, using all four limbs, up to 60 seconds as best of three trials, a test of grip 
strength (Oliván et al., 2015). 
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Figure 5.4. Visual Representations of Functional Motor Tests  
Top. Left: Mouse performing inverted grid test Right: mouse performing a loaded grid test Bottom. Series of grids 
presented to mice for loaded grid test. 
_____________________________________________________________________________________________ 
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SOD1G93A/RIPK3-/- mice did not hold longer on average compared to SOD1G93A/RIPK3+/+ 
mice (Figures 5.5, a, 5.7, a). Student’s t-test for significance was performed for each time point, 
and p values were recorded (Figure 5.7, a), none were significant. Non-transgenic mice not 
carrying the SOD1G93A mutant transgene were also tested for both RIPK3 genotypes and always 
held the entire 60 seconds, with no variation, data not shown. There was no difference in sexes on 
the inverted grid test (Figure 5.6 a,c-d, Figure 5.8, a, e, f).  
 
5.2.2.1 Grip Strength Measured by Loaded Grid Test 
Starting at 6 weeks of age, mice were tested twice per week by recording their weight and 
maximum time holding a series of weighted grids, using all four limbs, up to 30 seconds as best 
of three trials, a test that was established by Barnéoud et al. (1997) to detect early changes in grip 
strength in ALS mouse models. Briefly, the mouse was suspended by the tail and allowed to grip 
a series of grids with increasing weights (10, 20, 30, 40g) and a behavioral score was calculated 
as follows: score= [Σ(tw x W)]/body weight where tw corresponds to the maximum time the mouse 
was able to hold the grid at weight W. Body weight is the weight of the animal at the time of the 
test. A maximum period of 30 seconds was allowed for each weight and best of three trials was 
recorded.  
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Figure 5.5. Functional Motor Tests on SOD1G93ARIPK3-/- Mice 
a. Mice were tested once per week starting at 9 weeks of age and maximum hold time was recorded up to 60 seconds. 
SOD1G93A/RIPK3-/- mice did not perform better on inverted grid test compared to SOD1G93A/RIPK3+/+ mice. Student’s 
t-test was performed for each time point and found in Figure 5.7 a. b. Starting at 6 weeks of age, mice were tested 
twice per week by recording their weight and maximum time holding a series of weighted grids, using all four limbs, 
up to 30 seconds as best of three trials, to calculate an integrated score (see text). Student’s t-test was performed for 
each time point and found in Figure 5.7 a. n=12-15 mice per group SOD1G93A, 5-6 mice per group NTg.  
_____________________________________________________________________________________________ 
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Figure 5.6. Functional Motor tests on Tests on SOD1G93ARIPK3-/- Mice by Sex 
Mice were separated by genotype and sex for grip strength analysis. a-b Loaded grid test a. Male and. female 
SOD1G93A mice inverted grid test b. Male and female SOD1G93A mice loaded grid test c-d. Inverted grid test c. Male 
SOD1G93A/RIPK3-/- and SOD1G93A/RIPK3+/+ mice d. Female SOD1G93A/RIPK3-/- and SOD1G93A/RIPK3+/+ mice e-f. 
Loaded grid test. e. Male SOD1G93A/RIPK3-/- and SOD1G93A/RIPK3+/+ mice f. Female SOD1G93A/RIPK3-/- and 
SOD1G93A/RIPK3+/+ mice. n=6-8 mice per group. 
______________________________________________________________________________ 
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SOD1G93A/RIPK3-/- mice did not hold grids longer on average compared to 
SOD1G93A/RIPK3+/+ mice (Figure 5.5, b). Student’s t-test for significance was performed for each 
time point, and p values were recorded (Figure 5.7, b). Non-transgenic mice not carrying the 
SOD1G93A mutant transgene were also tested for both RIPK3 genotypes for score comparison 
(Figure 5.5, b). No differences were observed (Figure 5.7, c).  
Grip strength tests were re-analyzed separating male and female mice. There was no 
improvement between SOD1G93A/RIPK3-/- and SOD1G93A/RIPK3+/+ mice of the same sex (Figure 
5.6, b, e-f, Figure 5.8, b, c-d). The female SOD1G93A/RIPK3+/+ did perform better on the loaded 
grid test at some time points compared to female SOD1G93A/RIPK3-/- mice (Figure 5.6, f, 5.8, d). 
In my study, SOD1G93A females performed better on the loaded grid test than males at some time 
points during symptom onset (Figure 5.6, b, 5.8, b).  
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Figure 5.7. Statistical Results of Functional Motor Tests in RIPK3-/- Mice 
a-c. Multiple two-tailed Student’s t-tests were run comparing the indicated groups at each time point. There was no 
statistical difference in at any time point in SOD1G93A/RIPK3-/- and SOD1G93A/RIPK3+/+ mice overall (n=12-15 mice 
per group) in a. inverted grid or b. loaded grid or between c. non-transgenic RIPK3-/- and RIPK3+/+ mice.  
______________________________________________________________________________ 
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Figure 5.8. Statistical Results of Functional Motor Tests in RIPK3-/- mice by Sex 
Multiple two-tailed Student’s t-tests were run comparing the indicated groups at each time point. There was no 
difference at any time point between male and female SOD1G93A mice in a. inverted grid, but b. females performed 
better at some time points (red). There was no difference in at any time point between male SOD1G93A/RIPK3-/- and 
SOD1G93A/RIPK3+/+ mice for c. loaded grid or e. inverted grid. d. Female SOD1G93A/RIPK3+/+ performed better at 
some time points (red) compared to SOD1G93A/RIPK3-/- at loaded grid but not f. loaded grid. NA= scores not available. 
n=6-8 mice per group. 
______________________________________________________________________________ 
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5.2.3. Sex-Specific Improvements in Onset and Survival Did Not Correlate with 
Morphological Markers Either 
5.2.3.1. Quantification of Motor Neuron Loss at End Stage 
Motor neuron number was quantified as number of cytoplasmic choline acetyltransferase (ChAT)-
positive neurons per hemisection in the lateral ventral horn of a 20-micron section of lumbar spinal 
cord from the lumbar L4 and lumbar L5 segment (Figure 5.9). Figure 5.10, a, shows an example 
of ChAT staining of motor neurons in the ventral horn of the lumbar spinal cord of an adult wild-
type mouse. A neuron would be counted if the nucleus was also present on the section, identified 
by using a DAPI counterstain (not shown). 
______________________________________________________________________________ 
 
Figure 5.9. Schematic Representation of Lumbar Section Used for Motor Neuron Counting 
Motor neuron number was quantified as number of cytoplasmic ChAT-positive neurons per hemisection in the lateral 
ventral horn of a 20-micron section of lumbar spinal cord from the lumbar L4 and lumbar L5 segment (blue) identified 
by the roots under a microscope. Left. End-stage SOD1G93A mouse Right. ChAT+ staining in the ventral horn of a 
20-micron section of lumbar spinal cord. 
______________________________________________________________________________ 
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Figure 5.10. Example of Immunostaining Used for Quantifications 
a. Example of ChAT immunostaining of motor neurons in the ventral horn of the lumbar spinal cord of an adult wild-
type mouse. 20-micron thick section was imaged by confocal microscopy and maximum intensity projection of the z-
plane was used b. Example of completely innervated neuromuscular junction staining by colocalization of BTX (Alexa 
594 conjugated alpha-bungarotoxin, red) and VAChT (anti-voltage gated acetylcholine transporter, green) in the 
tibialis anterior muscle of a wild-type adult mouse. Scale bar 20 micron. 
______________________________________________________________________________ 
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Motor neuron number was measured at end-stage postnatal day 140 (P140). There was no 
difference between the number of motor neurons present in P140 SOD1G93A/RIPK3-/- mice 
compared to SOD1G93A/RIPK3+/+ mice (Two-tailed Student’s t-test, p= 0.4221) (Figure 5.11, a). 
There were no inherent differences in motor neuron number at P140 between non-transgenic 
RIPK3-/- and RIPK3+/+ mice (Two-tailed Student’s t-test, P=0.2192) (Figure 5.11, a). 
Representative images show ChAT-positive immunostaining in sections used for motor neuron 
counting from each genotype (Figure 5.12). 
______________________________________________________________________________ 
a       b   
Figure 5.11. Quantification of Pathology in SOD1G93A/RIPK3-/- Mice 
a. Motor neuron number was quantified at end-stage postnatal day 140 (P140). There was no difference between the 
number of motor neurons present in P140 SOD1G93A/RIPK3-/- mice compared to SOD1G93A/RIPK3+/+ mice (Two-
tailed Student’s t-test, p= 0.4221) There were no inherent differences in motor neuron number at P140 between non-
transgenic RIPK3-/- and RIPK3+/+ mice (Two-tailed Student’s t-test, P=0.2192). b. At least 100 neuromuscular 
junctions on 20-micron tibialis anterior sections were stained and counted for each mouse in symptomatic mice at 
postnatal day 120. There was no difference between number of innervated or denervated neuromuscular junctions 
between SOD1G93A/RIPK3-/- mice and SOD1G93A/RIPK3+/+ mice (Two-tailed Student’s t-test, p=0.6650 innervated, 
P=0.4847 denervated). There was no difference in partially-innervated neuromuscular junctions (Two-tailed Student’s 
t-test, p=0.5636). n= 3 biological replicates per condition. Error bars represent SEM of the mean. 
______________________________________________________________________________ 
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5.2.3.2. Quantification of innervation at the neuromuscular junction in symptomatic mice 
Sections of tibialis anterior (20-micron thickness) were cut and neuromuscular junctions were 
immunostained for presynaptic voltage gated acetylcholine transporter (VaChT) and post-synaptic 
using fluorescence conjugated alpha-bungarotoxin (BTX). Neuromuscular junction innervation 
was quantified by identifying BTX-positive NMJs (red) and determining the extent of 
colocalization with VaChT (green) (Figure 5.10, b). Full innervation was defined as greater than 
70% overlap of BTX and VaChT, partial at 30-70% overlap, and denervation at 0-30% overlap.   
______________________________________________________________________________ 
 
Figure 5.12 Representative Images of Motor Neuron Counting 
Lumbar ventral horns show ChAT+ immunostaining in representative images used for motor neuron quantification.  
Top left: NTg/RIPK3+/+ right: NTg/RIPK3-/- Bottom left: SOD1G93A/RIPK3+/+ right: SOD1G93A/RIPK3-/- 
20-µm sections were imaged on fluorescent microscope at 10X magnification. 
______________________________________________________________________________ 
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Figure 5.13. Representative Images of Neuromuscular Junction Innervation 
Representative images show neuromuscular junction staining (NMJ) by colocalization of BTX (Alexa 594 conjugated 
alpha-bungarotoxin, red, post-synaptic) and VAChT (anti-voltage gated acetylcholine transporter, green, presynaptic) 
in the tibialis anterior muscle of left: SOD1G93A/RIPK3+/+ right: SOD1G93A/RIPK3-/- mice at symptomatic 
postnatal day P120.  20-micron sections were labeled and imaged on a fluorescent microscope at 10X magnification. 
White arrows indicate neuromuscular junctions that would be counted based on BTX labeling (being within the plane 
of the image). In each image, 2 arrows are showing a denervated NMJ. 
______________________________________________________________________________ 
At least 100 neuromuscular junctions on 20-micron tibialis anterior sections were stained 
and counted for each mouse in symptomatic mice at postnatal day 120. There was no difference 
between number of innervated or denervated neuromuscular junctions between SOD1G93A/RIPK3-
/- mice and SOD1G93A/RIPK3+/+ mice (Two-tailed Student’s t-test, p=0.6650 innervated, p=0.4847 
denervated) (Figure 5.11, b). There was no difference in partially-innervated neuromuscular 
junctions (Two-tailed Student’s t-test, p=0.5636) (Figure 5.11, b). Representative images show 
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images neuromuscular junction staining in tibialis anterior muscle sections used for quantification 
(Figure 5.13).  
 
5.3. Discussion 
5.3.1. Sex-Specific Improvements in Male SOD1G93A Mice Lacking RIPK3 
My study was not powered to detect differences by sex, as both males and females were pooled 
per genotype to reach the desirable number of mice (N=12-15 mice per group). I therefore ran 
post-hoc analyses by separating sexes to determine whether there were differences biasing the 
study. Surprisingly, although sex differences in the C57Bl/6J background SOD1G93A have not been 
previously reported (Heiman-Patterson et al., 2005), my study did identify a difference in survival 
between male and female SOD1G93A mice, although not in onset or grip strength.  
Typically, sex differences have been seen on the B6/SJL background in SOD1G93A mice, in that 
females survive longer (Heiman-Patterson et al., 2005).  
Although both the SOD1G93Amice and RIPK3-/- mice used in this study were both on the 
C57Bl/6 background, there have been strain differences affecting phenotypes observed between 
C57Bl/6J (that the SOD1G93A mice originate from) and C57Bl/6N (that the RIPK3-/- mice originate 
from)(Newton et al., 2004; Simon et al., 2013). Since the mice in my study were of a mixed 
background (C57Bl/6N and C57Bl/6J) they could not be compared exactly to data on C57Bl/6J 
SOD1G93A mice that did not show sex differences in survival. However, my data do suggest that 
careful observation of both sexes during mouse studies of ALS is critical to the interpretation of 
the results. 
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Regardless of the reason for the difference, in light of my initial findings, I separated sexes 
and re-analyzed SOD1G93A/RIPK3-/- mice compared to SOD1G93A/RIPK3+/+ of the same sex. After 
performing this gender segregation, there were modest improvements in disease onset and survival 
in male SOD1G93A/RIPK3-/- mice that were not observed in female mice. However, these results 
did not correlate with improvements in grip strength. Furthermore, in light of these results all 
pathology analysis of tissue, including motor neuron number and innervation of neuromuscular 
junction were performed in male mice. I did not see improvements in SOD1G93A/RIPK3-/- mice 
pathology either, at any of the tested time points. 
______________________________________________________________________________ 
 
Figure 5.14. Average Weight of Mouse Cohorts Over Time in SOD1G93A/RIPK3-/- Study 
An average of the weights over time of all cohorts of SOD1G93A mice in the study at the indicated genotypes and sex 
(n= 10-15 mice per condition). Red arrow points to an earlier decline in weight as a cohort of male SOD1G93A mice. 
_____________________________________________________________________________ 
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Another approach to interpreting the onset data is to analyze average weight of each cohort 
over time, which I plotted (Figure 5.14). In these cohorts, SOD1G93A/RIPK3+/+ mice as a group 
appear to have accelerated weight loss compared to the other groups (red arrow). A possible 
interpretation is that in my case the cohort of male SOD1G93A mice that were RIPK3+/+ were 
representing a worse population due to random sampling and small sample size. In support of this 
hypothesis, my study was not sufficiently powered to detect differences in sex, as this was not 
considered in the initial study design. Perhaps with a larger sample size, I would not see inherent 
differences in onset in the sexes.  
Another interpretation is that the RIPK3-/- mice induced the SOD1G93A male mice to behave 
mechanistically more like the females. For example, there are previous reports implicating 
elevated estrogen, a female hormone, in reduced systemic inflammation (Au et al., 2016). 
Similarly, Shivers et al. (2015) found that estrogen reduces inflammation-induced cytokine levels 
in rat spinal cord at baseline and following injury (Shivers et al., 2015). While it has been noted 
that inflammation in neurodegenerative models such as ALS can be both neuroprotective and 
neurotoxic (McCombe and Henderson, 2011; Sargsyan et al., 2005), it is plausible that careful 
modulation of the inflammatory response to neuronal injury is important to maintain neuronal 
integrity. 
There is growing evidence that necroptosis machinery can activate inflammation 
independent of cell death (Najjar et al., 2016; Newton, 2015; Newton and Manning, 2016). Given 
that RIPK3 has known pro-inflammatory roles, independent of cell death, it is possible that 
deletion of RIPK3 in male mice leads them to have reduced inflammation, mimicking the effect 
of estrogen on female mice. This could explain why there is no further improvement in 
SOD1G93A/RIPK3-/- female mice, and no improvement in male SOD1G93A/RIPK3-/- mice past the 
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point of their female littermates. Figure 5.15 shows a representative pathway by which the 
necroptosis machinery can engage inflammation rather than cell death reproduced from Najjar et 
al. (2016). Najjar et al. (2016) showed that in primary macrophages, the RIPK1 and RIPK3 
necrosome drives pro-inflammatory signaling, rather than necroptosis, when TLR4 is activated by 
LPS and caspase-8 is inhibited. In mice, this signaling response was sustained during acute 
______________________________________________________________________________ 
 
Figure 5.15. A Model of RIPK1 and RIPK3 Mediated Cell-Death-Independent Inflammation 
Proposed by Najjar et al. (2016) 
Graphical abstract reproduced from Najjar et al. (2016) Immunity 45(1); 45-69. 
Najjar et al. (2016) showed that in primary macrophages, the RIPK1 and RIPK3 necrosome drives proinflammatory 
signaling, rather than necroptosis, when toll-like receptor 4 is activated by lipopolysaccharide (LPS) and caspase-8 is 
inhibited. In vivo this signaling response was sustained during acute inflammatory responses to LPS and did not 
require exogenous manipulation of caspases. RIPK1 and RIPK3 kinases promoted sustained activation of Erk, cFos, 
and NF-κB, which were required for inflammatory changes.  
______________________________________________________________________________
inflammatory responses to LPS and did not require exogenous inhibition of caspases. RIPK1 and 
RIPK3 kinases promoted sustained activation of Erk, cFos, and NF-κB, which were required for 
inflammatory changes such as the production of cytokines and chemokines. 
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Similarly, Ito et al. (2016) found that activation of RIPK1 kinase-dependent inflammatory 
pathways in microglia was linked to increased cytokine and chemokine production (Ito et al., 
2016). These RIPK3-dependent inflammatory pathways in microglia were increased in mice 
lacking optineurin (OPTN-/-), a mouse model they generated to study the role of optineurin in ALS, 
and which I introduced in Chapter 1.  
Given that increased cytokine and chemokine production correlates with reactive gliosis, 
this could be one contribution of RIPK3 to the overall phenotype of ALS, given that increased 
reactive gliosis is linked to progression and disease pathology in ALS mice (Burda and Sofroniew, 
2014; Frakes et al., 2014; Schiffer et al.,1996). However, Ito et al. (2016) proposed that this 
increase in reactive gliosis was not, as I would think, directly linked to motor neuron cytotoxicity. 
Instead, their proposed mechanism was that in OPTN-/- mice, increased inflammation in microglia 
signals oligodendrocyte cell death via TNF-α-induced necroptosis. Oligodendrocyte degeneration 
via this mechanism in OPTN-/- mice led to subsequent myelin defects, causing axonal degeneration 
(Figure 5.16 graphically represents this mechanism). This axonal damage was rescued by targeting 
necroptosis via pharmacologic (necrostatin-1-s treatment, a more stable form of Nec-1), genetic 
RIPK1 kinase inhibition (RIPK1D138N/D138N kinase deficient mice). Ito et al. (2016) also generalized 
this mechanism to the SOD1G93A mouse model, and found similar axonal defects that were rescued 
by targeting necroptosis genetically in RIPK3-/- mice or after necrostatin-1-s treatment. 
I would posit that if RIPK3-dependent signaling pathways play a role in increased cytokine 
and chemokine production by microglia, these signals could be cytotoxic to motor neurons as well. 
Surprisingly, while Ito et al. did observe some shifts in onset of motor symptoms and 
neuromuscular junction innervation in SOD1G93A/RIPK3-/- mice, correlating with their proposed 
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mechanism of axonal damage, they did not evaluate motor neuron number or overall survival as I 
have done in this chapter.  
______________________________________________________________________________ 
 
Figure 5.16. Mechanism of Necroptosis in ALS Proposed by Ito et al. (2016) 
In the spinal cord, Optn loss leads to an intrinsic sensitivity to RIPK1-dependent activation of microglia, leading to 
the release of proinflammatory cytokines including TNFα. Oligodendrocytes, sensitized by Optn loss to undergo 
RIPK1-dependent necroptosis, degenerate following stimulation by TNFα released from microglia. The death of 
oligodendrocytes leads to the observed formation of less compact myelin, increased denervation from nerve  
terminals, and axon degeneration. 
_____________________________________________________________________________________________ 
 
In their study, Ito et al. (2016) posited that necroptosis leads to increased inflammation in 
microglia and subsequent oligodendrocyte degeneration. They observe myelin defects associated 
with these changes in two models of ALS, OPTN-/- and SOD1G93A. Intrigued by their findings that 
necroptosis leads to axonal defects in two mouse models of ALS, I compared spinal cord sections 
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from wild-type, SOD1G93A and OPTN-/- mice (independently generated by the Shneider lab, 
Columbia University) via electron microscopy. However, while there were minor myelin 
abnormalities in the white matter of the spinal cord ventral horn, this phenotype occurred equally 
in wild-type mice rather than segregating with the SOD1G93A and OPTN-/- mice. Additionally, I 
did not observe abnormal myelin in the ventral roots of the lumbar spinal cord in any genotype.  
 
5.3.2. Lack of Beneficial Effect of RIPK3-/- in SOD1G93A Mice 
Taken together, my in vivo study targeting necroptosis via RIPK3 deletion did not show successful 
rescue of the ALS phenotype in SOD1G93A mice, including onset, survival, grip strength, motor 
neuron number, and axonal retraction from the neuromuscular junction. There are several possible 
interpretations of these results. The first is that overall, necroptosis has very little to do with the 
pathology in SOD1G93A mice, and that our in vitro studies were not recapitulating the in vivo 
context. Another possibility is that because RIPK3 deletion is constitutive from birth, the cells 
could have adapted compensatory mechanisms to circumvent this loss. In this scenario, multiple 
redundant pathways contribute to cell death in vivo, and that while RIPK3-dependent necroptosis 
is a dominant mechanism motor neuron cell death, in the absence of RIPK3 cells adapt alternative 
ways to die such as by RIPK1/Caspase-8 mediated apoptosis (Feltham et al., 2017). In order to 
begin to explore one aspect of this possibility, I looked to see whether RIPK1, RIPK3, or Caspase-
8 levels were increased in tissue from RIPK3-/- mice using similar methods developed in Chapters 
3 and 4. RIPK1 protein and mRNA levels were not increased in the spinal cord of RIPK3-/- mice 
compared to wild-type mice at 12 weeks postnatal age (Figure 5.17, a, c, d). Caspase-8 levels were 
not increased in embryonic spinal cord samples from RIPK3-/- mice (Figure 5.17, b). In one sample, 
MLKL mRNA levels were increased 1.5 fold in the spinal cord of RIPK3-/- mice at 12 weeks 
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postnatal age; this would need to be repeated to generate a larger sample size to determine whether 
this increase is biologically significant (Figure 5.17, d).  At least I can say from these attempts 
there is no obvious increase in cell death machinery as a result of RIPK3 deletion in the spinal 
cord of these mice.  
A third possibility is that, while the in vitro models from which this targeting strategy was 
derived capture the non-cell-autonomous contribution of astrocytes to motor neuron cell death, the 
in vivo model recapitulates the additional role of mSOD1 in cell-autonomous motor neuron cell 
death, by mechanisms I discussed in Chapter 1 such as ER stress and mitochondrial dysfunction. 
Therefore, if necroptosis is solely the result of non-cell-autonomous mechanisms of mSOD1, 
targeting this pathway may be insufficient to rescue the motor neuron loss in vivo. Given that 
targeting apoptosis alone does provide some beneficial effects in SOD1G93A mice, as I discussed 
in Chapter 1, it is clear that apoptosis does contribute to motor neuron disease.  The absence of 
Bax, which showed complete rescue of motor neurons both in our in vitro models and in vivo 
(Gould et al., 2006), suggests that Bax may be involved in both non-cell autonomous and cell-
autonomous pathways downstream of mutant SOD1. Is there a dependence of motor neuron 
necroptosis on Bax? Our in vitro data from Chapter 1 would suggest so, given that both Bax and 
necroptosis machinery are necessary for motor neuron death. However future studies to evaluate 
the role of necroptosis in motor neuron death in vivo and whether this pathway indeed engages 
Bax are necessary to confirm this role.    
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Figure 5.17. No Evidence of Compensatory Cell Death Mechanism in RIPK3-/- Mice 
a. Protein was extracted from spinal cord tissue (50 µg) from 19-week-old mice and western blot was performed to 
reveal RIPK1 as described in Chapter 3 and 4. c Shows quantification of the bands. At this time point, there was no 
difference in levels of RIPK1 protein in wild-type, SOD1G93A or RIPK3-/-/SOD1G93A mice (multiple unpaired t-tests, 
two-tailed, p>0.05) n=3 biological replicates per condition. b. qPCR was performed on extract from the spinal cord 
of mouse embryos at E12.5 of WT or RIPK3-/- mice using techniques defined in Chapters 3 and 4.  There was no 
change in caspase-8 or RIPK1 mRNA levels between conditions (trend, no statistical test, n=2). d. qPCR was 
performed on extract from the spinal cord of adult WT or RIPK3-/- mice at 12 weeks using techniques defined in 
Chapters 3 and 4.  There was no change in RIPK1 mRNA levels between conditions (trend, no statistical test, n=1). 
There was a 5-fold decrease in RIPK3 mRNA levels (n=1). There was a 1.5-fold increase in MLKL mRNA (trend, 
no statistical test, n=1). 
_____________________________________________________________________________ 
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Chapter 6: Discussion 
 
The mechanisms of neuronal cell death have been a primary focus of investigation for 
researchers of neurological disorders and, in particular, neurodegeneration. A complete 
understanding of these mechanisms could provide crucial insights into the complex biology of 
these disorders of the nervous system, and could also enable the development of targeted and 
effective therapies. My work in the Przedborski lab focused on delineating the pathogenic 
significance of necroptosis in ALS. Given its molecularly-controlled nature, I also sought to 
identify potential targets for therapeutic purposes. Toward this overarching goal, my work has 
been divided into four parts which can be defined as follows: (1) determine the role of necroptosis 
in neuron death in vitro models of ALS (Chapter 2); (2) shed light into the motor neuron-specific 
regulatory network of necroptosis (Chapter 3); (3) validate key reagents required to study 
necroptosis and use them in mouse and human postmortem tissue samples to generate histological 
data about necroptosis engagement (Chapter 4); and (4) test the effects of targeting a central 
determinant of necroptosis, namely RIPK3, on the diseases phenotype in a mouse model of ALS 
(Chapter 5). 
Although interpretations and discussions of my results took place, for the most part, in each 
respective chapter, I now provide additional elements of discussion mostly geared toward 
questions unresolved by my work and about future directions regarding this work. 
In Chapter 2, I showed that non-cell autonomous motor neuron cell death resulting from 
ALS astrocytes involves core components of the necroptosis machinery, namely RIPK1, RIPK3, 
and MLKL. While our data supporting the involvement of MLKL are compelling, as indicated in 
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Chapter 2, they rest on the use of a small molecule in our humanized model only. This factor is so 
critical in our understanding as to how neuronal death occurs, that it would be reassuring to 
complete this work by using additional pharmacological inhibitors as recently reported by 
Hildebrand et al. (2014) and/or effective viral vectors to silence MLKL in motor neurons. 
Strengthening the potential involvement of MLKL here is particularly important since it has been 
shown to be the actual molecular executioner via forming pores through the plasma membrane 
(Cai et al., 2014; Chen et al., 2014; Dondelinger et al., 2014; Hildebrand et al., 2014). As shown 
in the previous chapters, I found little evidence for robust expression of mRNA MLKL in motor 
neurons and spinal cord tissue, contrasting with the known abundant expression of mRNA Bax. 
Could it be that Bax in the case of motor neurons and ALS is substituting for MLKL? This idea 
would be fascinating as Bax-like MLKL is a pore-forming molecule (reviewed by Westphal et al., 
2011). Thus, in future studies I would like to examine whether in motor neurons under ALS-related 
stimuli, Bax rather than translocating to mitochondria translocates to the plasma membrane.  
Should this happen, I would also like to determine if MLKL is necessary for Bax localization to 
plasma membrane, for example by heterodimerizing with Bax. Alternatively, I would also wish to 
perform lipidomic analysis of motor neuron plasma membrane to determine if its lipid composition 
might have been modified by the diseases process, which, in turn, may promote Bax translocation 
(Martínez-Abundis et al., 2007) .  
In Chapter 3, through extracting a gene expression profile of motor neurons undergoing 
cell death and reverse gene engineering of drivers of the motor neuron cell death phenotype, a 
number of potential drivers were identified. These drivers will need to be experimentally-validated 
in future studies for their role in motor neuron death and potential role in necroptosis. 
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Re-evaluating this data with the goal of uncovering mechanisms of necroptosis, a few 
observations were made. First, the signature that was obtained was enriched for known drivers 
necroptosis derived from a screen of mouse fibrosarcoma cells (Hitomi et al., 2008). Second, the 
master regulators identified driving the death phenotype could be grouped categorically into 
pathways involving NF-κB, which had been previously validated as a motor neuron death driver, 
increased TGF-β signaling, and proteins activated during development. The contributions of TGF-
β signaling and developmental pathways to motor neuron necroptosis warrant further exploration. 
Furthermore, one gene that was increased in the signature, zfp451, is a transcription factor 
that was also identified as a necroptosis driver in mouse fibrosarcoma cells (Hitomi et al., 2008), 
and was identified as a master regulator of motor neuron cell death (Ikiz et al., 2015). While little 
is currently known about zfp451, its regulon is enriched in functional pathways that could be 
related to ALS and to necroptosis. Therefore, understanding the role of zfp451 during motor 
neuron death and necroptosis could be an interesting area of exploration. 
While this data generated interesting leads, a more directed screen for necroptosis could 
have uncovered additional insight into the regulatory network of necroptosis in motor neurons. For 
instance, it would have been quite powerful to run a new unbiased reverse gene engineering 
analysis by exposing motor neurons to ALS astrocyte-conditioned media, as was done in Chapter 
2, but this time with or without targeting necroptosis drivers, such as RIPK1, either by 
pharmacologic or genetic inhibition. With this design, the idea would be to rescue the cell death 
in a necroptosis-dependent manner and identify those elements of the motor neuron death signature 
reversed by blocking RIPK1. Thus, from these proposed experiments, a necroptosis-specific 
signature could be extracted from motor neurons. Once completed, like before, I would propose to 
validate these candidate necroptosis drivers by silencing each in motor neurons and see if down-
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regulating these factors protect against death. With this design in mind, I attempted to carry out 
such an experiment. My pilot run showed feasibility but the data generated were too noisy to be 
usable. In addition, and likely as a result, biological replicates also did not show clustering as I 
would have expected. Thus, this attempt will have to be repeated. At the bioinformatics level, it 
may be interesting to try to force my future analysis through the Bax regulator network, since we 
know how significant Bax is here. One challenging aspect of using Bax as an extra-constraint is 
the fact that Bax is not a master regulator, i.e., transcription factor. One element known to activate 
the Bax regulatory network is p53 (Miyashita and Reed, 1995). However, p53 was not a master 
regulator identified by Ikiz et al. (2015) to drive motor neuron death, and inhibiting p53 activity 
did not rescue motor neuron death, as demonstrated by the work of Diane Re.  
In Chapter 4, I showed that while there are increases in RIPK1, RIPK3, and MLKL mRNA 
in the spinal cords of symptomatic SOD1G93A, the levels of RIPK3 and MLKL mRNA in the spinal 
cord are quite low, and these proteins are undetectable by western blotting using the given 
techniques. Do RIPK3 and MLKL indeed play a role in motor neuron death given their levels are 
quite low? One possibility is that RIPK3 and MLKL are only expressed in a small subset of cells. 
The most optimal way to study this would be to identify trustworthy immunoreagents against 
RIPK1 and MLKL to look for localization of these proteins in specific cell types in mouse spinal 
cord, and their activation at various time points during disease progression in SOD1G93A mice. 
Perhaps, non-radioactive in situ hybridization could be used to provide at least approximation, but, 
since most of the cascade of necroptosis is regulated at the post-translational level, the value of 
such approach would be limited. Of note since, we have not found evidence that any of the anti-
RIPK1, -RIPK3, -MLKL immunoreagents are valid for immunohisto- or immunocytochemistry, 
we are not confident about the data published by several groups over the past few years about the 
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use of the exact same antibodies to study necroptosis in tissues (Ito et al., 2016; Kanno et al., 2015; 
Ofengeim et al., 2015). More work would be needed to resolve this important dilemma.  
To further answer the question, in Chapter 5, genetic targeting of RIPK3 in the SOD1G93A 
mouse model was performed. Using a constitutive RIPK3 knockout mouse model (generated by 
Newton et al., 2004), I generated SOD1G93A/RIPK3-/- mice and evaluated onset, survival, grip 
strength and motor and axonal pathology during the progression of the disease. While some modest 
improvements in onset and survival were observed in male mice, these did not correlate with motor 
function or pathological hallmarks. Taken together, targeting RIPK3 in the SOD1G93A model did 
not show meaningful improvement of the phenotype. Since the germline deletion of RIPK3 is 
constitutive, we cannot exclude that some compensatory mechanisms did develop in these mice 
which, in turn, did mask the true role of this necroptosis factor in the disease phenotype. Should 
conditional RIPK3 knockout mice become available to us, the study with transgenic SOD1G93A 
mice might be worth repeating.  
Given that RIPK1 has many non-redundant roles in cell death signaling (Dondelinger et 
al., 2015; Feltham et al., 2017), it would be interesting to see if targeting RIPK1 in motor neurons 
would have any benefit that we did not capture by RIPK3 deletion. Ito et al. (2016) did explore 
targeting RIPK1 kinase function in SOD1G93A mice through early administration of necrostatin-1s 
(a more stable form of necrostatin-1 with increased specificity for RIPK1). While oral 
administration of necrostatin-1s correlated with a shift in onset of motor symptoms in those mice, 
the authors did not evaluate overall survival or look at later time points for protection of motor 
neuron loss, which a future study should explore. In addition, given that we found that in vitro 
silencing of RIPK1 in motor neurons did not have the deleterious effect as in other cells, as I 
discussed in the previous chapters, it would be interesting to see whether silencing RIPK1 
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specifically in motor neurons would have any benefit that we did not capture by RIPK3 constitutive 
deletion. A targeted deletion strategy by in vivo viral delivery of RIPK1 shRNA to motor neurons, 
which we have established in the Przedborski lab for other targets, would be an optimal method to 
evaluate the hypothesis that motor neuron death can occur from multiple redundant RIPK1-
dependent signaling pathways. I began working toward this strategy during my thesis work. 
However, this work in part relies on identification of reliable immunoreagents in order to evaluate 
whether subsequent RIPK1 protein levels are indeed reduced in motor neurons in the spinal cord 
following targeted silencing of RIPK1, which I sought to identify in Chapter 3.  
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Chapter 7: Experimental Procedures 
 
Most methods and reagents used in my work were identical to those previously published 
by the Przedborski lab and have been cited throughout this document. As such, only new or 
significantly modified methods are detailed below.  
 
7.1. Mouse Motor Neuron Cultures  
Primary spinal motor neuron cultures were prepared as in Nagai et al. (2007) and Re et al. (2014) 
using embryonic day 12.5 (E12.5) old transgenic embryos expressing GFP driven by the mouse 
Hb9 promoter (Wichterle et al., 2002). Briefly, cells were plated at 1,500 eGFP+ cells/mL for 
Hb9::eGFP either on coverslips coated with 0.01% poly-D-lysine and 15 µg ml–1 laminin (poly-
D-lysine/laminin) or on astrocyte monolayers. The culture medium was either motor neuron 
medium supplemented with a cocktail of trophic factors composed of 0.5 ng/ml glial cell-derived 
neurotrophic factor (GDNF), 1 ng/ml brain-derived neurotrophic factor (BDNF) and 10 ng/ml 
ciliary neurotrophic factor (CNTF, trophic factor cocktail, R&D Systems); or astrocyte-
conditioned motor neuron medium supplemented with trophic factors. Primary MNs cultured from 
embryos that did not express GFP under the HB9 promoter were quantified using SMI32+ 
immunostaining (1/500, Sigma #NE1023).  
Mouse ES-derived spinal motor neurons, expressing cell surface antigen CD2 and eGFP 
under the HB9 promoter, were differentiated from ES cells as described in (Wichterle et al., 2002) 
and purified prior to plating by magnetic activated cell sorting as described in (Ikiz et al., 2015).  
 
 
157 
 
7.2. Lentiviral-mediated Gene Silencing in Mouse Primary Neurons 
All shRNAs used in this study were constructed in pLKO.1-puro plasmids (Sigma MISSION®). 
This plasmid contains a puromycin resistance cassette inserted behind a human phosphoglycerate 
kinase eukaryotic promoter. For mouse Ripk1 silencing, the clone TRCN0000022468 was used. 
As control, SHC002H, a pLKO.1-puro expressing a non-mammalian targeting sequence was used. 
Prior to plating, primary motor neurons were transduced with lentiviral particle at multiplicity of 
infection (MOI) 20 by spinoculation as previously described (Re et al., 2014). Briefly, after 
isolation, cells were counted and placed into sterile 1.5 mL Eppendorf tubes at 100,000 cells/mL 
with the viral particles at MOI 20. Cells were spun at 800×g for 30 minutes and gently resuspended 
in fresh motor neuron growth medium and plated onto postnatal astrocyte monolayers. Plating 
density was 35,000 infected motor neurons on astrocyte layer for co-culture experiments and 
15,000 motor neurons on coated-well for determination of knockdown efficiency. 
 
7.3. Western Blotting 
7.3.1. Lysis Buffers 
7.3.1.1. RIPA Buffer 
RIPA buffer consisted of 150 mM NaCl, 25 mM Tris pH 8.0, 1% Triton X-100, 0.5% sodium 
deoxycholate, 1 mM ETDA, 0.1% SDS, protease inhibitor cocktail and phosphatase inhibitor 
(Sigma, Complete™, PhosSTOP™). 
 
7.3.1.2. Urea buffer 
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Urea buffer consisted of 6 M urea, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM 
EGTA, 50 mM NaF, 10 mM b-glycerophosphate, 5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1 mM benzamidine, 1 mM PMSF, 5 mM N-ethylmaleimide, 1 mM DTT, complete 
protease inhibitor cocktail and phosphatase inhibitor (Sigma, Complete™, PhosSTOP™). 
 
7.3.2. Mouse Tissue Preparation for Western Blotting 
Wild-type or mutant SOD1G93A mice on a B6/SJL background (stock #002726, Jackson 
Laboratory) were perfused with ice-cold PBS (Cat. No #14190136, ThermoFisher) for 4 minutes 
at 10 ml/minute and spinal cords were carefully dissected out from the spinal column. For all 
Western blots, the lumbar L1-L5 region was dissected out from the rest of the spinal cord in ice-
cold PBS under a microscope. Spinal cords were immediately frozen on dry ice and stored at -
80°C in pre-weighed 1.5 mL tubes prior to tissue lysing. On the day of the assay, proteins were 
extracted at a W/V ratio of 1 mg of tissue per 9 µL of RIPA or 6 M urea buffer containing protease 
and phosphatase inhibitor cocktail. Tissue was homogenized in RIPA lysis buffer on ice using a 
Dounce homogenizer and placed on ice for 30 minutes, homogenized twice, and centrifuged at 
13,000 rpm for 15 minutes. For the 6 M urea lysis buffer, the exact protocol of Ito et al., (2016) 
was used. Here, tissue was first homogenized in buffer containing all the ingredients except 6 M 
urea, then sonicated and incubated for 1 hour at 4°C with rotation. After centrifugation at 15,000 
rpm for 20 minutes, the supernatant was removed and the pellet was washed twice in PBS (Cat. 
No #14190136, ThermoFisher). 6 M urea-containing buffer was added and the pellet was 
resuspended, sonicated, then re-incubated at 4°C with rotation for 1 hr. Protein concentrations 
were determined using the Bradford Quick Start™ assay (Bio-Rad). Samples were then diluted to 
2 µg/µL protein, using ultrapure water and stock sample buffer at a dilution of 1/5 (v/v): (Tris-HCl 
 
159 
 
pH 6.8, 10% SDS, 25% Glycerol, 5% β-mercaptoethanol, 0.05% Bromophenol blue). Samples 
were boiled for 10 minutes at 95°C prior to storage at -80°C, and 1.5 minutes prior to loading.  
Then, 50-60 µg of protein preparation was loaded per lane onto a 5-12% Bis-Tris gel 
(NuPAGE®, Thermofisher) using running buffer prepared by diluting commercially-available 
MOPS buffer (NuPAGE®, Thermofisher) at a 1/20 dilution (v/v) in ultrapure water. After running, 
proteins were transferred onto 0.45-µm pore–size nitrocellulose membrane using transfer buffer 
prepared fresh in Tris/Glycine transfer buffer containing 20% methanol and 0.05% SDS at 300 
mA/35 V for 1.5 hours. Membranes were rinsed with ultrapure water prior to blotting. 
After blocking [Li-Cor® buffer for fluorescent Western blotting, Rockland, Enhanced 
chemiluminescence (ECL) preparation: 5% non-fat dry milk in 0.1% Phosphate Buffered Saline 
Tween-20 (PBST) prepared using commercially-available PBS (Cat. No #14190136, 
ThermoFisher)], the indicated antibodies (Table 4.1) were incubated in a 1/1,000 dilution of 
antibody (Li-Cor® buffer for fluorescent Western blotting, Rockland, ECL: 0.1% PBST) 
overnight at 4°C. The next day, anti-mouse β-actin antibody (Sigma) was added at 1/40,000 and 
incubated for an additional 1 hour at room temperature. Membranes were washed three times for 
10 minutes in 0.1% PBST, incubated in secondary antibody (Li-Cor® buffer 1/20000 IR-700 dye 
conjugated, ECL: HRP-conjugated 1/3000) for 1 hour at room temperature, then washed three 
times for 10 minutes in 0.1% PBST prior to imaging. ECL (Bio-Rad) was added for 2 minutes 
prior to imaging (Li-Cor® Odyssey Imaging system). 
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7.4. ELISA 
For the multiplex human cytokine ELISA, astrocyte media without serum were prepared by 
conditioning for 7 days with confluent astrocyte layers and prepared as in Nagai et al., (2007). 
ELISA was performed using 100 µL of undiluted human astrocyte-conditioned medium following 
the manufacturer’s recommendations (EA-4002; Human Cytokine ELISA Plate Array- 
Colorimetric, Signosis, Santa Clara, CA). Plate was imaged at 450 nm wavelength using 96-well 
microplate spectrophotometer (Infinite® 200 PRO, Tecan).  
 
7.5. Generation of the Motor Neuron Cell Death Signature  
Purification of mouse ES-MN, application of astrocyte-conditioned media for 3 days, RNA 
extraction and purification, RNA-seq and Reverse Gene Engineering were performed to generate 
the motor neuron death signature as described extensively in Ikiz et al., (2015) and in the thesis of 
Burcin Ikiz (https://academiccommons.columbia.edu/catalog/ac:155922).  
Re-analysis of the RNA-seq data was performed as follows. While the mapping and 
generation of the gene expression signature were similar to the data used in Ikiz et al., (2015), the 
main improvement in the analysis was the use of multi-sample virtual inference of protein activity 
by enriched regulon (msVIPER) (Alvarez et al., 2016). This new algorithm is an updated platform 
from the MARINa, used by Ikiz et al. (2015), to infer protein activity based on the differential 
expression of transcriptional targets using the mouse whole brain interactome (Gene Expression 
Omnibus Accession #GSE10415) as the cell context-specific interactome. 
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7.6. Quantitative Reverse Transcriptase PCR 
7.6.1. Mouse Tissue Preparation for RNA Extraction 
Tissues from wild-type or mutant SOD1G93A mice on the B6/SJL background (stock #002726, 
Jackson Laboratory) were perfused with cell culture grade ice-cold PBS (Cat. No #14190136, 
ThermoFisher) for 4 minutes at 10 ml/minute and spinal cords were carefully dissected out. For 
all western blots, the lumbar L1-L5 region was dissected from the rest of the spinal cord in ice-
cold PBS under a microscope. Spinal cords were immediately frozen on dry ice and stored at -
80°C in pre-weighed 1.5 mL tubes prior to RNA extraction. 
RNA was extracted using TRI Reagent (TRI Reagent®, cat. # T9424, Sigma) following 
the manufacturer’s protocol. Mouse tissues were placed in TRI Reagent and dissociated using a 
series of syringe needles until the preparation could pass through a 27-gauge needle three times. 
After initial RNA extraction, DNAse treatment was performed for 25 minutes at 37°C using 
rDNAseI (Ambion cat #AM2235). After DNAse treatment, an additional phenol-chloroform 
extraction of the RNA was performed and the pellet was resuspended in DEPC-treated water 
(ThermoFisher) and quantified by Nanodrop (Thermo Scientific). Next, 1 µg of RNA per cDNA 
reaction was used for the RevertAid First Strand cDNA Synthesis Kit (ThermoFisher) following 
manufacturer’s protocol and primed with both random hexamers and oligo(dT) primers.  
A three-step real-time qPCR was carried out with the Realplex 4 Mastercycler PCR System 
(Eppendorf) using SYBR™ Green dye (ThermoFisher). 
The following primers were used for the real-time qPCR: 
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Gene name Oligo name Oligo sequence qPCR 
product size 
Ripk1 mRipk1-E5-J6F GGAGCCCTATGAGaATGTCATCTG 78 
mRipk1-6R TCCTCTACATTTGGCCTGTTCC 
Ripk3 mRipk3-E7-J8F ATCCTTCCAGgACTGCGAACCAAA 69 
mRipk3-E8R GCAGCATCTACCTTGTCCTTTACCAG 
Mlkl Mlkl-E3-J4F CCTGAAGCAAtGCTCACTAAAACCC 90 
Mlkl-E4R CACGGAGGTCCAAGATGTTCCTTT 
 
7.7. Mouse Breeding 
RIPK3-/- and RIPK3-/+ females (C57Bl/6N) (Newton et al., 2004), kindly provided by Genentech, 
were bred with male mutant SOD1G93A mice on the C57Bl/6J background (stock# 004435, Jackson 
Laboratory). Their progeny was assessed for motor function via grip strength tests, motor neuron 
number in the lumbar spinal cord, and innervation of the neuromuscular junction at the tibialis 
anterior muscle.  
Genotyping for RIPK3 deletion and the mutant SOD1G93A human transgene was performed 
using tail DNA and PCR using protocols and primer sequences obtained from Newton et al., (2004) 
and from Jackson Laboratory (SOD1G93A).  
 
7.8. Mouse Behavioral Tests 
The loaded grid test was performed as previously described by Barnéoud et al., (1997). Briefly, 
the mouse was suspended by the tail and allowed to grip a series of grids with increasing weights 
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(10, 20, 30, 40 g) and a behavioral score was calculated as follows: score= [Σ(tw × W)]/body weight 
where tw corresponds to the maximum time the mouse was able to hold the grid at weight W. Body 
weight is the weight of the animal at the time of the test. A maximum period of 30 seconds was 
allowed for each weight. The best of three trials was recorded with at least 15 seconds resting 
period between each trial of the same weight and at least 30 seconds resting period between each 
weight. Animals were tested twice a week at roughly the same time of day (afternoon defined as 
2 pm – 5 pm) throughout the trial.  
Inverted grid or “wire-hang” test was performed by first allowing the mouse to grip a grid 
and then inverting the grid, thus allowing the mouse to hang. Score was recorded as maximum 
hold time up to 60 seconds, as the best of three trials with at least 3 minutes resting period between 
each trial. This test was always performed on a day other than the loaded grid test day. Animals 
were tested once per week at roughly the same time of day (afternoon defined as 2 pm – 5 pm) 
throughout the trial.  
 
7.9. Quantification of Innvervated Neuromuscular Junctions 
7.9.1. Preparation of the Tibialis Anterior Muscle 
Mice were perfused with 0.1M PBS for 4 minutes at 10 mL/minute followed by ice-cold 4% 
paraformaldhyde in 0.1 M PBS for 8 minutes at 10 ml/minute. Tibialis anterior muscle was 
dissected out and incubated in PBS (Cat. No #14190136, ThermoFisher) overnight at 4°C, then 
transferred to 30% sucrose in 0.12M phosphate buffer at 4°C for at least 48 hours and subsequently 
placed in OCT (Tissue-Tek®) in molds on dry ice and stored at -80°C prior to cryosectioning. 
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Cryosections of tibialis anterior (20 µm) were cut and slide-mounted. Neuromuscular 
junctions were immunolabeled for presynaptic voltage-gated acetylcholine transporter (anti-rabbit 
VaChT, 1/2000, Sigma-Aldrich, St. Louis, MI) and post-synaptic nicotinic acetylcholine receptors 
using fluorescent-conjugated alpha-bungarotoxin (BTX; 1/200 α-bungarotoxin conjugated to 
Alexafluor-594, Invitrogen, Carlsbad, CA).  
Neuromuscular junction innervation was quantified by identifying BTX-positive NMJs 
(red) and determining the extent of colocalization with VAChT (green). Full innervation is 
considered greater than a 70% overlap of BTX with VaChT, partial at 30-70% overlap, and 
denervation at 0-30% overlap. Imaging was performed with a fluorescence microscope at 10× 
magnification. At least 100 neuromuscular junctions on 20 µm tibialis anterior sections were 
imaged and counted for each mouse.  
 
7.10. Quantification of Motor Neurons in the Mouse Spinal Cord 
Mice were perfused with 0.1 M PBS for 4 minutes at 10 ml/minute, followed by ice-cold 4% PFA 
for 8 minutes at 10 ml/minute. Spinal cords were removed and post-fixed overnight at 4°C. The 
L4-L5 segment, identified by its ventral roots, was carefully dissected out with a razor blade under 
a microscope and incubated at 4°C in 10% sucrose in 0.12 M phosphate buffer for at least 48 hours. 
The spinal cord was then incubated in 7.5% gelatin/10% sucrose solution at 37°C for 1.5 hours, 
followed by embedding in a gelatin/sucrose solution in a plastic mold at 4°C until firm for not 
more than 1 day. Cords in gelatin were then cut into blocks and flash frozen for 45 seconds in 2-
methylbutane, dry ice cooled to -60°C and stored at -80°C until sectioning. Next, 20 µm sections 
were cut on a cryostat and every other section was collected for immunostaining. An entire set of 
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20-µm sections from L4/L5 was counted and the average number of motor neurons per lateral 
ventral horn was obtained.  
Motor neuron number was quantified as number of cytoplasmic ChAT positive neurons 
per hemisection in the lateral ventral horn of a 20-µm section of lumbar spinal cord. Every other 
section for the L4-L5 segment was counted using a fluorescence microscope. A neuron would be 
counted if the nucleus, as identified by a DAPI counterstain, was present in the optical plan. The 
anti-ChAT antibody (1/100, goat anti-ChAT, Millipore, Billerica, MA) was incubated overnight 
at room temperature.  
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